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Nitrochemicals are currently widely used as solvents, drugs, biocides, fuels and 
explosives and are consequently widely distributed in the environment. Explosive 
compounds such as 1,2,3-trinitroglycerin (TNG) and 2,4,6-trinitrotoluene (TNT) do not 
have any known naturally occurring counterparts and are present in the soil and 
groundwater of some EPA superfund sites. The reductive nitrite elimination from 
explosive compounds is catalyzed by two FMN-dependent, xenobiotic reductases (XenA 
or XenB). These genes for these regiospecific enzymes were cloned from Pseudomonas 
putida and P. fluorescens I-C respectively and isolated from the soil of a contaminated 
World War II munitions manufacturing plant. These enzymes enable the microbes to 
fulfill their nitrogen requirements from nitroglycerin by catalyzing the regiospecific, 
NADPH dependent, reductive denitration of nitroglycerin with differing selectivities 
toward nitro groups on nitroglycerin. The two enzymes also transform a number of 
additional nitrocompounds in vitro, e.g. TNT and metronidazole, a leading drug in the 
treatment of Helicobacter pylori, a causative agent of human ulcers.  
Single crystals were obtained for XenA and XenB and complete X-ray diffraction 
datasets have been collected and analyzed to better understand these characteristics. The 
XenA crystals belong to space group P21212 with unit cell dimensions a = 84 Å, b = 157 
Å and c = 57 Å. The XenB crystals are in spacegroup P41212 with a = b = 198 Å and c = 
95 Å . Matthews coefficient analysis reveals two molecules in the asymmetric unit for 
XenA and four molecules in the asymmetric unit for XenB. Experimental phasing from 
MAD data analysis of Se-Met XenA reveal a local two-fold screw axis approximately 
 xx 
parallel to the c* axis that relates the two molecules in the asymmetric unit. The 1.6 Å 
resolution structure of XenA reveals a dimer of (β/α)8-TIM barrels, but the 2.3 Å 
resolution structure for XenB is a monomer. The (β/α)8-TIM barrel protein fold is the 
most common fold in the PDB. However, the XenA structure exhibits a unique, C-
terminal domain-swapped topology. Thus a portion of each active site is comprised of 
residues from the neighboring monomer. 
To probe the reaction cycle, crystal structures of ligand complexes and the 
reduced enzyme have been refined. For example, our structure of the XenA-
metronidazole complex shows that ligands bind parallel to the FMN si-face. Our 1.5 Å 
resolution structure for reduced XenA reveals an FMN isoalloxazine ring with an angle 
of ~165° along the N5-N10 axis. We have also generated models of the reduced enzyme-
nitroglycerin complexes by molecular dynamics. The results with both XenA and XenB 
reveal differences in enzyme-ligand hydrogen bonding. These differences correlate 
remarkably well with the regiospecific differences observed for nitrite elimination from 
nitroglycerin and reduction of TNT by the two enzymes. 
 xxi 
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1. A STRUCTURAL PERSPECTIVE ON NITRITE 










 Nitrochemicals from natural and anthropogenic sources are widely distributed 
throughout the environment. They are often mutagenic or toxic, in part because nitro 
group metabolism yields reactive nitrogen intermediates that modify DNA. Nevertheless, 
many microbes catabolize natural and xenobiotic nitrochemicals as sources of nitrogen. 
The crystal structures and functional analyses of the xenobiotic reductase from 
Pseudomonas putida (XenA) and the nitroalkane oxidase from Fusarium oxysporum 
(NAO) are discussed. XenA catalyzes the regiospecific, NADPH-dependent 
transformation of nitroglycerin to yield nitrite and 1,2-dinitroglycerin. It is a member of 
the (β/α)8-TIM barrel, FMN-dependent oxidoreductase family, but exhibits a unique, C-
terminal domain-swapped topology. Thus a portion of each active site is comprised of 
residues from the neighboring monomer. Ligand complexes and redox perturbations are 
used to probe the reaction cycle of XenA. In contrast, NAO catalyzes the oxidation of 
naturally-occurring, neutral nitroalkanes to the corresponding aldehydes or ketones with 
production of H2O2 and nitrite. The structural analysis of active and inhibited NAO in the 
oxidized state are compared to NAO trapped during turnover as a covalent 5-(2-
nitrobutyl)-1,5-dihydro-FAD adduct. The results highlight important mechanistic 
differences between NAO and the acyl-CoA dehydrogenases, which are structural but not 
functional homologs of NAO. 
 
1.2 Introduction 
 Many organic nitrochemicals are widely used as drugs, herbicides, pesticides and 
explosives [1, 2]. They are also present in the exhaust of internal combustion engines and 
tobacco smoke. Consequently, they have been distributed throughout the environment 
from man-made sources in vast excess over naturally occurring examples. Some naturally 
occurring nitrochemicals include nitropropionic acid, chloramphenicol and azomycin 
(Figure 1.1). In addition, nitrated protein residues, such as 3-NO2-Tyr, are now important 
post-translational markers for oxidative damage, septic shock, Alzheimer’s disease as 
well as many cardiovascular, neurodegenerative and malignant conditions [3-8]. 
Explosive compounds, like nitroglycerin (TNG) and 2,4,6-trinitrotoluene (TNT), do not 
have any known naturally occurring counterparts; therefore, they are to be considered 
xenobiotics [2, 9, 10]. Nitroglycerin was first synthesized by Sobrero in 1846, whereas 
the more powerful explosives RDX (~1920) and CL-20 (>1975) are more recent. 
Nitroglycerin is also currently one of the 100 most frequently prescribed drugs;  
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Figure 1.1: Chemical structures of some nitrochemicals dispersed throughout the 
environment.
 
principally for the treatment of angina pectoris [1]. Indeed, this was first reported in 1879 
just 33 years after nitroglycerin was invented [11]. The biotransformation of nitroglycerin 
is a complex process, but in at least one pathway it is converted by vascular smooth 
muscle cells and yields 1,2-dinitroglycerol, nitrite, and eventually nitric oxide (•NO). 
Chen et al. demonstrated in 2002 that a novel activity of mammalian mitochondrial 
aldehyde dehydrogenase (mt-ALDH) catalyzes the regiospecific, reductive denitration of 
nitroglycerin to yield nitrite and 1,2-dinitroglycerin [12]. 
 Many nitrochemicals are toxic at concentrations well below their solubility limit. 
For example, Prowl® and related nitroaromatic explosives and pesticides are proton-
transporting ionophores, which uncouple oxidative phosphorylation. Metronidazole is 
now a leading drug in the treatment of Helicobacter pylori, a causative agent of human 
ulcers. The pathogen contains the rdxA gene, which encodes for an NADPH-dependent, 
3 
oxygen insensitive nitroreductase [13]. The enzyme reduces the nitro group of 
metronidazole to yield the cytotoxic derivatives that kill the pathogen [14-17]. Thus, the 
reductive biotransformation of nitro groups often yields reactive nitroso (R-NO) and 
hydroxylamino (R-NHOH) intermediates, which are capable of modifying DNA [18]. For 
example, ethylnitrosourea, a potential product of reduction of some nitramines, is a 
strong alkylating agent that causes genetic transversions. Nevertheless, studies of 
microbes isolated from environments containing natural or xenobiotic nitrochemicals 
have established that many are catabolized. In fact, nitroesters (R-O-NO2), nitroaromatics 
(Ar-NO2), nitroalkanes (R-CH2-NO2) and nitramines (R2-N-NO2) each serve as sources 
of nitrogen, carbon and/or energy to some microbes [2, 10, 19-21]. Reductive 
transformation of R-O-NO2 typically yields an alcohol and eliminates nitrite. In contrast, 
reduction of Ar-NO2 tends to yield nitroso and hydroxylamino derivatives, but does not 
liberate nitrite. Oxidation of Ar-NO2 by some flavoenzymes eliminates nitrite 
commensurate with hydroxylation. Finally, oxidative nitrite elimination from 
nitroaliphatics occurs with incorporation of either solvent or molecular oxygen into the 
aldehyde or ketone products. 
 
1.3. Nitrite Elimination by Xenobiotic Reductases 
 Prokaryotes continually evolve to exploit chemicals introduced into the 
environment by natural sources or by recent human activities [22, 23]. Indeed, they are 
responsible for most of the transformations and flux of the chemical cycles in the 
biosphere [23]. The xenobiotic reductase A from Pseudomonas putida II-B (XenA) or B 
4 
from P. fluorescens I-C (XenB) were purified from bacterial strains isolated from the 
same site at the contaminated, World War II era, Badger munitions manufacturing plant 
in Baraboo, WI [24, 25]. The plant produced propellants and nitroglycerin for small arms 
ammunition between 1942 and 1975. The bacterial strains were identified because they 
not only tolerate concentrations of nitroglycerin that are toxic to nearly all other 
microbes, but they can also obtain all their nitrogen for growth from the xenobiotic 
compound. The two homologs share 34% sequence identity and 51% sequence similarity. 
Both XenA and XenB catalyze NADPH-dependent reductive nitrite elimination from 
nitroglycerin. However, the main product of XenA is 1,2-dinitroglycerol, whereas that of 
XenB is 1,3-dinitroglycerol (Figure 1.2). The enzymes also exhibit differences in their 
NADPH-coupled reactions with 2,4,6-trinitrotoluene (TNT). XenB exhibits five times 
higher specific activity than XenA when TNT is the acceptor molecule in the oxidative 
half-reaction [26]. Approximately 50% of the reducing equivalents yield nitro group 
reduction and the other half yield aromatic ring reduction. Thus, TNT reduction by two 
and four electrons yields the hydride-Meisenheimer (H-TNT, λ  = 477 nm) and 
tautomers of the dihydride-Meisenheimer (2H-TNT; λ  = 449-492 nm) products, 
respectively [26]. The expression host, E. coli DH5α, transformed with the genes for 
either XenA or XenB can survive on nitroglycerin as the sole source of nitrogen, but only 
when expressing those genes. The expression host also becomes sensitive to 
metronidazole (Figure 1.1), a nitro-containing pro-drug commensurate with XenA or 
XenB gene expression. In contrast, the untransformed expression host can not utilize 
nitroglycerin as a source of nitrogen and it is not naturally sensitive to metronidazole 





Figure 1.2: Some Characteristics of XenA and XenB [24-26]. 
 
 To better understand the structural bases for these characteristics of XenA and 
XenB, we initiated their crystallographic analysis. The preliminary analysis of XenA and 
XenB has been reported [27, 28]. As illustrated in Figure 1.3, XenA has been refined to 
1.65 Å resolution, although the refinement of XenB is still ongoing. The resulting 
structures for both enzymes are (β/α)8 TIM barrels with the FMN located at the N-
terminal end of the barrel. This protein fold is the most common topology in the Protein 
Data Bank [29]. XenB is a monomeric structure, which is consistent with previous 
biochemical analysis [24, 25]. However, the XenA structure from P. putida II-B, exhibits 
a unique, C-terminal domain-swapped topology. Analysis of the refined XenA structure 
shows that approximately 3050 Å2 of surface area is buried at the dimer interface located 
at the first α-helix of the eight-fold barrel topology. Moreover, one portion of the active 
site is comprised of the domain swapped, C-terminal region. Most importantly, 
tryptophan 357 (Trp357b in Figure 1.3), which is from the other subunit, packs against 
the dimethylbenzene portion of the FMN. This increases the solvent excluded surface 
area of the isoalloxazine ring by more than 20%. Several residues within the first α-helix 
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stabilize the dimer interaction and are not conserved in most of the XenA homologs. To 
our knowledge, this is the first example of such a domain-swapped topology in (β/α)8 
barrels. 
 
Figure 1.3: The crystal structure of XenA reveals a novel, domain-swapped dimer at the 
-terminus (top left). In contrast, the structure of XenB is monomeric (bottom left). The 
We have recently completed the refinement for several crystal structures of XenA. 
 
C
2mF  o – DFc electron density (1.5σ) for XenA calculated to 1.6 Å resolution (right). Note 
that Trp357b is from the domain-swapped region. 
 
 
This includes at least two, independent crystal structures each of oxidized XenA (1.65 Å 
resolution, R = 16.2 %, Rfree = 18.7 %), oxidized XenA co-crystallized with 1.6 mM 
metronidazole (1.73 Å resolution, R = 17.5 %, Rfree = 22.6 %) and aerobically reduced 
XenA (1.51 Å resolution, R = 17.6 %, Rfree = 21.0 %). The structural analysis reveals that 
substrates bind parallel to the si-face of the FMN and the active-site residues that 
influence substrate binding. Most of the first-shell residues in XenA are shown or listed 
in Figures. 1.3 and 1.4 and includes Cys24, Tyr26, Ala56, Ile65, His177, His180, Tyr182, 
Trp301 and Trp357 from the other subunit. The structurally analogous residues in XenB 
and other homologs are shown in Figure 1.4. The crystal structures support proposed 
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reaction mechanisms involving hydride transfer to and from the N5 of FMN. Thus some 
of the potential contributions toward catalysis of these residues in XenA include: a) 
providing hydrogen bond donor and acceptor atoms that orient substrate molecules, b) 
establishing both hydrophobic and hydrophilic environments to enhance substrate and 
FMN binding and, c) serving as a proton donor for the oxidative half-reaction. Further 
studies are in progress to test some of these mechanistic hypotheses. 
 
 
Figure 1.4: Similarity between XenA, XenB and several homologs. 
 
 Our primary sequence analyses, catalytic studies, and structural results indicate 
that XenA and XenB are members of the FMN-dependent oxidoreductase subfamily of 
the (β/α)8 TIM-barrel superfamily [24, 29]. XenA shares 27% identity and 45% 
similarity with old yellow enzyme (OYE) [30, 31], the prototypical member of the 
subfamily, but whose physiological role has been difficult to unambiguously determine. 
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Several additional homologs include: a) many putative oxidoreductases from genomic 
sequencing of humans and other organisms, b) additional nitroester reductases isolated 
from other bacterial sources obtained at different contaminated munitions sites, c) 
morphinone reductase and d) N-ethylmaleimide reductase [32-39]. The other 
crystallographically characterized members of this subfamily (Figure 1.4) include 
pentaerythritol tetranitrate reductase [33, 40], morphinone reductase [32], the 12-
oxophytodienoate reductase isoforms 1 [41] and 3 [42], 2,4-dienoyl-CoA reductase [39] 
and the isoforms of trimethylamine dehydrogenase [43, 44]. A significant body of work 
on these enzymes from several laboratories has established a hydride transfer mechanism 
for both the reductive and oxidative half reactions [19, 21, 45, 46]. 
 
 
Figure 1.5: Reactivity of Cys24 and Cys69 in some crystal structures of XenA. 
 
 In addition to those resides shown in Figures 1.3 and 1.4, the active site of XenA 
also contains Cys69, a second-shell residue that is adjacent to Cys24. The structures of 
XenA exhibit interesting features in the high resolution 2mF  o – DFc electron density 
maps (1σ contour), which are illustrated in Figure 1.5. For example, the native structure 
clearly shows that the two cysteine residues are present as thiols. In contrast, the co-
9 
crystal complexes between XenA and metronidazole suggest that Cys69 is oxidized to at 
least the sulfenic acid (Cys-SOH), and possibly the sulfinic acid (Cys-SOOH) state. In 
addition, our 1.5 Å resolution structures for aerobic XenA crystals soaked in 117 mM 
NADPH and ~280 μM O2 from the atmosphere are consistent with Cys24 in two 
conformations, both of which are common rotomers. In one orientation, the maps suggest 
that a disulfide bond between Cys24 and Cys69 is present in a fraction of the enzymes 
within the crystal. Moreover, the maps also suggest that another fraction of enzymes 
contain Cys69 in an oxidized state. The NADPH soaked XenA crystals are bleached and 
the structures also show that the isoalloxazine ring system is bent by an angle of ~165° 
along the FMN N5-N10 axis. These conformations resemble gas-phase, theoretical and 
crystallographic studies of reduced flavins and flavin analogs. Those studies show that 
the two electron reduced isoalloxazine ring is “bent” by up to 30°, primarily along the 
N5-N10 axis. Therefore, we hypothesize that the alterations observed at Cys24 and 
Cys69 result from reduced FMN, produced by either x-ray irradiation, photoreduction or 
by excess NADPH, that reacts with O2 to yield H2O2. Some of the H2O2 is proposed to 
react with the active site cysteine residues to yield the oxidation products illustrated in 
Figure 1.5. Further experiments are in progress to test this hypothesis. However, it is 
worth noting that the homolog, YqjM from B. subtilis is induced by H2O2 and is thought 
to alleviate oxidative stress in that organism [47]. It is also tempting to speculate about 
the potential for a NADPH peroxidase reaction similar to that of other flavin-dependent 
NAD(P)H oxidases and peroxidases [48-51]. For example, a sulfenic acid intermediate at 
either Cys24 or Cys69 residue could be reduced by formation of a disulfide bond between 
the two residues. The FMN si-face remains accessible and presumably NADPH could 
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reduce the FMN. In the next step, the reduced FMN could reduce the disulfide bond to 
yield resting enzyme containing oxidized FMN and Cys24 and Cys69 in their thiol states. 
Thus it is possible that XenA may exhibit an NADPH peroxidase activity, which could 
play a role in managing oxidative stress for the P. putida strain. 
 
1.4. Nitrite Elimination by Nitroalkane Oxidase and 2-Nitropropane 
lkane oxidase (NAO) from Fusarium oxysporum and 2-nitropropane 
Dioxygenase  
 The nitroa
dioxygenase (2NPD) from either Hansenula mrakii or Neurospora crassa are induced by 
naturally occurring nitroaliphatic compounds [52-60]. This suggests that the oxidation of 
a nitroaliphatic species is the physiological role of the enzymes. Moreover, these 
enzymes enable these lower eukaryotes to obtain all their nitrogen from various 
nitrocompounds. This is remarkable because nitroalkanes are toxic to most organisms 
since they are very potent inhibitors of the citric acid cycle. Thus NAO and 2NPD are 
also hypothesized to protect the host from nitroalkanes produced as defensive toxins by 
many plants. The enzymes use either FMN or FAD to eliminate the nitrite from primary 
and secondary nitroalkanes such as nitroethane and 2-nitropropane and longer chain 
nitrocompounds (Figure 1.6). NAO and 2NPD do not share any significant amino acid 
sequence similarity, but they do turnover the same types of nitro substrates. However, 
they exhibit different preferences for either the neutral or anionic forms of the nitro 
substrates [57, 58, 61, 62]. NAO is active exclusively with neutral nitroalkanes. An active 
site base (Asp402) in NAO abstracts an α proton to generate the carbanion in the rate 
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limiting step of the reaction. Thus, NAO is unique in being the only flavoprotein to date 
for which a carbanion is definitively established as an intermediate in catalysis [63]. In 
contrast, the 2-nitropropane dioxygenases (2NPDs) are more active with the anionic form 
of similar substrates. Moreover, 18O2 tracing experiments demonstrate that both O2 atoms 
are incorporated into two acetone molecules [64]. Thus the chemistry catalyzed by 
2NPDs is also unique; they are currently the only known examples of flavoprotein 
dioxygenases and incorporate one atom of O2 into two different substrate molecules. 
 
 
Figure 1.6: Some characteristics of NAO and 2NPD [58, 61, 62]. 
 
1.5. The Crystal Structure of NAO-E*, a Trapped Covalent 
Intermediate 
he preliminary 
tive form of the enzyme [65]. Oxidized NAO readily crystallizes in a 
 We have crystallized NAO in several space groups and published t
analysis of the ac
trigonal space group, diffracts to beyond 1.6 Å, but with a c unit cell edge of 485 Å. 
These characteristics push data collection facilities to the limit. Indeed, as of January 
2005 only 158 x-ray structures (out of 29,040) deposited in the PDB contain a c-axis unit 
cell edge greater than 450 Å. Moreover, only 16 of these structures were to at least 2.5 Å 
resolution. However, we have observed diffraction data to at least 1.6 Å resolution at 
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several synchrotron x-ray sources. Therefore, to solve the structure of NAO, we used the 
covalent adduct form of NAO described by Gadda and Fitzpatrick [66] and termed NAO-
E*. In this state, the FAD is covalently modified as a 5-(2-nitrobutyl)-1,5-dihydro-FAD 
adduct (see Figure 1.8). The Se-Met enriched NAO-E* was trapped during turnover of 
nitroethane in the presence of nitroethane anion, stabilized at low temperature and 
crystallized. This form of the enzyme crystallized in a smaller, orthorhombic unit cell 
compared to oxidized NAO. A three wavelength MAD dataset data from Se-Met 
enriched NAO-E* was used to solve the structure via anomalous Se scattering. The initial 
analysis (SOLVE) to 3.0 Å resolution in space group P212121 located 30 Se sites of an 
expected 52 (13 Se-Met residues per chain). Further analysis using all three wavelengths 
of data to 2.2 Å resolution with SHARP revealed the location of the remaining 22 Se 
sites. The 52 sites were refined and the electron density map was solvent flattened to 
 
 
Figure 1.7: The NAO holoenzyme crystal structure and one subunit colored from N-
terminal (blue) to C-terminal (red) with the N5-FAD adduct in space filled atoms. 
 
produce superb 2.2 Å resolution 2mFo – DFc maps and an overall figure of merit of 0.95. 
The experimental maps were used to fit nearly the entire amino acid sequence and the 
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flavin moiety in each of four chains for the holoenzyme (Figure 1.7). The structure of 
NAO-E* has been refined to 2.2 Å resolution and an R and Rfree of 20.2% and 23.2%, 
respectively.  
 The crystal structure of NAO-E* is a homotetramer with 222 symmetry relating 





chains A:B), the structure can be described as a dimer of dimers (A:B-C:D). Consistent 
with this, analytical ultracentrifugation results of NAO show a homotetramer-homodimer 
equilibrium with a Ka for tetramerization of 8 x 106 M-1 for identical subunits of 
molecular weight 47,955 [58]. Each subunit is comprised of two α-helical domains 
(approximately residues 1-125 and 260-438) and a β-sheet domain between them 
(approximately residues 125-260). The FAD is bound in an extended conformation 
within a crevice between the three domains of the subunit. Although the isoalloxazine 
ring is deeply buried, the adenine moiety projects out of the FAD binding crevice in each 
subunit. However, several additional interactions from the 2-fold related subunits pack 
around the FAD. Consequently very little surface area of the FAD in NAO-E* is exposed 
to solvent. 
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1.6. Comparison of the Crystal Structures of Active NAO with NAO-E* 
 We used the structure of NAO-E* to solve the structure of oxidized NAO by 
molecular replacement in the trigonal space group (P3221, a = b = 103.4 Å, c = 485.7 Å). 
The asymmetric unit contains 1½ holoenzymes (six subunits) and the structure has been 
refined to 2.07 Å resolution to an R and Rfree of 18.8% and 22.7%, respectively. The NAO 
and NAO-E* holoenzyme structures overlap with an average RMS difference of 0.33 Å 
for 1720 Cα atoms from throughout all four subunits. Interestingly, spermine (HCl)4 is 
present in four of the six chains in the structure of oxidized NAO. It was added to the 
crystallization conditions and is a weak competitive inhibitor of NAO (Ki ~ 250 mM). 
Thus we have three examples of active site conformations, a) the resting state, b) an 
inhibited state, and c) the trapped intermediate. A comparison of theses active sites is 
shown in figure 1.8 with the refined 2mFo – DFc electron density maps contoured at 1 σ. 
The electron density for the N5-FAD adduct of NAO-E* clearly shows it nestled between 
Asp402 and Phe401 and above the re-face of FAD cofactor. The isoalloxazine ring is 
bent by approximately 15° to greater than 25° in NAO and NAO-E*, respectively. 
 
 
Figure 1.8: Examples of the electron density in the active sites in NAO and NAO-E* 
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The distortion is more pronounced in the NAO-E* adduct complex, which is consistent 
with a reduced, N5-adduct FAD species. There is also a shift in the hydrogen bonding 
pattern between the FAD and Ser171 in the two crystal structures. Similar distortions to 
the isoalloxazine ring systems have also been observed recently for N5 and C4a covalent 
adducts of monoamine and polyamine oxidases, which have structures that are otherwise 
completely unrelated to NAO [66-70]. Our NAO structures also correlate well with 
previous biochemical studies, which identified several active site residues that are 
important to function. This includes the location of Asp402 as the critical active site base 
[59, 71-73], which is poised directly above the re-face of the FAD. An active site tyrosine 
residue has been identified by tetranitromethane modification [74] and our structures 
shows that Tyr398 is located on one side of the active site cavity [75] . The Cys397 
residue that was identified by chemical modification experiments is also in the active site 
cavity. The 2-nitrobutyl moiety in NAO-E* and the spermine molecules in NAO each 
occupy a pocket above the re-face of the FAD, which is bordered by Ile92, Val95, Ala96, 
Leu99, Ser171, Phe273, Ser276, Val280, Met283, Phe401 and Asp402. Thus, the 
nitroalkane substrate binding cavity is formed almost exclusively with hydrophobic 
residues. This correlates with the preference for hydrophobic nitroalkane substrates 
(Figure 1.6) and the observation that each methylene group contributes ~2.6 kcal mol-1 
binding energy [58, 61]. Moreover, the binding of spermine in this cavity also suggests 
that substrates likely access the FAD from a solvent channel that extends from the 
exterior of the protein to the N5 side of the flavin. This is in direct contrast to the 
substrate access channels observed in several crystal structures of the acyl-CoA 
dehydrogenases (reviewed in [76, 77]), which are homologous to NAO. Together, our 
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structural studies strongly support the carbanion-based reaction mechanism discussed by 
Fitzpatrick et al., in an earlier chapter of this volume. 
 
1.7. Structural, But Not Functional Homologs of NAO 
 The structural homologs of NAO include the acyl-CoA dehydrogenases (ACAD) 
([76] and references therein), acyl-CoA oxidases (ACO) from rat liver peroxisomes or 
Arabidopsis thaliana [78, 79] and the Acyl-ACP dehydrogenases from polyketide 
biosynthetic pathways [80]. The structures for NAO clearly establish the homology with 
other members of the superfamily. Moreover, at least one crystal structure is available 
from each branch of the family of homologs. These provide structural-functional insights 
into NAO and the whole family and we have reported some of these observations in a 
recent review article [63]. Fore example, the medium chain acyl-CoA dehydrogenases 
(MCAD) is 25% identical (45% similarity) to NAO [59, 76, 81-83], but nevertheless, 
failed to yield a molecular replacement solution for the structure of NAO-E*. 
Remarkably, the structure of the 661 residue, α2 holoenzyme of ACO is also similar to 
NAO, despite only 9% sequence identity. Overlays of NAO with the different MCAD 
and ACO family members yield RMS differences that range from 1.6 to 2.1 Å at Cα 
positions of the homologous core. The homology between NAO and the ACADs extends 
throughout the entire subunit chain length. In contrast, the homologous region in the 
ACOs is between residues 21 to 440, which adopts a similar topological fold as the other 
members of the superfamily [78, 79]. 
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 Despite the structural similarity, the homologs have divergent amino acid 
sequences and also catalyze quite different reactions. Mechanistic studies of the ACAD 
enzymes were pioneered by Helmut Beinert almost five decades ago (reviewed in [76, 
77]) and the research area is still very active. Indeed, the structural, mechanistic, 
mutagenic and spectroscopic analysis of the medium chain ACAD (MCAD) provides 
exquisitely detailed proposals for the structural contributions to catalysis. However, to 
our knowledge none of the ACAD or ACO enzymes will transform nitroalkanes, nor will 
NAO transform acyl-CoA substrates [59]. The structures of MCAD bound to transition-
state analogs, substrates or products clearly shows that the acyl-CoA moiety binds 
adjacent to the ribitol portion of FAD (Figure 1.9) [76, 84]. In contrast, our structures of 
NAO show that spermine occupies a binding site that projects in the opposite direction. 
Moreover, several residues pack closer to the ribityl group of FAD in the NAO structures, 
suggesting that steric occlusion prevents acyl-CoA substrate access. Comparisons of 
these structures also highlight differences in the hydrogen bonding associated with the 
active site base, FAD and substrates, all of which are important determinants in guiding 
each particular reaction coordinate. 
 The active site bases in NAO and MCAD are Asp402 and Glu376, respectively 
(Figure 1.9). Sequestration of Glu376 in MCAD has been proposed to be at least partially 
responsible for matching the pKa of the substrate and the active site base [76, 77]. 
Binding of substrate to MCAD results in lowering the pKa of the α-proton by 
approximately 12 units (from ~20 to ~8-9). The same event also raises the pKa of the 
active site Glu376 by approximately 6 units (from ~3.5 to ~9.2). Both events are thought 
to derive from exclusion of solvent by substrate binding and the formation of several  
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Figure 1.9: Active site comparison of NAO and MCAD + Acyl-CoA-TSA. 
 
critical hydrogen bonds. The atoms analogous to the substrate α−β carbons of the 
transition state analog 3-thio-octanoyl-Co (Acyl-CoA-TSA) and the Glu376 side chain in 
MCAD complex are completely shielded from solvent, supporting the hypothesis [76, 
77]. However, the pKa for the nitroalkane α proton of NAO substrates is much closer to 
neutrality and thus solvent shielding of substrate and Asp402 may not be as critical in the 
NAO reaction. Consistent with these mechanistic considerations, we observe different 
hydrogen bonding patterns within the NAO active site compared to the MCAD 
homologs. For example, Asp402 hydrogen bonds with Arg409 in NAO, but Gln382 is the 
analogous residue in MCAD. However, Arg256 in MCAD occupies a structurally 
analogous location as NAO-Arg409, but it does not form hydrogen bonds with Glu376 in 
MCAD. In addition, Ser171 in NAO is also analogous to Thr168 in MCAD. This residue 
contributes a hydrogen bond to the N5-FAD which is thought to withdraw electron 
density and consequently make the flavin more electrophilic [76, 77]. A similar 
interaction is clearly possible in NAO. However, the consequences of all these 
interactions yield different outcomes; in MCAD a hydride is transferred, whereas in NAO 
an adduct forms. Further analysis will be required to understand the structural bases for 
19 




 Structural studies of XenA and XenB support a hydride transfer reaction 
mechanism. However, XenA also exhibits evidence for redox activity between Cys24 and 
Cys69. Structural studies of NAO strongly support the carbanion-based reaction 
mechanism as discussed by Fitzpatrick et al. in an earlier chapter of this volume. 
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2. CRYSTALLIZATION AND PRELIMINARY ANALYSIS 
OF XENOBIOTIC REDUCTASE A AND LIGAND 









 Diffraction-quality crystals have been obtained of the xenobiotic reductase A 
(XenA) from Pseudomonas II-B, which was originally cultured from the contaminated 
soil of aWorldWar II era munitions-manufacturing plant. Several complete X-ray 
diffraction data sets have been collected and analyzed. The native XenA data set includes 
reflections between 35 and 1.65 Å. Four-wavelength MAD data sets from 
selenomethionine-enriched XenA and from three different ligand complexes are also 
reported. The XenA crystals belong to space group P21212, with unit-cell parameters a = 
84 Å, b = 158 Å, c= 57 Å. Experimental phasing from analysis of the MAD data from 
selenomethionine-enriched XenA reveals the presence of two molecules in the 
asymmetric unit. They are related by a non-crystallographic 21 screw axis nearly parallel 
to the c axis, but offset by a quarter unit-cell translation. Thus, the local symmetry 
produces approximate systematic absences along the (00l) principal axis and complicates 
the space-group determination. 
2.2. Introduction 
 Microbes have evolved over billions of years to the point where they are now 
responsible for most of the transformations and flux of the chemical cycles in the 
biosphere [1-4]. The success and ubiquity of bacteria arises from their ability to 
metabolize diverse compounds in response to changes in environmental conditions [5]. 
Thus, virtually all compounds represent potential sources of carbon, nitrogen and/or 
energy upon transformation into central metabolic intermediates [6]. The ability to use 
novel chemicals, such as those recently produced by human activity, is thought to derive 
from unusual activities of pre-existing enzymes, from the altered reactivity of naturally 
arising enzyme isoforms or from horizontal gene transfer [7-13]. The structures, ancestry 
and regulation of enzymes that participate in newly emerged catabolic pathways have 
only infrequently been documented. However, these results are of interest because they 
impact diverse areas, including microbial drug resistance, bioremediation of priority 
pollutants and the evolution of enzyme structure and function [14-16]. 
 Nitrochemicals are an important class of chemicals that are used as drugs, 
biocides, fuels, explosives and solvents. Since nitro group reduction can yield reactive 
nitrogen intermediates capable of modifying DNA, these compounds are considered to be 
mutagenic and toxic [17-21]. Consequently, the US Environmental Protection Agency 
regulates many sites contaminated with these molecules. The nitro-containing explosives 
nitroglycerin and 2,4,6-trinitrotoluene (TNT) were first synthesized in 1846 and 1863, 
respectively, and have since become widely distributed in the environment. Their 
relatively recent introduction and unique chemical properties relative to naturally 
occurring compounds make them attractive examples for the study of the processes 
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leading to xenobiotic transformation. Although no pathways for the complete aerobic 
catabolism of nitroglycerin or TNT are currently known, recent studies have established 
that these compounds are indeed transformed by a variety of enzymes to diverse products 
[22-24]. A documentation of the mechanisms by which these catabolic activities have 
emerged and continue to evolve would be of great interest. Toward this goal, the present 
work originated with the isolation of Pseudomonas putida II-B from nitrocontaminated 
soil at the Badger Army Ammunition Plant in Wisconsin, USA. This bacterium was 
enriched by the ability to obtain all nitrogen required for growth from nitroglycerin 
through the reductive elimination of nitrite. This reaction is catalyzed by a monomeric 39 
kDa flavin mononucleotide-containing enzyme called xenobiotic reductase A (XenA). It 
catalyzes the successive NADPH-dependent nitrite elimination of nitroglycerin, with an 
apparent preference for the removal of a terminal nitro group. XenA will also reduce the 
nitro groups of TNT and metronidazole and the double bond of 2-cyclohexenone to yield 
cyclohexanone [25, 26].  
 Here, we report the initial crystallization and analysis of X-ray diffraction data 
from the native XenA, selenomethionine-enriched (SeMet) XenA and ligand complexes 
formed by co-crystallization with nitroglycerin, TNT and metronidazole. The data are of 





2.3. Material and Methods 
2.3.1. Protein Expression and Purification 
 P. putida II-B was isolated as reported previously [27]. XenA was cloned and 
expressed in Escherichia coli and purified as reported previously [25, 27]. The enzymes 
isolated from P. putida II-B and E. coli were indistinguishable. SeMet XenA was 
produced in E. coli B834 (DE3) using fed-batch fermentation [28] and purified as 
previously reported except that 5 mM DTT was added to all buffers [25, 27]. Mass-
spectral analysis of the purified SeMet XenA showed that the N-terminal methionine was 
completely removed and that the average SeMet enrichment was approximately 95%. 
 
2.3.2. Crystallization and X-ray Data Collection 
 The initial crystallization conditions for XenA were determined from a sparse-
matrix approach and optimized using additive screens from Hampton Research (Laguna 
Nigel, CA, USA). Hanging drops were equilibrated by vapor diffusion in Linbro 24-well 
plates at room temperature in Styrofoam insulated boxes. Typically, 2 ml protein solution 
(5-10 mg ml-1 in 20 mM HEPES buffer pH 7.0) was mixed with either 2 ml reservoir 
solution or 2 ml reservoir solution plus 1 ml ligand solution on a silanized cover slip. 
XenA crystals (Figure 2.1) were obtained from 0.1 M HEPES pH 7.4, 20 mM spermine 
tetrahydrochloride, 5% polyethylene glycol (PEG) 400 or PEG 8000 and 1.4-1.6 M 
ammonium sulfate. The ligand complexes of XenA were obtained by mixing SeMet 
XenA with nitroglycerin (1.1 mM final concentration from a 4.4 M stock solution 
dissolved in ethanol; VWR Inc.), TNT (2.2 mM final concentration from a 4.4 mM stock 
solution dissolved in acetonitrile; VWR Inc.) or metronidazole (1.6 mM final  
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Figure 2.1: A, Crystals (~0.3 × 0.1 mm) of SeMet XenA grown in the presence of 1.1 
mM nitroglycerin photographed without polarization. B, The X-ray diffraction pattern 
obtained at 100 K from SER-CAT beamline 22-ID, 1 s exposure, 1° rotation about the 
vertical axis (vertical line), 150 mm crystal-to-detector distance, MAR CCD 165 detector. 
The arcs indicate 2.0, 2.7, 4.0, 8.0 and 28 Å resolution, respectively. C, An expanded and 
contrast adjusted view of the high-resolution diffraction perpendicular to the rotation 
axis. The dashed arc indicates 2.7 Å resolution. D, Intensities of principal axis reflections 
for the XenA-metronidazole complex, which are typical of all data sets. Systematic 
absences along (h00) (red diamonds) and (0k0) (green squares) and pseudo-systematic 
absences along (00l) (blue triangles) are indicated by periodic I/σ(I) values, which are the 
root-mean-square value of the intensity divided by the estimated standard deviation. The 
lines connecting the points are included solely to help illustrate the relationship between 
reflections along the each principal axis. 
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concentration from a 6.5 mM stock solution in water; ICN Biomedical Inc.) prior to 
setting up the hanging-drop experiment as above. Large single crystals required ~3 d of 
undisturbed equilibration time. The crystals were harvested from the drop with nylon 
loops and transferred into a cryoprotectant, which was Paratone-N most often (Hampton 
Research). The crystals were centered in the loop and the excess mother liquor was 
removed by briskly pulling the viscous cryoprotectant away from the crystal along the 
long axis of the crystal habit. The crystals were flash-frozen by either plunging the loop 
into liquid N2 or by using the cold stream at the X-ray source. Several data sets were also 
collected at ~283 K with a crystal mounted and sealed in a 0.3 mm glass capillary. 
 The X-ray diffraction data sets (Table 2.1) were collected at either the Stanford 
Synchrotron Radiation Laboratory or the Advanced Photon Source beamline 22-ID 
operated by the South East Regional Collaborative Access Team. The 283 K native data 
set was collected in one continuous 80° wedge of ϕ rotation with a MAR 345 image-plate 
detector and a 225 mm crystal-to-film distance. All other data sets were collected using 
CCD-based area detectors. Fluorescence scans of the SeMet XenA crystals were analyzed 
to select the peak, inflection point and high- and low-energy remote wavelengths. The 
MAD data set for Se-Met XenA was collected using the inverse-beam method; two 
wedges of ϕ rotation that covered all the unique area of reciprocal space and two 
complementary wedges of ϕ + 180° were collected at each wavelength. The diffraction 
images were typically integrated with MOSFLM [29] and merged and scaled with SCALA 
from the CCP4 suite of programs [30]. Occasionally, a data set was integrated with 
HKL2000 and scaled with SCALEPACK [31]. The data sets were further analyzed and 
merged with FHSCAL or SCALEIT. The SeMet XenA MAD data were analyzed with 
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SOLVE [32] to locate the Se sites using the theoretical X-ray scattering factors calculated 
for each wavelength (CROSSEC). The resulting sites were refined with respect to all four 
wavelengths of the MAD data set with SHARP [33]. The solvent-flattened experimental 
maps revealed clearly interpretable density for two monomers in the asymmetric unit. 
 
2.4. Results and Discussion 
 Crystals of XenA exhibited an elongated bipyramidal habit (Figure 2.1) that was 
easily oriented with the long axis parallel to the long axis of the cryoloop and 
consequently also with the goniometer ϕ-rotation axis. As indicated by the diffraction 
pattern for XenA aligned in this manner, the longest reciprocal cell axis was also aligned 
with the longest feature of the crystal habit. The X-ray diffraction data sets from XenA 
were all consistent with a primitive orthorhombic unit cell with approximate parameters 
57 Å, 84 Å and 158 Å (Table 2.1). Cryopreservation and co-crystallization of three 
potential ligand complexes did not significantly perturb the unit-cell parameters (Table 
2.1). Upon assumption of a reasonable molecular weight per unit volume (VM = 2.47 Å3 
Da-1 and 50% solvent content; [34], two XenA molecules were assigned per asymmetric 
unit. Analysis of self-rotation functions with GLRF v.1.1 [35] did not reveal any 
significant peaks in the κ = 90 or 120° sections and revealed three peaks (~21σ) centered 
at (0, 0, 180°), (0, 90, 180°) and (90, 90, 180°) in the κ = 180° section. Therefore, the two 
molecules were likely to be related by at least twofold symmetry, which was also nearly 




Table 2.1: Typical data-collection statistics for XenA. Values for the highest resolution shell of data are given in parentheses. 
 
  SeMet XenA    












X-ray source SSRL SSRL SSRL SSRL SSRL SER-CAT SER-CAT SER-CAT 
Beamline 9-1 1-5 1-5 1-5 1-5 22-ID 22-ID 22-ID 
Wavelength (Å) 0.98 0.979764 0.979609 1.06883 0.925256 0.979324 1.0332 1.0 





Temperature (K) 283 100 100 100 100 100 100 100 
Resolution range (Å) 35.6-1.65 33.0-2.5 35.1-2.5 37.0-2.5 31.1-3.0 28.2-2.0 32.8-2.3 27.1-1.8 
Mosaic spread (°) ~0.2 ~0.6 ~0.6 ~0.6 ~0.6 ~0.9 ~1 ~0.9 
Unit-cell parameters (Å)         
a 84.7 83.9 83.9 83.9 83.9 84.1 83.8 84.3 
b 157.9 157.5 157.5 157.5 157.5 157.8 158.1 158.2 
c 58.7 57.0 57.0 57.0 57.0 57.2 57.0 57.3 
Total reflections 312545 171463 208342 194373 89489 318610 221776 347467 
Unique reflections 94132 24191 24297 23455 13929 43335 32984 70825 
Multiplicity 3.3 (3.3) 7.1 (7.0) 8.6 (8.5) 8.3 (6.7) 6.4 (6.4) 7.2 (4.9) 6.6 (5.6) 4.9 (5.4) 
Completeness (%) 98.9 (98.9) 91.1 (91.1) 91.5 (91.5) 88.4 (88.4) 89.8 (89.8) 87.2 (70.0) 97.8 (95.9) 99.6 (99.2) 
Anomalous completeness(%) --- 89.9 (90.0) 90.5 (91.2) 86.8 (64.0) 81.4 (84.5) 86.2 (56.9) --- --- 
Rsym† 0.051 (0.39) 0.128 (0.497) 0.121 (0.442) 0.105 (0.369) 0.173 (0.478) 0.027 (0.138) 0.097 (0.325) 0.052 (0.316) 
I/σ(I) ‡ 17.5 (4.5) 5.4 (1.5) 5.7 (1.7) 6.5 (2.0) 4.1 (1.6) 21.8 (4.1) 6.6 (2.3) 11.1 (2.5) 
† Rsym(I) gives the average agreement between the independently measured intensities such as ∑h∑i|Ii – I|/∑h∑i Ii, where I is the mean intensity of the i 
observations of reflection h. ‡ I/σ(I) is the root-mean-square value of the intensity measurements divided by their estimated standard deviation. 
 Primitive orthorhombic space groups are differentiated by the presence of 
crystallographic twofold screw axes. If present, 21 symmetry requires that odd reflections 
are systematically absent along the principal axis. Consequently, the observed I/σ(I) of 
the principal axis reflections (when scaled in space group P222) strongly suggested that 
XenA crystallized in space group P212121 (Figure 2.1D). Indeed, the average I/σ(I) for 
reflections along the three principal axes for the XenA-metronidazole complex are (even, 
0, 0) = 14.55, (odd, 0, 0) = 0.14, (0, even, 0) = 17.35, (0, odd, 0) = 1.79, (0, 0, even) = 
13.77 and (0, 0, odd) = 4.30. However, a few reflections along each principal axis in each 
data set violated the systematic absence condition; for example, in the XenA-
metronidazole complex the reflection (17, 0, 0) has I/σ(I) = 3.4, (0, 15, 0) = 15.4, (0, 43, 
0) = 29.7, (0, 0, 9) = 23.2, (0, 0, 11) = 12.1 and (0, 0, 13) = 9.8. Therefore, an 
unambiguous determination of the space group was not possible using only the observed 
reflections along the three principal axes.  
 Furthermore, analysis of the SeMet XenA MAD data with SOLVE v.1.16 did not 
yield reasonable solutions in space group P212121. In the best case, only three Se sites (of 
an expected ten sites) were located with a figure of merit of 0.32, a Z score of 38.2 and an 
average peak height/σ of 11.6. Consequently, the data were systematically re-indexed 
into the other orthorhombic space groups with permutations of the unit-cell parameters. 
Reproducible results with SOLVE were only obtained in space group P21212, with a = 84 
Å, b = 158 Å, c = 57 Å. For example, using a subset of the MAD data comprised of the 
inflection, peak and low-energy remote wavelengths and reflections between 3.0 and 35 
Å resolution, nine Se sites were located with a maximum and minimum peak height/σ of 
20.3 and 11.1, respectively, and an average of 14.9. The figure of merit for this solution 
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was 0.39 and the Z score was 27.8. The nine original Se sites refined to convergence with 
the four-wavelength data set in SHARP. A greater than +5σ difference peak clearly 
indicated the tenth Se site, which superimposed with the tenth Se site determined by 
analysis with SOLVE. The phasing statistics included a phasing power of 2.78 for centric 
reflections between 2.5 and 30 Å resolution using the peak wavelength (0.979609 Å). 
The overall figure of merit was 0.471 for 2437 centric reflections and 0.493 for 22 091 
acentric reflections, which improved to 0.808 (22,966 reflections) after solvent flattening. 
The resulting electron-density maps were clearly interpretable and of sufficient quality 
for complete model building.  
 






(molecule A) † 
Observed Se 
coordinates 
(molecule B) † 
Molecule A sites 
after 21 
transformation‡ 
(A21) B-A21§ (Å) 
B-A21§  
(% of unit cell) 
1 x = 35.38 
y = 58.27 
z = 12.07 
x = 8.43 
y = 19.86 
z = 40.12 
x = 6.59 
y = 20.47 
z = 40.56 
Δx = 1.84 
Δy = -0.61 
Δz = -0.44 
|Δx| = 2.19a 
|Δy| = 0.39b 
|Δz| = 0.78c 
2 x = 31.73 
y = 60.67 
z = 7.74 
x = 11.82 
y = 17.26 
z = 35.54 
x = 10.23 
y = 18.07 
z = 36.23 
Δx = 1.59 
Δy = -0.81 
Δz = -0.69 
|Δx| = 1.90a 
|Δy| = 0.51b 
|Δz| = 1.20c 
3 x = 18.23 
y = 69.25 
z = 5.71 
x = 24.44 
y = 7.41 
z = 33.66 
x = 23.73 
y = 9.49 
z = 34.20 
Δx = 0.71 
Δy = -2.08 
Δz = -0.54 
|Δx| = 0.85a 
|Δy| = 1.32b 
|Δz| = 0.95c 
4 x = 40.12 
y = 51.09 
z = 0.78 
x = 4.18 
y = 27.59 
z = 28.40 
x = 1.84 
y = 27.65 
z = 29.27 
Δx = 2.34 
Δy = -0.06 
Δz = -0.87 
|Δx| = 2.79a 
|Δy| = 0.04b 
|Δz| = 1.53c 
5 x = 12.55 
y = 46.26 
z = 52.01 
x = 32.27 
y = 29.83 
z = 23.01 
x = 29.41 
y = 32.48 
z = 23.52 
Δx = 2.86 
Δy = -2.65 
Δz = -0.51 
|Δx| = 3.40a 
|Δy| = 1.69b 
|Δz| = 0.88c 
† The position of the Se atoms in the asymmetric unit after refinement by SHARP. ‡ Location of the Se 
atoms after a 21 symmetry transformation of the molecule A sites. § Distance between the Se sites of 
molecule B and the 21 symmetry transformed Se sites of molecule A. ¶ The same distance between sites, 
but normalized to a percentage of the given unit-cell parameter. 
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 The ten refined Se sites in the asymmetric unit were also used to determine the 
non-crystallographic symmetry between the two XenA molecules in the asymmetric unit. 
Application of a 21 symmetry operator to chain A yielded sites that could be compared 
with the observed locations of Se atoms in chain B. As illustrated in Table 2.2, only small 
differences were identified between crystallographic 21 symmetry and the observed local 
symmetry. Therefore, the local symmetry can be described as a 21 screw axis which is 
displaced approximately one quarter off and nearly parallel to the c axis (Table 2.2). 
Consequently, the resulting local symmetry yields intensities along (00l) that can be 
described as pseudo-systematic absences.  
 Primary sequence analyses, catalytic studies and the emerging structural results 
indicate that XenA is a member of the FMN-dependent oxidoreductase subfamily of the 
(β/α)8 TIM-barrel superfamily [25-27, 36]. XenA shares 27% identity and 44% similarity 
with old yellow enzyme (OYE), the prototypical member of the subfamily [37-39], while 
other structurally characterized members of this subfamily include pentaerythritol 
tetranitrate reductase [40], 2,4-dienoyl-CoA reductase [41], morphinone reductase [42] 
and the 12-oxophytodienoate reductase isoforms 1 [43] and 3 (PDB code 1q45). Several 
unsuccessful molecular replacement attempts were made with search models comprised 
of OYE and other homologs. All of these enzymes are capable of the reduction of 
unsaturated carbonyl compounds. Thus, it appears that XenA may have evolved from an 
ancestral enzyme that catalyzed a similar reaction, but structural differences are also 
likely to be present. More detailed comparisons between the structure, function and 
evolution of these enzymes will be presented elsewhere. The phases from the refined 
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XenA structure have been used to calculate electron-density maps that are consistent with 
ligands such as metronidazole in the active site. 
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3. CRYSTALLIZATION AND PRELIMINARY ANALYSIS 










 Single crystals have been obtained of xenobiotic reductase B (XenB), a 
flavoenzyme isolated and cloned from Pseudomonas fluorescens I-C. The enzyme 
catalyzes the NADPH-dependent elimination of nitrite from nitroglycerin with an 
approximately fivefold kinetic preference for the middle nitro group, primarily yielding 
1,3-dinitroglycerol. X-ray diffraction data sets have been collected from native crystals to 
2.3 Å resolution. The space group is P41212, with unit-cell parameters a = b = 140 Å, c = 
95.6 Å. The asymmetric unit is likely to contain at least two XenB molecules (VM = 3.2 
Å3 Da-1, 61% solvent) and a molecular-replacement solution has been determined in 





 Organic nitrochemicals have been distributed throughout the environment from 
man-made sources in vast excess over naturally occurring sources. Many of these 
compounds do not have any known naturally occurring counterpart and present metabolic 
challenges to many organisms. Moreover, because nitro group metabolism can create 
reactive nitrogen intermediates [1], the US Environmental Protection Agency often 
regulates sites contaminated with nitrochemicals.  
 Elimination of nitrite from an organic nitrochemical is an effective method to 
initiate catabolism that avoids some of the most reactive nitrogen intermediates. Recent 
studies have shown that flavoenzymes can utilize at least two mechanistic strategies to 
catalyze nitrate elimination and permit the organism to obtain all the nitrogen required for 
growth from the nitrochemical [2]. One strategy, utilized by some lower eukaryotes, 
exploits enzymes that catalyze the oxidative elimination of nitrite from naturally 
occurring organic nitrochemicals. The best characterized examples include nitroalkane 
oxidase (NAO) and 2-nitropropane dioxygenase (NPD) [3-6]. Another strategy, utilized 
by several prokaryotes, employs enzymes that catalyze reductive nitrite elimination. 
Indeed, several microbes that utilize nitroglycerin or other organic nitrochemicals as a 
sole nitrogen source have recently been isolated from the contaminated soil of World 
War II-era munitions-manufacturing sites [2, 7-9]. In particular, two nutritionally distinct 
Pseudomonas strains isolated from the same munitions-manufacturing site expressed 
similar flavoenzymes termed xenobiotic reductases A and B (XenA and XenB). While 
both catalyze NADPH-dependent reductive elimination of nitrite from nitroglycerin, the 
main product of XenA was 1,2-dinitroglycerol, whereas that of XenB was 1,3-
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dinitroglycerol [8]. These two enzymes also exhibited differences in their reactions with 
2,4,6-trinitrotoluene, with XenB giving ~50% yield of aromatic ring reduction products at 
pH 7 [10]. XenA and XenB are members of a class of FMN-dependent old yellow 
enzyme (OYE) oxidoreductases [11, 12], several of which transform xenobiotic explosive 
compounds [2, 7-9, 13-25]. The XenA and XenB enzymes have between 27 and 50% 
sequence identity with these homologs [13]. 
 Clearly, the correct interactions between the enzyme active site residues, the nitro 
substrate and flavin cofactor are all essential to achieve catalytic nitrite elimination. 
However, the structural and mechanistic elements that control these interactions, the 
partition between oxidative and reductive nitrite-elimination reactions and the 
regiospecificity of catalysis have not been well established. To that end, we have recently 
reported the crystallization and preliminary characterization of XenA cloned from 
Pseudomonas putida II-B [25]. The focus of this report is the crystallization of XenB 
cloned from P. fluorescens I-C [8, 10, 13]. 
 
3.3 Material and Methods 
3.3.1. Protein Expression and Purification  
 P. fluorescens I-C was isolated as previously reported [8] from nitro-
contaminated soil at the Badger Army Ammunition Plant, Wisconsin, USA. This 
bacterium was enriched by its ability to obtain all nitrogen required for growth from 
concentrations of nitroglycerin that are toxic to nearly all other species. XenB (37 441 Da 
monomer) was cloned, expressed and purified as previously reported [8, 13] The enzyme 
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was indistinguishable when isolated from either P. fluorescens I-C or the Escherichia coli 
expression host, including the presence of one oxidized FMN per protein monomer. 
 
3.3.2. Crystallization 
 Crystallization conditions for XenB were determined from sparse-matrix screens 
and optimized using additive and detergent screens from Hampton Research (Laguna 
Nigel, CA, USA). Typically, 2 ml protein (5-10 mg ml-1 in 20 mM HEPES buffer pH 7.0) 
was mixed with an equal volume of reservoir solution on a silanized cover slip and 
equilibrated at 277 K or room temperature by vapor diffusion in 24-well Linbro plates. 
XenB crystals typically required more than three weeks to grow when the drops were 
suspended over well solutions containing 100 mM PIPES buffer pH 5.5-6.5 with 
approximately 24% polyethylene glycol (PEG 4000, 6000 or 8000) and 200 mM MgSO4. 
The crystals first appeared as long needles at the border of a phase-separated region of 
the drops. The addition of 1 ml detergent (e.g. 0.7 mM HEGA-10, 0.25 mM n-
decanoylsucrose or 0.2 mM Zwittergent 3-12; Anatrace Inc., Maumee, OH, USA) to the 
drop reduced phase separation and increased the reproducibility of crystal formation. 
 
3.3.3. X-ray Diffraction Data Collection and Analysis 
 Crystals were harvested with a nylon loop and transferred to cryoconditions, 
which included either briefly passing the crystals through mother liquor augmented with 
at least 17% glycerol or transferring the crystals to Paratone-N (Hampton Research). The 
crystals were flash-frozen by either rapidly plunging them into liquid N2 or by exposing  
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Table 3.1: Data-collection statistics for XenB. Data were collected at SSRL beamline 9-1 
with 0.9778 Å X-rays and a Quantum 4R detector. Values for the highest resolution shell 
of data are given in parentheses. 
 
Dataset Native 1 Native 2 
Distance (mm) 225 250 
Exposure time (s) 20 10 
Oscillation per image (°) 0.75 1.0 
No. images 132 90 
Resolution range (Å) 28-2.3 30-2.3 
Space group P41212 P41212 
Unit-cell parameters a = b (Å) 140.4 139.9 
 c (Å) 95.6 94.8 
Total reflections 305018 225745 
Unique reflections 40812 35056 
Multiplicity 7.4 (4.9) 6.2 (3.7) 
Completeness (%) 92.1 (97.1) 87.2 (87.2) 
Rsym† 0.126 (0.41) 0.095 (0.34) 
I/σ(I)‡ 4.7 (1.8) 6.2 (2.2) 
Mosaic spread (°) ~0.8 ~0.6 
† Rsym(I) gives the average agreement between the independently measured 
intensities such as ∑h∑i|Ii – I|/∑h∑i I, where I is the mean intensity of the i 
observations of reflection h. ‡ I/σ(I) is the root-mean-square value of the 
intensity measurements divided by their estimated standard deviation. 
 
them to the cold-stream of the X-ray source. All diffraction data were collected at 
beamline 9-2 of the Stanford Synchrotron Radiation Laboratory from crystals held at 
approximately 100 K. The detector was an ADSC Quantum 4R CCD detector (Poway, 
CA, USA). Various exposure times, crystal-to-detector distances and oscillation ranges 
per frame were used (table 3.1). The data were integrated with MOSFLM [26] and 
internally scaled with SCALA from the CCP4 suite of programs [27]. Molecular 
replacement was carried out with the MOLREP routine in CCP4 by searching for two or 
three molecules in the asymmetric unit with an input search molecule derived from 
morphinone reductase (PDB code 1gwj; [28]) and the resolution range 28-3.0 Å. Rigid-
body refinement of the potential solutions took place using REFMAC5 from CCP4. 
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3.4 Results and Discussion 
 Crystals of XenB were birefringent elongated needles (Figure 3.1) that were 
intensely yellow when viewed with unpolarized light. They took much longer to appear 
than the equilibration of the hanging drops suspended over various well solutions. The 
enzyme did not precipitate in the drops during the incubation period; the drops often 
remained clear for several months, especially when incubated at 277 K. If detergents 
were omitted from the drops, they often separated into clear and yellow phases. The 
addition of various detergents reduced the tendency for phase separation and increased 
the reproducibility of obtaining crystals, but did not significantly reduce the time required 
for crystallization. Thus, it appears that crystal nucleation may be the rate-limiting step in 
the crystallization of XenB. 
 X-ray diffraction data-collection statistics for the two data sets are presented in 
Table 3.1. Analysis of the data suggested that the crystals belong to a primitive tetragonal 
space group. Both data sets included reflections along the (h00) principal axis that 
exhibited systematic absences. For example, the native 1 and native 2 data sets had 
average values for I/σ(I) for (even, 0, 0) reflections of 26.4 and 17.2, respectively, 
whereas the (odd, 0, 0) reflections yielded average values of 0.09 and 0.18, respectively. 
However, there were no reflections observed for the principal axis (00l) for any of the 
data sets. Therefore, the space-group determination remained ambiguous based upon 
reflection-intensity data, but they were all consistent with space groups P4212, P41212, 
P42212 or P43212. A reasonable assumption of the weight per unit volume suggested that 
two XenB molecules were present in the asymmetric unit (VM = 3.2 or 2.1 Å3 Da-1, 61 or 
41% solvent content, respectively; [29]).  
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Figure 3.1: A, Crystals of XenB measuring ~0.3 × 0.05 mm photographed with 
polarization. B, The X-ray diffraction pattern for native 1 with a 20 s exposure and 0.75° 
oscillation about the vertical axis. The arcs indicate 2.7, 3.6, 5.5, 10.9 and 28 Å 
resolution, respectively. C, An expanded view of the high-resolution diffraction 
perpendicular to the oscillation axis. 
 
 Morphinone reductase (PDB code 1gwj; [28]) has 50% sequence identity to XenB 
and was used to prepare a monomeric molecular-replacement search model comprised of 
276 residues out of the 349 residues in full-length XenB. All four space groups and both 
native data sets were analyzed for molecular-replacement solutions. For each data set the 
best solutions were for two molecules in the asymmetric unit in space group P41212. 
These yielded correlation coefficients of 0.58 and 0.57, which were significantly better 
than analogous trials in the other space groups (the correlation coefficients ranged 
between 0.45 and 0.49). Moreover, the crystal packing, solvent content and interpretable 
electron density maps are all consistent with two XenB molecules in space group P41212. 
Refinement of the atomic models to the high-resolution limit for each data set are in 
progress. 
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Widely divergent flavoenzymes catalyze a remarkable range of reactions in biology [30, 
31]. The results from XenB, in comparison to our emerging results for XenA [25], will 
help define the structural basis of regiospecific reductive nitrite elimination by 
flavoenzymes [13, 16, 24]. Moreover, by extending the comparisons to enzymes such as 
NAO and NPD, which catalyze oxidative nitrite-elimination reactions, broader 
mechanistic insights can be achieved. 
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4. CRYSTALLOGRAPHIC ANALYSIS AND STRUCTURE 
DETERMINATION OF XENOBIOTIC REDUCTASE B 









 The crystallization and preliminary analysis of xenobiotic reductase B (XenB) 
from Pseudomonas fluorescens I-C [1] reports the initial crystal characterization for 
XenB. Native XenB was originally indexed in space group P41212 with unit cell 
parameters a = b = 140.4 Å and c = 95.6 Å with two molecules present in the asymmetric 
unit and 61% solvent content. However, refinement of this solution never reached 
satisfactory statistics (R = 32.9 % and Rfree = 42.6 %) and large areas with mystery 
density were observed in the 2mFo – DFc electron density maps that could be interpreted 
as protein density and appeared to be ‘shadow’ images of XenB molecules overlapping 
with the original chains. These crystals for XenB were shown to exhibit pseudo-
symmetry where the initial space group is too small. The actual space group in which 
XenB crystallized was also primitive tetragonal P41212 but had unit cell dimensions of a 
= b = 197.8 Å and c = 94.8 Å where crystal packing for both space groups was nearly 
identical but differences in the asymmetric unit content and orientation resulted in the  
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formation of these ‘shadows’ in the smaller unit cell due solely to the space group 
symmetry of the actual, larger cell. 
 
4.2 Introduction 
 The crystallization and preliminary analysis of xenobiotic reductase B (XenB) 
from Pseudomonas fluorescens I-C [1] reports the initial crystal characterization for 
XenB. The X-ray diffraction sets that were collected had a resolution limit to 2.3 Å. Both 
datasets were indexed and integrated in space group P41212 with unit cell parameters a = 
b = 140.4 Å and c = 95.6 Å. Based on a reasonable assumption of the weight per unit 
volume, two XenB molecules were present in the asymmetric unit (VM = 3.2 or 2.1 Å3 
Da-1, 61 or 41% solvent content, respectively [2, 3], Figure 4.1). Table 3.1 lists the data 
collection and integration statistics for both native datasets. A molecular replacement 
solution based on the structure of morphinone reductase (PDB code 1gwj; [4]) was 
attempted to solve the three dimensional structure of XenB. Morphinone reductase has 
50% sequence identity to XenB and was used to prepare a monomeric molecular 
replacement search model comprised of 276 residues out of the 349 residues in full-
length XenB. At this stage in the structure determination of XenB, the exact tetragonal 
space group was ambiguous due to the absence of nearly all principle axes reflections, 
therefore, all eight space groups and both native data sets were analyzed for molecular 
replacement solutions (Table 4.1) using the same molecular replacement search model. 
For each data set the best solutions were found using two molecules in the asymmetric 
unit in space group P41212 and yielded a correlation coefficient of 0.77 for native data set 
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1, which is significantly better than analogous trials in the other space groups (the 
correlation coefficients ranged between 0.14 and 0.71). Moreover, the crystal packing, 
solvent content and interpretable electron density maps were all consistent with two 
XenB molecules in the asymmetric unit of a space group P41212. 
 Table 4.1 also lists the refinement statistics for the atomic models of XenB both 
native datasets to the resolution limit of 2.3 Å. Although the two chains for XenB fit the 
density very well (Figure 4.2A), the resulting R and Rfree values are troublesome. More 
accurately, an Rfree value deviating by more than 10 % from the accompanying R value is 








where R represents the quality of the fit of a model to the diffraction data by measuring 
the discrepancy between the observed (Fo) and calculated (Fc) structure factor 
amplitudes. However, this R value is easily corrupted by increasing the parameter to 
observation ratio. Several examples of models with acceptable R values are known that 
had serious errors [5-7]. This problem was overcome by the introduction of an Rfree [7-9], 
a factor that is the same as the conventional R-factor but is calculated from a small 
percentage (usually ~5-10 %) of reflections that were excluded from the refinement. The 
Rfree then measures the agreement between observed and calculated structure factor 
amplitudes for a test set of reflections that is omitted in the modeling and refinement 
process and therefore cannot decrease during wrong refinements of a model but only 
during the course of successful model refinement. In practice, this means that a very high 
Rfree value (> 0.40) is indicative of a model with serious errors and becomes unrelated to 
the value for the conventional R, which can be very low (~ 0.20). Ideally, the difference 
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between R and Rfree should be as small as possible and depends on multiple factors [8]: a) 
the quality of the data (Rsym, I/σ(I), completeness and multiplicity), b) the global 
correctness of the model, c) the completeness of the model and d) the degree of over-
fitting which is reflected by a high parameter to observation ratio. Tickle et al. (1998) 
describes how to calculate an estimate for the ratio of Rfree and R [10]. As a general rule, a 
large difference between R and Rfree can be defined as more than 0.1 at 3 Å resolution or 
0.05 at 2 Å resolution. A survey conducted by Kleywegt & Brünger (1996) lists an 
average value for R of 0.20 and an average value for Rfree of 0.26 for some of the major 
journals in which macromolecular X–ray structures were published during January 1st 
and June 30th of 1996, totaling 179 structures for which an Rfree was published [6]. Table 
4.2 shows acceptable values for R and Rfree with respect to resolution. 
 









Refinement statistics for 
dataset indexed in P41212 
(bold) 
Native 1 Native 2 
P4 4/4 R=0.92, Corr.=0.17 Resolution range (Å) 28-2.3 30-2.3 
P41 4/4 R=0.54, Corr.=0.71 Number of reflections 37311 33031 
P42 4/3 R=0.92, Corr.=0.15 R (%) 32.9 32.1 
P43 4/3 R=0.89, Corr.=0.18 Rfree (%) (10 % data) 42.6 41.4 
P422 2/1 R=0.93, Corr.=0.15 Number of non-H atoms 5340 5344 
P4212 2/2 R=0.71, Corr.=0.49 Number of protein residues 699 699 
P4122 2/1 R=0.81, Corr.=0.38 Number of water molecules --- --- 
P41212 2/2 R=0.50, Corr.=0.77 Average B values (Å2) 16.4 12.1 
P4222 2/1 R=0.94, Corr.=0.14  Protein 12.2 16.4 
P42212 2/2 R=0.68, Corr.=0.53  FMN 7.6 16.5 
P4322 2/1 R=0.90, Corr.=0.21 R.m.s.d from ideal geometry   
P43212 2/1 R=0.90, Corr.=0.20  Bond lengths (Å) 0.05 0.06 





Table 4.2: Generally acceptable values for R and Rfree with respect to resolution range. 
 
Resolution (Å) R range Rfree range 
3.5 ~ 0.25 - 0.3 ~ 0.3 - 0.35 
2.5 ~ 0.17 - 0.25 ~ 0.23 - 0.3 
2.0 ~ 0.15 - 0.22 ~ 0.2 - 0.25 
 
4.3 The Electron Density Maps for XenB 
 Electron density maps were calculated for both native datasets for XenB based on 
the models listed in Table 4.1. The quality of these σA-weighted 2mF  o – DFc and mF  o – 
DFc electron density maps to 2.3 Å are reasonable (Figure 4.2A). However, upon closer 
examination, unusual features were observed (Figure 4.2B). Although two complete 
chains for XenB were built into the density with reasonable certainty, large portions of 
mystery density remained. Initially it was assumed that this mystery density could be 
explained with detergent molecules lining the protein monomers, but this strategy was 
quickly abandoned since no detergent molecules could be placed in this mystery density 
with any degree of certainty. In addition, it appeared that this mystery density was only 
present on one side of the protein monomer and was the same for each monomer in the 
asymmetric unit. Further inspection of this mystery density lead to the observation that it 
resembles actual protein density. Electron density that appeared α-helical in nature could 
be clearly seen. Since both monomers were built in completely with reasonable certainty, 
this α-helical mystery density could stem from additional monomers in the asymmetric 
unit. Although according to solvent content analysis [2], XenB was thought to have two 
monomers per asymmetric unit (VM = 3.2 Å3 Da-1, 61% solvent), three molecules per 




Figure 4.1: Matthew’s probability curve for XenB to 2.3 Å resolution calculating the 
number of monomers per asymmetric unit possible based on solvent content (blue) and 
Matthew’s coefficient (red) (http://ruppweb.dyndns.org, [3]). 
 
The possibility for four molecules per asymmetric unit is virtually zero [3]. However, the 
mystery density observed in the electron density maps occurs near the active site on one 
side of the monomer, is the same for both monomers in the asymmetric unit and is 
supported by observed mF  o – DFc electron density (3σ). Since it is not possible to 
account for all observed mystery density with placement of one additional monomer (C) 
of XenB and placing two additional monomers (C and D) is excluded as a possibility by 
solvent content analysis, it is unlikely that a wrong number of monomers per asymmetric 
unit can account for the unusual features observed in the σA-weighted 2mF  o – DFc and 
mF  o – DFc electron density maps. 
 If full length XenB chains (C and D) are built into the observed electron density, 
these additional chains perfectly account for all unexplained mystery density (Figure 
4.2C). However, C and D would overlap with the two original monomers (A and B) from 
which the phases were calculated. More precisely, two-fold symmetry axes relate A with 
C and B with D and are located approximately at special positions (x , ½ , ¼) and (x , ½ , 




Figure 4.2: Unusual features observed in the σA-weighted electron density maps (1σ 
contours, 28 – 2.3 Å resolution) calculated for XenB (R = 32.1 %, Rfree = 41.4 %). A, The 
2mF  o – DFc electron density is shown in blue with chain A and the FMN drawn in black 
and orange ball-and-sticks respectively. An example of α-helical mystery density is 
indicated by a red arrow. B, The same as (A) with added in red the σA-weighted mF  o – 
DFc electron density (3σ contours, 28 – 2.3 Å resolution). C, The same as (B) with added 
in green the Cα-trace for an additional monomer, C, accounting for all mystery density 
and satisfying the expected α-helical mystery density indicated by a red arrow. D, A 
representation of the unit cell of XenB (a = b = 139.9 Å and c = 94.8 Å) showing all four 
monomers (A, B, C and D) that can be placed in the electron density calculated using 
phases derived from chains A and B and the manner in which they overlap. Chains are 
drawn as black (A and B) or green (C and D) ribbons with the FMN represented by 
orange (A and B) or purple (C and D) ball-and-sticks. The 2-fold symmetry axes that 
relate these monomers are indicated by red ellipses. 
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now present (A, B, C and D). In case of the first pair of overlapping monomers (A and 
C), the difference between special position (x , ½ , ¼) and the actual position of the two-
fold symmetry axis calculated from the three dimensional coordinates of A and C is 
negligible: (x, 69.93, 23.70) vs. (x, 69.95, 22.14) with percent errors of (x, 0.01%, 1.6%) 
and the difference between the special position (x , ½ , ¾) and the actual position of the 
two-fold symmetry axis relating B and D is (x, 69.93, 71.1) versus (x, 69.89, 69.55) with 
percent errors of (x, 0.03%, 1.6%). Constructing a ‘CD’-dimer from their symmetry 
mates in the same orientation with respect to each other as initial ‘AB’ dimer results in an 
additional asymmetric unit that is translated with respect to the asymmetric unit of the 
‘AB’ dimer by 53.6 Å in the z-direction (Figure 4.3). This is a translation of a little more 
than half a unit cell in the z-direction CD. 
 
 
Figure 4.3: Schematic representation of the two possible ‘dimers’ in the asymmetric unit 
of XenB. Chains A and B are shown as black ribbon drawings with their FMNs drawn as 
orange ball-and-sticks. Chains C and D are shown as green ribbon drawings with their 
FMNs drawn as purple ball-and-sticks. The two-fold symmetry elements are indicated by 
red ellipses. The figure shows the relationship between the two possible unit cells and 
illustrates the translation in the z-direction between them 
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 Several crystallographic phenomenon could potentially explain the behavior 
observed for both native data sets collected for XenB: a) twinning, b) anisotropy, c) 
pseudo-centering and d) pseudo-symmetry.  
4.4 Crystallographic Phenomenon Potentially Occurring in XenB  
4.4.1. Twinning 
 Twinning is an anomaly in crystal growth where the crystal is composed of 
separate domains that differ in their orientations with respect to each other in a distinct 
and well-defined manner [11]. Many different crystal growth anomalies are known, but 
twinning refers to very special cases whe
 
re some or all of the lattice directions in the 
separate domains are parallell and leads to either partial or complete coincidence between 
 
 
and 2) the additional symmetry elements must be encountered in crystal morphology, i.e. 
the lattices of the distinct domains. Twinning was detected early on by crystallographers 
such as Bravais, Mallard and Friedel [12-14]. and can easily prevent successful structure 
determination and more often than not the problem is circumvented completely by 
searching for crystallization conditions that do not give twinned crystals or entirely
different crystal forms.  
Two important facts in twinning need to be considered: 1) in a twinned crystal 
composed of two or more domains, the orientations of these domains are related by one 
or more symmetry elements that are not part of the space group symmetry of the crystal, 
a center of symmetry, a mirror plane (parallel to a lattice plane) or a 2-, 3-, 4- or 6-fold 
rotation axis (parallel to a lattice row common to all domains) [15]. There are two 
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fundamentally different categories of twinning, non-merohedral or ‘epitaxial’ twinning 
an rohedral twinning. d me
 
 4.4.1.1 Non-merohedral Twinning 
Non-merohedral twinning (Figure 4.4A) can be recognized during data collection 
ns of 
multiple sets of reciprocal lattices. This is an example of twinning where the overlap of 
the different domains occurs in fewer than three dimensions, their crystal lattices are not 
super-imposable. The reflections in the diffraction pattern can be integrated if an 
indexing routine can identify one lattice exclusively and ignoring the presence of the 
second lattice. No evidence of non-merohedral twinning was observed in diffraction 
images of XenB. 
 
when difficulties with indexing are observed or the diffraction pattern shows sig
 
 4.4.1.2 Merohedral Twinning 
 Merohedrally twinned crystals (Figure 4.4B) have twin symmetry elements that 
are not part of the space group symmetry but are part of the same Laue group. In this type 
of twinning, different domains have exactly overlapping lattice in three dimensions, 
direct and reciprocal. This way, the crystal appears to be a single crystal until near the 
end of refinements. The diffraction patters will not reveal obvious abnormalities, but each 
observed intensity will contain contributions from crystallographically unrelated 
reflections that are related by a twin operator (twin law). For proteins, domains that have 
crystallographically distinct orientations can have super-imposable lattices when the 
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rotational symmetry of the lattice exceeds the rotational symmetry of the crystal space 
group. This can only be true for space goups that are based on point symmetries 3, 32 
(hexagonal but not rhombohedral), 4, 6 and 23. The only kind of merohedral twinning 
that has ever been reported in macromolecules is hemihedral twinning, where only two 




Figure 4.4: Hypothetical examples for non-merohedral and merohedral twinning. A, 
Non-merohedral twinning, left: a monoclinic crystal presents a rectangular arrangement 
of molecules at one of its faces. Rotation about the indicated axis produces a second twin 
domain with mo
diffraction pattern f
lecular spacings that match those of the first domain. Right: The 
rom the resulting twinned specimen consists of two distinct lattices 
that overlap exactly when l is zero and nearly overlap elsewhere (e.g., when l is 5). B, 
erohedral twinning, left: Separate domains with P3 symmetry are related by a 180° 
rotation about an axis parallel to the three-fold crystallographic axis. The arrows 
winning is hemihedral, having two distinct domain 
 are indicated by bold lines. Right: The observed 
M
represent individual molecules. The t
orientations. The domain boundaries
diffraction pattern appears to be normal. But each of the observed intensities contains 
contributions from two reflections, h1 and h2, which are related by the twinning operator 
but are crystallographically independent. (for l ≠ 0). A set of related reflections is 
indicated. If the two distinct domain orientations are represented equally in the specimen 
(twin fraction of ½), the observed intensities of twin-related reflection (open and filled 
circles) are equal and the diffraction pattern gains additional symmetry. This figure was 






 4.4.1.3 Hemihedral Twinning 
 Hemihedrally twinned crystals have two distinct domains that overlap exactly in 
their direct and reciprocal lattices, resulting in diffraction patterns where each observed 
intensity has contributions from two crystallographically unrelated reflections that are 
related to each other by a twin operator. They do so with weights determined by their 
fractional volumes called the twinning fraction α, where α = 0 represents an untwinned 
rystal. Depending on this twin fraction, two different types can be distinguished. First, 
the case where α ≈ ½ is called perfect twinning, In this case, the symmetry of the 
twinning operation is imposed on top of the Laue symmetry leading to erroneously high 
symmetry. The true crystallographic intensities cannot be recovered directly, but require 
more elaborate measures. Secondly, partial twinning is defined by α < ½, and does not 
etry. The observed intensity of any given 
c
obscure the true crystallographic symm
reflection is equal to: 
( ) ( ) ( )'''1 lkhhkl II ×−+× αα  
Where hkl and h’k’l’ are twin-related indices. Statistical analysis can be used to estimate 
the twin fraction, after which the date can be corrected [11]. 
 
 4.4.1.4 Is XenB Twinned? 
 XenB has been extensively analyzed for twinning. Common simple indicators for 
the presence of twinning in a crystal are; -the unit cell is too small to contain the known 
molecule(s) under the apparent space group symmetry, -the intensity distribution does not 
follow Wilson statistics [16], -the space group appears to be either tetragonal or trigonal, 
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-The structure will not solve from apparent good data and -irreducible R factor from 
pparen data sets collected for XenB showed some of these a tly good diffraction data. The 
twin indicators, but others were not observed. Although XenB can be indexed and 
integrated in a number of space groups varying from tetragonal to orthorhombic, 
monoclinic and, of course, primitive, in neither of these space groups could a twin 
operator be found. In addition, a Wilson’s statistical test can be performed by a web-
server (http://nihserver.mbi.ucla.edu/Twinning) to inspect a data set for the presence of 
partial or perfect merohedral twinning [11]. This web-server uses normalized data or thin 




. The expected value is 1.5 for (acentric) perfectly 
twinned data and 2.0 for (acentric) untwinned data. The data sets collected for XenB both 
resulted in very different values calculated for 2
2I
, in the range of 2.5 – 5.1, which 
I
can be indicative of a crystal that diffracts highly anisotropically or pseudo-centering, 
both of which gives rise to weak and strong classes of reflections. This tends to have the 
opposite effect from twinning. 
4.4.2. Anisotropy 
The X-ray scattering power of an atom decreases as the scattering angle 
ecreas f an electron cloud. The larger the cloud, the more 
 
 
d es, due to the finite size o
rapidly the scattering power falls off with scattering angle. The electron cloud of a 
vibrating atom, averaged over time, is larger than that of a similar atom at rest. The 
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individual atomic scattering contributions f should be corrected to account for this 
















⎢ ⎟⎟⎜⎜−= 0 8exp π uff  
2> is the mean-square amplitude of vibration of an atom, θ is the corresponding 
scattering angle and λ is the X-ray wavelength. The parameter u is called ‘displacement’ 
parameter and is usually reported in crystallography by 228 uπ=B  where B is the 
temperature factor and measures the displacement of an atom by thermal motion. This 
thermal vibration (in additional to conformational and lattice disorder) results in a falloff 
of scattering power by ( ) ⎟⎞2exp λθ , leading to smearing of the electron density. 
















is isotropic. This parameter can be expanded into a 3 × 3 symmetric tensor to account for 




The six independent components of the tensor are the anisotropic displacement 
arameters (ADPs) for an atom [18, 19]. The temperature factor B now becomes 





 If a crystal behaves isotropically, the same falloff will be expected in a plot of 
λ
θsin2vs.F  in all three directions, where F is a structure factor and represents the 
total scattering form the unit cell and λ
θsin2 -1 equals (resolution (Å))  [17]. Differences 
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in the falloff rate in these three directions will indicate anisotropy in the data. This plot 
was constructed for both native data sets collected for XenB [20] and shows no indication 
of high anisotropy in either dataset (Figure 4.5). The third dimension, c*, appears to 
deviate somewhat from dimensions 1 and 2 (a* and b*). This deviation is, on average, no 
z
larger than 83% with respect to a* and b*. Therefore, this dataset cannot be considered 
very anisotropic. In addition, anisotropy will introduce smearing in the electron density. 
This is also not observed in the maps for XenB. Instead, a defined ‘shadow’ of the 













0 0.025 0.05 0.075 0.1 0.125 0.15 0.175 0.2
(2sinθ) / λ ( = 1 / resolution (Å))
<F(overall)>
( ) λθsin2vs.FFigure 4.5: A plot of the  for all three dimension in the crystal of 
XenB [20] e 
overall <F> values are drawn in black. The inset was reproduced from Merrit (1999) [19] 
cloud and represent shapes ranging from prolate ‘cigar’ (left) to oblate ‘pancake’ (right) 




. The dimensions a*, b* and c* are drawn in red, blue and green resp. and th
and shows the effects of anisotropic displacement parameters (ADPs) on an electron 





 When non-crystallographic symmetry causes molecules to pack in the unit cell 
with an approximate crystallographic translation, the diffraction pattern may display 
pseudo-centering, with strong and weak reflections in an alternating arrangement. This 
can occur when a crystal starts out with true body centering that breaks down to pseudo 
centering due to radiation damage or if the crystal is pseudo centered all the time. In case 
of XenB, his could result in the true space group being body-centered (I4122 or I41) 
instead of primitive (P41212). Data can be inspected for pseudo-centering by calculating 
the average intensity ratios for reflections with h+k odd/even, h+l odd/even, k+l odd/even 
and h+k+l odd/even [21]. If, for instance, the h+k odd/even ratio is small (< 0.5), this 
means that the h+k odd reflections are ‘systematically weak’ and can indicate pseudo-C-
face centering. This will also be true for h+l (B face) and k+l (A face). If all three ratios 
are low, this could indicate pseudo-F centering (all faces). If the ratio is low for h+k+l 
odd/even, this could indicate pseudo-I centering (body) [21]. Ratios close to 1.0 indicate 
that there is no pseudo-centering.  
 Table 4.3 lists the average intensity for the odd and even reflections with h+k, h+l, 
k+l and h+k+l calculated for one native dataset of XenB [21] The odd to even ratios were 
calculated as for these sets of reflections. All ratios calculated for XenB were close to 1.0, 
meaning neither odd nor even reflections are systematically weak and leading to the 
 no signs of pseudconclusion that XenB shows o-centering. The calculation was repeated 
for the second native data set collected for XenB with identical results. Neither native 




Table 4.3: The odd and even average intensities for reflections with h+k , h+l, k+l and 
+k+l and their odd/even ratios [21]. 




<I(h+k)> odd 280693.562 
 even 278538.969 
<I > odd 276385.125 
 even 282847.781 




<I(k+l)> odd 279387.031 
<I > odd 278023.656 (h+k+l)
 even 281204.562 
0.989 
† All intensities were calculated using xdlDATAMAN from the Uppsala 
Software Factory (http://alpha2.bmc.uu.se/~gerard/manuals, [21]) 
 
4.4.4. Pseudo-symmetry 
 The existence of pseudo-symmetry in a crystal structure is indicative of a slightly 
distorted structure of higher symmetry [22]. Meaning, the apparent space group of a 
crystals as determined from autoindexing routines is a space group of higher symmetry 
than the actual space group of the crystal. When identical molecules are present in the 
asymmetric unit, they can be related to each other by some general transformation. This 
is referred to as non-crystallographic symmetry or local symmetry, since the symmetry 
ed that does not include this non-
operation relating the molecules is not defined by the space group. These non-
crystallographic symmetry axes can occur at special positions in the unit cell, making 
them appear to be crystallographic. This can lead to confusion when trying to determine 
the actual space group (see chapter 2).  
 When a symmetry axis that exist in a crystal of a particular space group is actually 
non-crystallographic, it should not be considered by the space group and therefore a 
space group of lower symmetry should be select
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crystallographic symmetry. This space group of lower symmetry is referred to as a 
ace group of lower symmetry than the given group but contained within it and capable 
of separate existence as a space group. Consider now space group G and its subgroup H. 
It is always possible to represent their re ediate maximal 
subgroups Z [23]: 
G n >>  
There are, in g neral, a num f spa lating G to ure 4.6A lists all 
possible maxi up in which XenB 
 thought to have crystallized. 
1 1
maximal subgroup. A maximal non-isomorphic subgroup of a given space group is a 
sp
lationship by a chain of interm
HZZ >> ...1
e ber o ce groups re H. Fig




Figure 4.6: All possible subgroups for P41212. A, The maximal non-isomorphic 
subgroups of P4 2 2 (second row) are listed along with their maximal non-isomorphic 




Table 4.4 lists integrations statistics for one native dataset in various space groups along 
with some molecular replacement trials conducted in them. Re-integrating the data was 
necessary instead of reindexing the P41212 solution obtained since space groups of lower 
symmetry are under investigation. Reindexing can only be used when a space group of 
higher symmetry is the objective.  
 
Table 4.4: Integration statistics for XenB (MOSFLM, [25]) in various crystal systems and 
molecular replacement (MOLREP, [20]) and initial refinement statistics (REFMAC, [20]) 
for P41212 and its subgroups. 
 
nal  Primitive Monoclinic Orthorhombic Tetrago
 P1 P2 C2 P222 C222 P4 / P
Resol. (Å) 28 – 2.3 28 – 2.3 27 – 2.3 28 – 2.3 28 – 2.3 28 – 2.3 
422 
Unit cell       
 b (Å) 140.6 140
 c (Å) 140.4 140.
 a (Å) 95.4 95.6 95.6 95.6 95.6 140.4 
.4 140.4 140.2 140.4 140.4 
3 140.4 140.3 140.3 95.6 
 α (°) 89.9 90.0 90.0 90.0 90.0 90.0 
 β (°) 90.0 89.9 89.9 90.0 90.0 90.0 
 γ (°) 90.0 90.0 90.0 90.0 90.0 90.0 
Rsym (%)† 0.072(0.266) 0.087(0.294) 0.088(0.306) 0.101(0.328) 0.101(0.323) 0.126(0.41) 
I/σ(I)‡ 7.0(2.7) 6.4(2.3) 4.7(2.3) 6.2(2.2) 6.3(2.2) 4.7(1.8) 
Compl.(%) 59.4(40.7) 88.0(69.2) 84.6(63.3) 94.2(90.0) 94.5(91.0) 92.1(97.1) 
Multiplicity 1.6(1.5) 2.1(1.7) 2.2(1.9) 3.9(2.6) 3.9(2.6) 7.4(4.9) 
† Rsym(I) gives the average agreement between the independently measured intensities such as ∑h∑i|Ii – 
I|/∑h∑i I, where I is the mean intensity of the i observations of reflection h. ‡ I/σ(I) is the root-mean-square 
value of the intensity measurements divided by their estimated standard deviation. 
Space group No. molecules 
expected/found§ 
Molecular Replacement¶, 
20–4.0Å, R (%) and corr. coefficient 
Initial Refinements ₣, 
28-2.3Å, R and Rfree (%) 
P43212 (96) 2/1 R = 89.4, Corr. = 0.195 R = 54.3, Rfree = 55.1 
P41212 (92) 2/2 R = 50.0, Corr. = 0.770 R = 32.1, Rfree = 40.7 
P43 (78) 4/4 R = 91.3, Corr. = 0.183 R = 65.2, Rfree = 67.9 
P41 (76) 4/4 R = 53.8, Corr. = 0.707 R = 36.9, Rfree = 45.6 
C2221 (20) 4/4 R = 53.8, Corr. = 0.704 R = 35.8, Rfree = 51.4 
P212121 (19) 4/4 R = 51.1, Corr. = 0.756 R = 31.4, Rfree = 39.0 
P21212 (18) 4/2 R = 67.6, Corr. = 0.506 R = 45.9, Rfree = 54.6 
P2221 (17) 4/2 R = 70.2, Corr. = 0.484 R = 48.3, Rfree = 55.8 
C2 (5) 8/3 R = 60.6, Corr. = 0.575 R = 63.0, Rfree = 71.1 
P21 (4) 8/3 R = 60.3, Corr. = 0.584 R = 63.9, Rfree = 72.0 
P1 (1) 16/4 R = 64.3, Corr. = 0.571 R = 45.8, Rfree = 52.7 
§ Number of molecules in the asymmetric unit was based on solvent content analysis [2]. ¶ Full length 
XenB (chain A) obtained from P41212 analysis was used as the search model. ₣ Initial refinements included 
gid body refinement to 3 Å where the full length chains were defined as domains and restrained 





During scaling routines of the data, multiple observations of reflections are scaled 
together and multiple observations are merged into an average intensity according to the 
requirements of the space group used. These requirements are not the same for different 
space groups, in particular, for space groups of lower symmetry where less requirements 
are present due to the lower symmetry. Reindexing from a spacegroup of higher 
symmetry to a spacegroup of lower symmetry will then result in output that wrongly 
reflects requirements of the higher symmetry. Although some molecular replacement 
lutions seem plausible, P41212, P41 and P212121, upon inspection of the resulting 
n than not crystal packing violations occur. The same 
sults were o or both n ets of XenB. T as conc  
ls of o not gns o  sym
.5 ck to the Drawing ard to e the C tal Stru re of X  
vin yst re re an  ta  
, 
onoclinic and primiti swer for the f 
as found th fined to reaso es with no n 
 density ps. It was deci  drawing b e 
exing ro e for XenB. 
so
solution with its corresponding density maps, the ‘shadows’ are still present in the 
electron density maps and more ofte
re btained f ative data s herefore, it w luded that
the crysta  Xe B dn  sho  siw f ps udoe met y. r
 
4  Ba  Bo Solv rys ctu enB
 Sol g the cr al structu of XenB sulted in  arduous sk. Many
crystallographic phenomena were explored (twinning, anisotropy, pseudo-centering and 
m any di s were pseudo-sym etry) and m fferent space group tested (tetragonal
orthorhombic, m ve). No plausible an  crystal structure o
XenB w at re nable R and Rfree valu aberrant b avior ieh






Depending on the number of spots found and the particular diffraction im ages 
mitive space groups for this 
larger cell. Therefore, the solution for C222 obtained after integration was reindexed into 
41212. 
ll 
as primitive and face-centered orthorhombic (P222 and C222), primitive and face-
centered monoclinic (P2 and C2) and primitive (P1) molecular replacement calculations 
were carried out and are listed in Table 4.6. Also shown in this table are the integration 
statistics for these space groups. 
 
 
used, the autoindexing routing [25] will give differing results. Table 4.5 shows the results 
of the autoindexing that eventually led to the right answer for space group for solving the 
crystal structure of XenB. As can be observed from this table, the most logical selection 
in this list of options is the solution for a tetragonal space group (highlighted in blue) with 
a = b= ~139 Å and c = ~95 Å since this solution has the highest possible symmetry with 
the lowest possible penalty. Highlighted in red is the solution that has to be chosen to 
lead to the right answer for space group for XenB, face-centered orthorhombic (C222) 
with a = ~197 Å, b = ~198 Å and c = ~95 Å. After cell refinements and integration, the 
unit cell dimensions for this solutions remained a = b = ~197 Å and c = ~95 Å (Table 
4.6). In light of this result and past experience with these data sets, it was decided to also 
investigate primitive tetragonal space groups as well as primitive and face-centered 
orthorhombic, primitive and face-centered monoclinic and pri
P
 For all possible space groups, primitive tetragonal space groups (P4/P422) as we
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Table 4.5: Autoindexing results for XenB using MOSFLM [25]. 
No. Penalty a b c 
 
α β γ Possible Space Group 
28 406 139.51 312.30 95.24 89.9 90.1 116.3 C222,C2221
27 406 139.51 312.30 95.24 90.1 90.1 63.7 C2 
26 406 312.30 139.51 95.24 90.1 90.1 63.7 C2 
25 381 95.24 197.26 219.49 89.8 64.4 89.9 I222,I212121
24 379 294.60 95.24 197.26 89.9 131.8 71.3 C2 
139.51 139.94 90.2 90.0 90.1 P23,P213,P432,P4232,P4332,
P4132 
22 
21 222 168.72 169.25 219.84 106.5 73.6 108.6 H3,H32 (hexagonal settings 
1
P4 22,P4 2 2 
17 219 169.12 168.72 139.94 89.8 90.2 111.4 C2 
12 190 95.24 294.60 139.94 89.8 90.0 108.7 C222,C222
23 223 95.24 
223 169.12 169.25 218.91 106.4 73.8 108.4 H3,H32 (hexagonal settings 
R3 & R32) 
R3 & R32) 
20 220 168.72 169.12 139.94 90.2 90.2 68.6 C222,C222
19 220 95.24 139.51 139.94 90.2 90.0 90.1 P4,P41,P42,P43,P422,P4212,
P4122,P41212,P4222,P42212 
3 3 1
18 220 168.72 169.12 139.94 90.2 90.2 68.6 C2 
16 193 95.24 295.67 139.51 89.8 90.1 108.8 C222,C2221
15 192 95.24 294.60 139.94 89.8 90.0 71.3 C2 
14 192 95.24 295.62 139.51 89.9 90.1 71.2 C2 
13 191 295.67 95.24 139.51 90.1 90.2 71.2 C2 
1
11 189 294.60 95.24 139.94 90.0 90.2 71.3 C2 
10 5 139.51 139.94 95.24 90.0 90.1 90.2 P4,P4 ,P4 ,P4 ,P422,P42 2,1 2 3 1
P4122,P41212,P4222,P42212 
P4322,P43212 
9 3 197.94 197.26 95.24 90.1 90.1 90.2 C2 
8 3 197.26 197.94 95.24 89.9 90.1 89.8 C222,C2221
7 3 197.26 197.94 95.24 89.9 90.1 89.8 C2 
2 0 95.24 139.51 139.94 89.8 90.0 89.9 P1 
6 2 95.24 139.94 139.51 90.2 90.1 90.0 P2,P21
5 2 95.24 139.51 139.94 90.2 90.0 90.1 P2,P21
4 2 95.24 139.51 139.94 90.2 90.0 90.1 P222,P2221,P21212,P212121
3 1 139.51 95.24 139.94 90.0 90.2 90.1 P2,P21
1 0 95.24 139.51 139.94 90.2 90.0 90.1 P1 
 
4.5.2.Molecular Replacement 
 During data collection at the beamline, the smaller tetragonal cell was believed to 
collection were not optimal. During integration of the diffraction images in this larger  
be the space group of the XenB crystals and data was collected based on this choice. 
Since the actual unit cell of XenB turns out to be approximately 50 % larger in volume, 
with two dimensions of the unit cell increased by ~30%, the choices made for data 
11/23/2005 
77 
Table 4.6: Integration and molecular replacement statistics for various possible space 
 
groups for XenB in a larger unit cell with a = b = ~198 Å and c = ~95 Å. 
 Primitive Monoclinic Orthorhombic Tetragonal 
P1 P2 C2 P222 C222 P4 / P422 





nit cell       
a (Å) 199.9 198.9 198.4 198.8 198.8 197.8 
 b (Å) 198.9 198.6 198.9 198.4 198.4 197.8 
95.5 94.8 
α (°) 89.9 90.0 90.0 90.0 90.0 90.0 
8  89.8 90.0 90   
 °) .0 90.0 
N fl. 4 50 2  57 293145 305707 
U e refl 4 49  15 62093 41716 
R %)† 23 ) 0 .1 14 88) 0.128(0.442) 
I/ ‡ 1 1. 5 9 4.8(1.6) 
C l.(%) 9. 3 76 9) 89.2  ) 
Multiplicity 1.6(1.5) 1.6(1.5) 2.4(1.8) 4.1(2.8) 1(2.8) 7.4(4.9) 
† (I) g he  n n ep tly i – 
I|/∑h∑i I, where I is the mean intensity of the i observations of reflection h e root-mean-square 
v  of the u i  t ma v
 c (Å) 95.5 95.5 95.4 95.4 
 
 β (°) 9.6 .0 90.0 90.0
γ ( 90.0 90  90.0 90.0 90.0 
o. re 52482 456 8 75420 7663 
niqu . 02018 392 6 94572 0815 
sym ( 0. 0(0.684 0.140( .552) 0 03(0.364) 0.2 (0.774) 0.116(0.3
5.2(1.8) σ(I) .6(0.8) 3.7( 0) .4(1.8) 2. (0.9) 
omp  5 8(39.4) 58.1( 8.4) .9(64. (82.7) 90.0(85.4) 48.6(47.6
4.
Rsym ives t  average agreeme t betwee the ind enden  measured intensities such as ∑h∑i|I
. ‡ I/σ(I) is th
alue  intensity meas rements d vided by heir esti ted standard de iation. 
Space group No. molecules 
/f
Molecular Replacement¶  
, R nd oef t
inements ₣, 
 and R  (%) expected ound§ 20–4.0Å  (%) a corr. c ficien  28-2.3Å, R
Initial Ref
free
P 2 (96) 4/4 , C 0.64321   R = 56.2 orr. = 14  
P4322 (95) 4/2 R = 61.9, Corr. = 0.581 
P4 2 2 (94) 4/4 R = 65.3, Corr. = 0.556 
P  (93) 4/ , C 0.5
 
 2 1
4222 4 R = 65.4 orr. = 54  
P 2 (92)4 21 1  4/4 R = 37.3, C 0.8orr. = 49 R = 24.4, Rfree = 29.5 
P  (91) 4/2 , C 0.5
P 90) 4/2 , C 0.5
P  (89) 4/2 , C 0.5
P 8) 8/ , C 0.6
P 7) 8/6 , C 0.5
4 221
42 2 (
 R = 67.3 orr. = 11  
1
422
 R = 59.5 orr. = 08  
 R = 66.6 orr. = 12  
4  (73
4  (7
6 R = 53.3 orr. = 56  
2  R = 58.8 orr. = 95  
P 6) 4  (71 8/8 R = 36.4, C 0.8orr. = 47 R = 24.4, R  = 30.3 
P 5) 8/ R , C 0.5
C222 (21) 4/2 R = 91.8, Corr. = 0.147 
C2221 (20) 4/4 R = 53.8, Corr. = 0.704 
free
4 (7 6  = 59.1 orr. = 91  
 
 
P2 21 (19) 1 12 8/8 R , C 0.8 = 36.4 orr. = 49 R = 26.9, Rfree = 34.0 
P2 2 (18) 8/ R , C 0.2
P2 1 (17) 8/ R , C 0.0
P2  (16) 8/4 , C 0.4
C2 ) 8/3 , C 0.5
P2 ) 16/ , C 0.5
P2 (3) 1 , C 0.5
P1 (1) 32/ , C 0.8
§ N mber of le  t m it se olv o t analysis [2]. ¶ Full length 
XenB (chain A) obtained from P41212 analysis was used as the search model. ₣ Initial refinements included 
gid body refinement to 3 Å where the full length chains were defined as domains and restrained 
refinement to 2.3 Å. No flavin molecules or water molecules had been included in these refinements. 
1 1
22
2 8  = 85.5 orr. = 67  
8  = 38.2 orr. = .831  
22  R = 89.6 orr. = 06  
 (5  R = 60.6 orr. = 75  
1 (4 4 R = 59.3 orr. = 60  
6/4 R = 60.5 orr. = 73  
30 R = 40.4 orr. = 27  





c any reflections were now rejected due to overlaps. This resulted in much lower 
completeness for the integrations.  




ell. However, upon inspection of the crystal packing and the electron density maps, no 
 and hadow e obs After
nt, the solutions obtained for P4 41 and 21 were of similar quality in 
 their R free values (Table 4.6
Fin ment s for tive d for Xe P41212
Data d in P Nativ ve 2 
1212 or P41 (highlighted in red and yellow respectively), or a primitive 
orthorhombic space group, P212121 (highlighted in yellow), have the best molecu
replacement results. This is the same result as obtained for XenB indexed in the smaller 
c
violations  ‘sno s er’ w er . ved  initial rigid body and restrained 
ref einem 1212, P P2121
terms of  and R ).  
 
Table 4.7: al refine  statistic both na ata sets nB in . 
 
set indexe 41212 e 1 Nati
Resolution range (Å) 28-2.3 31-2.3 
Unit cell parameters   
 a = b (Å) 198.6 197.8 
 c (Å) 95.5 94.8 
Number o 26 33153 
R (%)  18.4 
Rfree (%) (  27.1 
Number o 64 11603
Number o 2 1392 
Number o  879 
Average B  
 Protein  23.0 
 FMN  20.2 
 water  22.6 
R.m.s.d fr  
 Bond 0.010 
 Bond a 1.3 
f reflections 37.4
20.9
10 % data) 28.6
f non-H atoms 113  
f protein residues 139
f water molecules 640




om ideal geometry  
lengths (Å) 0.012 
 ngles (°) 1.5
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Therefore, the t space grou b = ~198 Å and c = ~95 Å since this 
 
er Primitive Tetragonal Space Group P41212 
 
ore reasonable and constant value (B = 50 
2). In Babinet’s principle it is assumed that the structure factors of the bulk solvent 
ectron 
density with strictly o nl  ns lower than ~15 Å, 
using observed protein phase d ce
 
4.5.4.Comparison of the Two Tetragonal Space Groups of XenB 
 XenB has been ‘solved’ in two different space groups, a ‘right’ or ‘large’ one and 
a ‘wrong’ or ‘small’ on p enB imitive tetragonal P41212 
with a = b = 197.8 Å and t all space group is also primitive 
 righ p is P41212 with a = 
is the solution with the highest possible symmetry. The same results were obtained for 
both native data sets. 
4.5.3.Refinement of XenB in a Larg
Table 4.7 shows the final refinement statistics for both native XenB data sets The 
final model for native XenB had an R of 18.4 % and an Rfree of 27.1 % with data between 
31 – 2.3 Å resolution. The final rounds of refinement using REFMAC [20] were done 
using non-crystallographic symmetry (ncs) averaging over the four chains present in the 
asymmetric unit. The main chain and side chain ncs-averaging constraints were set to 
medium and loose respectively. Since the resolution limit of either native data set does 
not exceed 2.3 Å, bulk solvent scaling was carried out using the Babinet principle [26] 
where bulk solvent correction is based on a m
Å
electron density are directly proportional to the structure factors of the protein el
pposite phases and is o y true at resolutio
 phases to estimate ifferen s. 
e. The large space grou for X  is pr
 and c = 94.8 Å he sm
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tetragonal P41212 with  139.9 Å and c = 94.8 Å. When comparing the overall 
crystal packing of both r e tetragonal unit cells found for XenB they seem identical 
at first sight (Figure 4 A wever, enc the z-coordinate of some 
molecules (Figure 4.7B). The unit cell and therefore the asymmetric unit is different for 
Figure 4.7: An overlay of the ‘right’ and ‘wrong’ primitive tetragonal space groups of 
Å (‘right’ or ‘large’ space group) has all molecules drawn as a Cα-trace colored in red 
cells are shown for this space group. Space group P41212 with a = b = 139.9 Å and c = 
awn as a Cα-trace colored in 
blue with the unit cell drawn in yellow. A total of 4½ unit cells are shown for this space 
group. B, A 90° rotated view of (A). 
 a = b = 
 p imitiv
.7 ). There are, ho  differ es in 
these space groups not only in size, but also orientation (Figure 4.8). 
 
 
XenB viewed in the xy-plane. A, Space group P41212 with a = b = 197.8 Å and c = 94.8 
with the unit cell drawn in white, including the symmetry elements. A total of 2¼ unit 




First, the smaller unit cell is 50% smaller in volume, with its asymmetric unit only 
content). Upon examination of the asymmetric unit of the larger space group, it is evident 
asymmetric unit to 
ymmetric unit of the large space group. Clearly, these pairs of AB monomers 
an be related by two-fold symmetry (crystallographic). 
containing 50% of the content of the asymmetric unit from the larger cell. Secondly, the 
unit cells are rotated 45° in the xy-plane with respect to each other (Figure 4.7). 
Moreover, the larger space group requires four molecules in the asymmetric unit [2] 
based on solvent content analysis (VM = 3.1 Å3 Da-1, 60% solvent content), but the 
smaller space goup will only allow for two molcules (VM = 3.2 Å3 Da-1, 61% solvent 
Figure 4.8: The asymmetric unit of the large and small space groups of XenB viewed in 
the xy-plane (left) and the yz-plane (right). A, The large space group has four molecules 
in the asymmetric unit (A = yellow, B = blue, C = green and D = red) with no non-
crystallographic symmetry present to relate the four molecules in the asymmetric unit. B, 
The small space group has two molecules in the asymmetric unit (A = yellow and B = 
blue). The additional two molecules (left) stem from an adjoining 
that no non-crystallographic symmetry is present relating these four molecules to each 
other (Figure 4.8A). This makes it impossible for the smaller space group to accurately 
describe the crystal packing of these XenB crystals with just two molecules. When 








with the equivalent molecules in the smaller cell, it should also be noticed that that one of 
the molecules in the asymmetric unit of the larger cell (D) has an orientation that disrupts 
regular packing in this cell. A 45° rotation in the xy-plane would make the packing in this 
asymmetric unit identical to the corresponding packing in the smaller cell and would then 
allow for non-crystallographic symmetry to relate A and C with B and D (Figure 4.8B). 
 4.8). 
This molecule now overlaps with a chain in the larger cell in an orientation identical to 
These non- crystallographic symmetry axes would then be located at special positions ( ¼ 
, y , ½) and ( ¾ , y , ½) and would alter the space group from this larger cell to a smaller 
cell that requires two molecules in the asymmetric unit. 
 How do these two space groups account for the observation of ‘shadows’ in the 
smaller cell? Figure 4.9 illustrates the occurrence of this observation in the smaller cell 
due to the space group symmetry of the larger cell. The asymmetric units of the larger 
(red) and smaller (blue) cells are shown in the top left of Figure 4.9. These molecules 
align exactly with each other with no deviation in their z-coordinates. Going down in 
Figure 4.9 represents the addition of an asymmetric unit form an adjoining small cell 
(green). One of these additional molecules will then reflect the difference of a 45° 
rotation between chain D in the larger cell and chain A in the smaller cell (Figure
what is observed for chain A and its ‘shadow’ in the smaller cell (middle of Figure 4.9), 
resulting in a ‘ghost’ image of this chain in the smaller cell created solely by the crystal 
symmetry of the larger cell. Exactly the same happens with a symmetry mate (½-y, ½+x, 
¼+z) of the asymmetric unit of the smaller cell (Figure 4.9, top right, green molecules) 
with a symmetry mate (½+x, ½-y, ¾-z) of the asymmetric unit of the larger cell (Figure 




Figure 4.9: The appearance of ‘shadows’ in the P4 2 2 smaller space group of XenB as a 
consequence of the P4
1 1
1212 symmetry of the larger cell illustrated in the xy-plane. Shown 
in red are the four molecules in the asymmetric unit of the larger cell overlayed with the 
asymmetric unit of the smaller cell in blue (top left) with their corresponding unit cells 
drawn as red and blue boxes, respectively. Addition of an adjoining asymmetric unit of 
the smaller cell (bottom left) and a symmetry mate (top right) are shown in green with the 
additional unit cell drawn as a green box. The addition of a symmetry mate of the larger 
asymmetric unit (bottom right) is shown in yellow. In the middle is shown the orientation 
of the ‘shadows’ [27] with respect to chain A and B (green) in the smaller cell. Sites of 
‘shadows’ are indicated with white arrows. No difference in z-coordinate exist in the 
view of this figure. All molecules shown exist in the same section of the xy-plane. 
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B chain of the smaller cell identical to what is observed for the B chain and its ‘shadow’ 
in the smaller cell (middle of Figure 4.9). 
 Figure 4.10 illustrates the behavior resulting in the observation of ‘shadows’ for 
the entire cell of the larger space group. The sites of ‘shadow’ formation are indicated 
with green arrows. The view on the left represents the xy-plane with all molecules drawn 
in the same section of this plane. These molecules only represent 50% of the unit cell 
content. Noticably, only four occurrences of ‘shadows’ are observed in this smaller unit 
cell. This is 25% of the its entire content and explains the much lower σ-levels of the 
mystery density that results from this behavior. 
 
 
Figure 4.10: The appearance of ‘shadows’ (green arrows) in the smaller space group 
(blue molecules) illustrated for the entire cell of the larger space group (red molecules) 
with their unit cells drawn as yellow and white (with symmetry elements) boxes, 




 Although initial data analysis did result in a complete three-dimensional model 
for XenB, the refinements could not be completed satisfactorily. Unusual mystery density 
was observed in the electron density maps that appeared to be ‘shadows’ of additional 
monomers overlapping with the models already present. This behavior was the result of 
assignment of a wrong space group. The actual space group of XenB turned out to be 
50% larger than originally anticipated, with four instead of two molecules in the 
asymmetric unit. Also, the unit cells were rotated with respect to each other by 45º. The 
crystal packing for both space groups is nearly identical with the only differences 
occurring in the z-dimension. The observation of ‘shadows’ in the smaller space group 
resulted form the space group symmetry of the actual, larger space group making this a 
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5. CRYSTAL STRUCTURES OF XENOBIOTIC 
REDUCTASES A AND B FROM PSEUDOMONAS PUTIDA 
II-B AND PSEUDOMONAS FLUORESCENS I-C: TWO 










 Pseudomonas putida II-B and Pseudomonas fluorescens I-C were isolated from 
the contaminated soil at the Badger Army Ammunition Plant in Baraboo, Wisconsin, 
USA. The enrichment strategy selected for bacteria with an ability to obtain all nitrogen 
required for growth from nitroglycerin. The FMN-dependent enzymes partly responsible 
for the phenotype have been named xenobiotic reductase A (XenA) and xenobiotic 
reductase B (XenB) from P. putida II-B and P. fluorescens I-C, respectively. They both 
catalyze the NADPH-dependent nitrite elimination from nitroglycerin or the reduction of 
trinitrotoluene (TNT) to yield a variety of products. Here we report the crystal structures 
of XenA and XenB to 1.6 Å and 2.3 Å resolution, respectively. Both proteins fold as 
(β/α)8 barrels as anticipated from previous amino acid sequence homology analysis. 
However, the structures show that XenA is a C-terminal, domain-swapped dimer. The 
point of closest contact between the two subunits in XenA occurs at the exterior face of 
α-helix 1 and includes residues Val39 and Ser43. The analogous XenB residues in α-
helix 1 are Glu40 and Gln44, and consequently, it is a monomer. As a result of the C-
terminal domain-swap in XenA, Trp357 from one subunit packs against the 
dimethylbenzene portion of the FMN in the other subunit. In contrast, each monomer of 
XenB places Phe334 and Tyr335 from the same subunit against the dimethylbenzene ring 
of the FMN. Comparisons of the active sites of XenA, XenB and homologs reveal a 
number of key differences that likely govern the regiospecific reactions of XenA and 
XenB with nitroglycerin and TNT. The following paper describes several crystal 
structures of XenA ligand complexes and docking experiments of nitroglycerin and TNT 
with reduced XenA and XenB that correlate well with previous functional studies [1-3]. 
 
5.2 Introduction 
 Nitroglycerin is currently one of the 100 most frequently prescribed drugs [4-7]. 
Indeed, the use of nitroglycerin for the treatment of angina pectoris was first reported in 
1879 just 33 years after it was invented [8]. However, the precise mechanism of 
bioactivation of nitroglycerin has been difficult to define [4-7, 9-11]. It has been 
proposed to result from both oxidative and reductive processes. For example, enzymes 
such as cytochrome P450, cytochrome P450 reductase, glutathione S-transferases or 
xanthine oxidoreductase all yield a range of products including nitrite, 1,2- and 1,3-
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dinitroglycerols, and mononitroglycerols [6, 12-22]. Mammalian transformation of 
nitroglycerin by vascular smooth muscle cells is known to yield 1,2-dinitroglycerol, 
nitrite, and eventually nitric oxide. Physiologically, nitric oxide is normally derived from 
arginine by nitric oxide synthase and has many important physiological functions, 
including vasodilation [23-26]. Chen et al. demonstrated in 2002 that a novel activity of 
mammalian mitochondrial aldehyde dehydrogenase (mt-ADH) catalyzes the 
regiospecific, reductive elimination of nitrite from nitroglycerin to yield 1,2-
dinitroglycerol [27]. The nitrite appears to be converted into nitric oxide by other 
mitochondrial enzymes, which then activates guanylate cyclase-dependent signal 
cascades. Furthermore, Chen et al. suggested that bioactivation of nitroglycerin by mt-
ADH i) involves active site cysteine residues to achieve catalysis, ii) may contain a 
covalent S-nitrosothiol as a key reaction intermediate, iii) likely forms an intramolecular 
disulfide bond, and iv) the reaction requires a source of two electron reducing 
equivalents. Thus, more than a century after the physiological effects of nitroglycerin 
were first observed, at least one rather detailed description for its regiospecific 
bioactivation has been proposed. It is the consequence of a novel activity elicited from an 
essential metabolic enzyme. However, most of the other proposed enzymatic 
transformations also yield intermediates that can generate nitric oxide. Moreover, the 
biotransformation of nitroglycerin also differs in dose-dependent, tissue, cell and 
subcellular specific manners to yield a range of products. Therefore, the 
biotransformation of nitroglycerin is a complex process, which has yet to be fully 
characterized. 
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 Organic nitrochemicals from man-made sources have been distributed throughout 
the biosphere in vast excesses over naturally occurring examples. This includes many 
explosive compounds such as 2,4,6-trinitrotoluene (TNT) and nitroglycerin, which have 
no known naturally occurring analogs and are therefore considered xenobiotic. 
Nevertheless, microbes have been isolated from contaminated soil at munitions 
manufacturing sites that metabolize explosives as sources of nitrogen and/or carbon [1-3]. 
Xenobiotic reductase A (XenA) from Pseudomonas putida II-B and xenobiotic reductase 
B (XenB) from Pseudomonas fluorescens I-C were purified from bacterial strains 
isolated from the World War II era, Badger munitions manufacturing plant in Baraboo, 
WI. These strains were identified because they not only tolerate concentrations of 
nitroglycerin that are toxic to nearly all other organisms, but they can also obtain all their 
nitrogen required for growth [2]. The enzymes responsible for this process, XenA and 
XenB, catalyze the NADPH-dependent nitrite elimination from nitroglycerin via a ping-
pong kinetic scheme. However, the organic product of the oxidative half-reaction from 
XenA is 1,2-dinitroglycerol, whereas from XenB it is 1,3-dinitroglycerol. Therefore, the 
two enzymes use the same substrates for the reductive and oxidative half-reactions 
(NADPH and nitroglycerin, respectively), but the latter reaction yields different products. 
XenA exhibits selectivity for removal of a terminal nitro group of nitroglycerin, whereas 
XenB is selective for an internal nitro group. XenB and XenA also reduce 2,4,6-
trinitrotoluene (TNT) to yield a variety of products, although the reactivity by XenB is 
more robust than that of XenA [2, 3]. Metronidazole is also reduced in vitro and in vivo 
by XenA and XenB as evidenced by the observation that E. coli DH5α transformed and 
expressing the genes for either XenA or XenB die in the presence of metronidazole 
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(unpublished data). Since the E. coli is not normally sensitive to metronidazole, the 
reactivity of XenA and XenB is probably analogous to that of pathogens that are 
susceptible to this class of pro-drug [28-30].  
 Amino acid sequence analysis of XenA and XenB indicate that they are both very 
likely members of the class I (β/α)8 barrel family of FMN-containing flavoenzymes [1, 2, 
31]. The prototypical member of the family is old yellow enzyme (OYE) [32, 33]. Other 
structurally characterized members include pentaerythritol tetranitrate reductase 
(PETNR) [34], morphinone reductase (MorR) [35], 12-oxophytodienoate reductase 
isoforms 1 (OPR-1) [36] and 3 [37] (OPR-3), 2,4-dienoyl-CoA reductase (DCR) [38], the 
isoforms of trimethylamine dehydrogenase (TMADH) [2, 3, 39, 40] and YqjM, an OYE 
homolog from Bacillus subtilis [41, 42]. With the exception of TMADH, all these 
homologs use a ping-pong kinetic mechanism and NAD(P)H in the reductive half-
reaction. The reduced enzymes are typically relatively stable under aerobic conditions, 
but as a group they exhibit remarkable substrate diversity in the oxidative half-reactions. 
Therefore, on the one hand, this family of enzymes binds identical substrates during the 
reductive half reactions, but on the other hand, they discriminate between diverse 
substrate molecules to complete the oxidative half-reactions. Moreover, XenA and XenB 
are unique among the family, since they also yield different reaction products in their 
oxidative half-reactions from identical substrates. Here we report the crystal structures of 
XenA and XenB from Pseudomonas putida II-B and Pseudomonas fluorescens I-C. 
Theses structures reveal active site binding sites of similar size, but with different 
distributions of hydrogen bond donors and acceptors, and different electrostatic surface 
features. An important feature is the observation that XenA is a functional dimer with a 
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domain-swapped C-terminal region that comprises a portion of the active site. In contrast, 
XenB is a functional monomer with similar, but distinctly different interactions within 
the active site compared to XenA. 
 
5.3 Material and Methods 
5.3.1. Protein Expression and Purification  
 XenA from Pseudomonas putida II-B and XenB from Pseudomonas fluorescens 
I-C were purified and crystallized as previously reported [1, 2, 43, 44]. 
 
5.3.2. Crystal Structure Determination 
 The structure of oxidized XenA was solved with MAD phasing techniques with 
Se-Met enriched crystals as previously described and briefly summarized here [43]. The 
space group is P21212 with a = 84 Å, b = 157 Å, c = 57 Å. Nine selenium sites were 
located with SOLVE [45] using diffraction data from four X-ray wavelengths with data 
between 2.5 and 30 Å resolution collected at 100 K. The sites were refined to 
convergence in SHARP [46] (Table 5.1). The Se-Met experimental phases between 30 
and 2.5 Å resolution were appended to a 1.65 Å resolution dataset for oxidized XenA 
collected at 283 K. Phase extension and solvent flattening to 1.65 Å was performed with 
the CCP4 suite of programs [47].  
 The refined crystal structure for XenB is in space group P41212 with unit cell 
dimensions of a = b = 198 Å and c = 95 Å and four XenB molecules in the asymmetric 
unit. This assignment differs from our previous characterization [44] of the space group 
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as P41212, with unit-cell parameters a = b = 140 Å, c = 95.6 Å because this smaller unit 
cell, which contained two XenB molecules per asymmetric unit, did not refine to an 
acceptable R-free value. The structure of native XenB was solved by molecular 
replacement in MOLREP [47] using a search model derived from native morphinone 
reductase (PDB code 1gwj [35]). All the solvent molecules and the FMN were removed, 
the B-factors were set to the Wilson B (typically about 28 Å2) and all non-identical 
residues were either truncated to alanines or deleted from the search model.  
 




SeMet-enriched oxidized XenA Native 
XenB 









Temperature (K) 283 100 100 100 100 100 
Wavelength (Å) 0.98 0.979764 0.979609 1.06883 0.925256 0.9778 
Resolution range (Å) 35 – 1.65 33 – 2.5 35 – 2.5 37 – 2.5 31 – 3.0 31 – 2.3 


















































Rcullis centric (iso) d --- 0.50 0.47 --- 0.90 --- 
Rcullis acentric 
(iso/ano) d
--- 0.50 / 0.94 0.49 / 0.87 --- 0.89 / 0.94 --- 
Phasing Power, 
centric (iso) d
--- 2.34 2.30 0 0.03 --- 
Phasing Power, 
acentric (iso/ano) d
--- 2.86 / 1.11 2.78 / 1.51 0 / 0.86 0.02 / 1.27 --- 
Figure of Merit d --- 0.471e 0.493f 0.808g 0.902h --- 
a Numbers in parenthesis are for the highest resolution shell. b The average agreement between the 
independently measured intensities. c The root-mean-squared value of the intensity measurements divided 
by their estimated standard deviation. d Compiled from SHARP [46]. e 2437 centric reflections. f 22091 
acentric reflections. g After solvent flattening, 22966 reflections. h After phase extensions to 1.65 Å and 
solvent flattening. Isomorphous (iso) and anomalous (ano) parameters are indicated. 
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 Model building for both structures was carried out with the program O [48] and 
refinements were with CNS [49, 50] and/or REFMAC5 [51]. Cross-validated, σA 
weighted 2mFo – DFc and mFo – DFc maps [47] were used to evaluate the model and 
correct errors. Water molecules were placed in the final stages of refinement with 
ARP/Waters and refined with REFMAC5. Refinement statistics for all datasets are 
presented in table 5.2. Validation of the models and Ramachandran analysis were done 
using SFCHECK [52] and PROCHECK [53]. Secondary structure assignments were 
made using KSDSSP [54]. The r.m.s.d. between models was calculated with CCP4, 
Swiss-PDBViewer (v3.7) [55] or with Q-score analysis by the protein structure 
comparison service SSM at the European Bioinformatics Institute 
(http://www.ebi.ac.uk/msd-srv/ssm) [56]. Structure figures were prepared using CCP4mg 
[57, 58], Swiss-PDBViewer (v3.7) [55] and PovRay (v3.6). A preliminary report 
describing some of these results has appeared in the Proceedings for the 15th International 
Symposium on Flavins and Flavoproteins, which was held from April 17-22, 2005 at the 
Shonan Village Center, Hayama, Japan [59]. 
 
5.4 Results 
5.4.1. Overall Description of the Structures 
 The crystal structures for both XenA and XenB are well refined and were 
repeated with at least two independent data sets obtained from two or more crystals of 
each enzyme. Table 5.1 summarizes the data collection and phasing statistics for XenA at 
283K and XenB at 100K, whereas Table 5.2 presents the refinement statistics for each 
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structure. The final model for native XenA had an R-factor of 15.5% and an R-free of 
18.2% with data between 35 – 1.65 Å resolution. The final model for native XenB had an 
R-factor of 18.4% and an R-free of 27.1% with data between 31 – 2.3 Å resolution. 
However, the native data set collected for XenA is of higher intensity and quality than the 
data set collected for XenB.  
 
Table 5.2: Model Refinement Statistics for Oxidized XenA and XenB 
 
 Native XenA Native XenB 
Temperature 283 K 100 K 
Resolution range (Å) 35.6 - 1.65 31.3 – 2.3 
No. of reflections 84621 33153 
R-factor / R-freea  (%) 15.5 / 18.2 18.4 / 27.1 
No. of non-H protein atoms 6270 11603 
No. of residues fit 722 1392 
No. of disordered residues 2 0 
No. of water molecules 598 879 
No. of FMN molecules 2 4 
Ligand molecules 2 Chloride ions / 
2 Sulfate ions 
4 Sulfate ions / 
4 Magnesium 
RMS deviations form ideal   
 Bond lengths (Å) 0.008 0.019 
 Bond angles (°) 1.1 1.9 
 Mean B, protein atoms (Å2) 16.6 10.1 
 Mean B, water molecules (Å2) 35.6 10.5 
 Mean B, FMN molecules (Å2) 11.8 8.2 
 Mean B, ligand molecules (Å2) 24.5/74.7 8.4 / 10.3 
Ramachandran analysis   
 Most favored regions (%) 89.6 86.8 
 Additional allowed regions (%) 9.8 11.2 
 Generously allowed regions (%) 0.7 1.3 
 Disallowed regions (%) 0.0 0.8 
PDB Code To be determined To be determined 
a Calculated with 10% of the data. 
 
 Ribbon diagrams of the functional dimer of XenA and the monomer of XenB are 
shown in Figure 5.1A and 5.1B, whereas an overlay of a monomer from each enzyme is 
shown in Figure 5.1C. Each monomer of XenA and XenB adopts a (β/α)8 barrel motif, 
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with a non-covalently bound flavin mononucleotide (FMN) at the C-terminal of the 
barrel. Therefore, they are both members of the class I (β/α)8 barrel family of FMN-
containing flavoenzymes [31]. The asymmetric unit for the XenA crystals contains two 
363 residue enzymes. Although non-crystallographic symmetry restraints were not 
applied during the refinement process, the structures for each chain of XenA in the 
asymmetric unit are nevertheless, very similar to each other (r.m.s. deviation of 0.23 Å 
over 361 Cα atoms). The crystals of XenB contain four 348 residue enzymes per 
asymmetric unit. Since the completeness in the highest resolution shells of data was 
lower than for the XenA data sets, non-crystallographic symmetry restraints and 
averaging were used for the refinement of the XenB structure. Each monomer of XenB in 
the asymmetric unit is independent of the other protein chains, suggesting that the 
enzyme is a functional monomer. 
 The secondary structure assignments and topology diagrams of the XenA and 
XenB are shown in Figures 5.2 and 5.3. The classic (β/α)8 barrel structure contains eight 
β/α motifs that form the eight-stranded parallel β-barrel, which is surrounded by eight α-
helices [31]. The XenB structure is an example of the classic barrel motif (Figure 5.1B). 
In contrast, although the two XenA monomers within the asymmetric unit do form a 
nearly classical (β/α)8 barrel motifs, each chain diverges from the classical topology after 
β-stand eight (Figures 5.1A, 5.2A and 5.3A). Thus the C-terminal region of each chain 
does not fold back upon the original barrel motif. Instead, after β -strand 8, the main 
chain crosses the asymmetric unit boundary and forms several important interactions with 
an adjacent monomer (Figures 5.2A and 5.4). As a consequence, the XenA dimer is  
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Figure 5.1: Divergent stereo images of the XenA domain-swapped dimer (A) and the 
XenB monomer (B). The subunits are colored according to secondary structure 
assignments (α-helix, red; β-strand, green; coil, purple). The FMN, Cl- (yellow sphere) 
and SO42- in each subunit are shown as CPK atoms with C, N, O, S and P atoms colored 
grey, blue, red, yellow and magenta, respectively. C, Divergent stereo image of the 
overlayed Cα-trace of XenA and XenB in red and blue respectively. The view in (A) is 
rotated ~90º around y (in the plane of the paper) to obtain (B), which is rotated ~90º 
around x (in the plane of the a paper) to obtain (C). 
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formed by monomers from adjacent asymmetric units, rather than the two chains within 
the asymmetric unit. In the normal topology, as illustrated with the structure of XenB, the 
α-helix 8 folds back onto the original subunit to complete the barrel motif (Figure 5.4A). 
 The XenA dimer is stabilized by the domain-swapped C-terminal regions and by 
interactions between α-helix 1 in adjacent subunits (Figures 5.3A, 5.5A and 5.5C). 
Analysis of the structure shows that 1540 Å2 per monomer (11% of the monomer surface 
area) is buried at the dimer interface. In contrast, crystal packing of the XenB monomers 
only buries an average of 1094 Å2 (8.5%) of each subunit. The subunit interface in XenA 
at α-helix 1 is stabilized by a combination of electrostatic, hydrogen bonding, and van 
der Waals interactions, particularly involving residues Trp36, Val39, Ser43 and Arg46, 
among others. For example, the closest contact at the dimer interface occurs at Ser43 in 
both chains (Figure 5.5A). They are separated by 2.8 Å and hydrogen bond with each 
other, which may contribute between -0.5 – -1.5 kcal/mol of stabilization [60]. 
Hydrophobic interactions between Val39 in one subunit and Ser43 and Arg46 in the other 
subunit flank the inter-subunit, Ser-43-Ser43 hydrogen bond. Finally two inter-subunit 
cation-π interactions occur between Arg46 and Trp36, which are separated by ~4.4 Å. 
The average contribution to stability of cation-π interactions involving an arginine 
residue is -2.9 kcal/mol [61]. Moreover, the terminal nitrogen atoms of the Arg46 
sidechain also form hydrogen bonds with to the carbonyl-oxygen atoms of Asp35 and 
Trp36 of the other subunit. In contrast to XenA, none of these interactions are possible in 
XenB (Figure 5.5). For example, the structural equivalents of XenA-Trp36, Val39 and 
Ser43 are XenB-Leu37, Glu40 and Gln44, respectively. Consequently, the bulkier 
residues in XenB prevent it from forming a similar domain-swapped dimer as observed in  
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Figure 5.2: Topology diagram and amino acid sequence alignments for XenA, XenB and 
selected homologs. A, The C-terminal, domain-swapped dimer topology of XenA. Alpha 
helices are illustrated as red and blue boxes for chain A and B, respectively. Beta strands 
are indicated as green and yellow arrows for chain A and B, respectively. B, The amino 
acid sequence alignment from CLUSTALW for the homologs. The secondary structure 
labels are as defined for XenA. Structural elements for XenB that do not align with XenA 
are indicated in green adjacent to that element. Every tenth residue is underlined.  
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the XenA structure. 
 The backbone traces for XenA and XenB are very similar to each other as 
evidenced by the overlay of 278 Cα atoms between XenA-Ala2 to Lys339 and XenB-
Thr2 to Ala322 with a r.m.s.d. of 1.3 Å (Figure 5.1C). The similarity between the two 
structures diverges at XenA-Glu340 and XenB-Asp323, where the C-terminal domain 
swap starts in XenA. Two sulfate anions are present in the dimer structure of XenA, 
which stabilize the interaction between helices α8a and α8b at residues Ala346, Ser347 
and Arg360 (Figure 5.4A). Helix α8b is the domain-swapped, C-terminal helix in XenA 
that packs against the active site FMN. This helix is structurally analogous to helix α8a of 
XenB, despite the fact that the two helices travel in opposite directions. The two alanine 
residues in the A337A338K339E340 sequence at the end of α-helix 8 in XenA correspond to 
the leucine and lysine residues from the spatially analogous L320K321A322D323 sequence in 
XenB. The two smaller residues in XenA allow for the domain crossover of the backbone 
trace, whereas the larger residues in XenB do not. Indeed, the side chain of XenA-Ala338 
forms hydrophobic interactions with Val343, Ala346 and Thr349. The corresponding 
residues in XenB are Leu326, Pro329 and Glu332, of which XenB-Glu332 occupies a 
similar three-dimensional space as the domain-swapped XenA-His356b. Moreover, the 
next residue is XenA-Trp357b (Trp357b in Figure 5.6A and Figure 5.7A), which packs 
against the dimethylbenzene ring of the FMN in subunit A. This interaction increases the 
solvent excluded area of the FMN cofactor in the active site by 12% (72 Å2). 
Consequently, one portion of the active site in XenA is comprised of the domain swapped 
C-terminal region. In contrast, the analogous FMN solvent excluded region in XenB 
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Figure 5.3:
nown to form dimers. A, The domain swapped dimer formed by XenA is shown in red 
  
2mFo – DFc electron density map 
superimposed with the refined coordinates for the FMN and some of the active site end 
5.4.2 Active Site Structure of XenA and XenB.
k
for monomer A and green for monomer B. Helices are indicated as circles and sheets are 
indicated as triangles. Connectivity is represented by black lines. Dimers as formed by 
OYE (orange) and OPR-3 (purple) were overlayed with chain A of XenA. Only their 
dimer partners were consequently drawn in this figure. B, The dimer as formed by MorR 
(blue) was overlayed with XenA and consequently only its dimer partner is shown. 
 
 
derives from Phe334 and Tyr335, both of which are donated from the same subunit 
(Figure 5.4, Table 5.3).  
 Overview of the dimer interfaces formed by homologous to XenA that are 
 Figure 5.6A shows the 1.65 Å resolution 
 Similarity Between XenA, XenB and Selected Proteins. 
Three-Dimensional Superposition of XenA, XenB and Selected Homologsa
Protein XenAb XenBc YqjMd OPR-3e OPR-1f MorRg OYEh PETNRi TMADHj R
PDB code ?? ?? 1z41 1q45 1icq 1gwj 1oyb 1h61 2tmd s
XenA % identityl  100 31 42 31 27 32 26 30 30 27 
 Q-scorem --- 0.54 0.79 0.51 0.52 0.49 0.44 0.51 0.25 1 
 r.m.s.d. (Å)n --- 1.50 0.96 1.51 1.54 1.52 1.64 1.54 1.78 0 
 Naligno --- 291 325 290 289 288 286 292 298 
XenB % identityl  31 100 32 44 42 52 39 49 24 29 
 Q-scorem 0.54 --- 0.59 0.8 0.8 0.8 0.62 0.78 0.25 9 
 r.m.s.d. (Å)n 1.5 --- 1.57 1.13 1.15 1.13 1.33 1.08 1.91 1 
 Naligno 291 --- 296 341 336 337 322 334 297 













XenA C24 Y26 A56 I65 T66 Q98 A100 H177 H180 Y182 R230 R325 W357b 
YqjM C26 Y28 A60 I69 T70 Q102 A104 H164 H167 Y169 R215 R308 R366b 
XenB T24 C26 A55 G64 Y65 Q97 W99 H172 N175 Y177 H224 R286 F334, Y3
OPR-3 T33 C35 G64 G73 F74 Q106 W108 H186 H189 Y191 R238 R344 F370, Y3
OPR-1 T37 Q39 A68 G77 Y78 Q110 W112 H187 H190 Y192 R239 R331 F357, Y3
MorR T32 S34 A62 G71 Y72 Q104 W106 H186 N189 C191 R238 R329 F355, Y3
OYE T37 M39 G72 G81 Y82 Q114 W116 H191 N194 Y196 R243 R348 F374, Y3
PETNR T26 L28 A58 G67 Y68 Q100 W102 H181 H184 Y186 R233 R324 F350, Y3
TMADH C30 G32 Y60 D69 T70 E103 W105 Y169 H172 Y174 R222 R322 I352, W3
DCR H26 G28 G58 G67 M68 Q100 L102 M161 E164 Y166 R214 R311 C341, L3 , 3
aBased upon overlays of the given PDB entries and amino acid sequence alignments by the Protein structure comparison service SSM at 
Bioinformatics Institute, http://www.ebi.ac.uk/msd-srv/ssm [56]. bP. putida II-B xenobiotic reductase A reported here. cP. fluorescens I-C xenobioti ct
B reported here. dB. subtilus probable NADH-dependent flavin oxidoreductase YqjM. eArabidopsis thaliana 12-oxophytodienoate reductase isof 3.
esculentum 12-oxophytodienoate reductase isoform 1. gP. putida morphinone reductase. hS. Carlsbergensis old yellow enzyme. iE. cloacae pent hr
tetranitrate reductase. jTIM barrel domain (residues 1-380) of methylotrophic bacterium trimethylamine dehydrogenase. kTIM barrel domain (resid -3
of E. coli 2,4-dienoyl-CoA-reductase. lSequence identity percentile, a quality characteristic of Cα alignment calculated by % sequence = (Nidet /Nali ) , wher
Nident is the number of identical residues and Nalign is the number of matched residues in the alignment. mQuality function of Cα alignment, Q = Nalign gn 
+ (r.ms.d. / R0)2 * Nres1 * Nres2), where Nalign is the number of matched residues in the alignment, Nres1 and Nres2 are the number of residues in the ct
aligned and R0 is an empirical parameter set to 3Å. nRoot mean square deviation calculated between Cα atoms of matched residues in the best 3D su si
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Figure 5.4: Structural analysis of the C-terminal domains of XenA and Xe
structural alignment of the C–terminal domains of XenB and XenA rendered as ribbons 
nB. A, The 
 
(XenA-E340, XenB-D323) in green ball and stick. Inset 2 shows a rotated and enlarged 
view of the structurally equivalent helices α8b of XenA (P351-E359) and α8a of XenB 
colored in red and blue respectively. The FMN of XenA and XenB are shown as orange 
ball and stick. Residues in the C-terminal domains that interact with the dimethylbenzene 
ring of the FMN are represented in ball and stick and colored the same as the rest of the 
protein. Inset 1 shows a rotated view of the structurally equivalent α8 helices of XenA 
(D330-V343) and XenB (A312-L326) with the residues at which the structures diverge
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(P329-Y335) with their directionality indicated by arrows colored the same as the 
protein. B, Amino acid sequence alignment covering the C-terminal domains of XenA 
and YqjM with α-helices indicated in red for XenA and cyan for YqjM and the amino 
acid sequence alignment covering the C-terminal domains of XenB, OPR-3, OPR-1, 
MorR, OYE and PETNR with α-helices indicated in blue for XenB, magenta for OPR-3, 
green for OPR-1, orange for MorR, yellow for OYE and purple for PETNR C, Structural 
alignment covering the C-terminal domains of both chains of XenA and XenB with α-
helices indicated in red and blue respectively. 
 
ring in XenA interacts with Trp357b from the domain-swapped region. The analogous 
region in XenB contains Phe334 and Tyr335, which establish a comparable hydrophobic 
environment for the dimethylbenzene ring. Another dramatic difference is apparent at 
XenA-Arg230 and XenB-His224. The former residue interacts with the FMN ribityl
chain and the N1 atom of the isoalloxazine ring. In contrast, the smaller XenB-His224 
residue allows a solvent to occupy the analogous position as the guanidino group of 
XenA-Arg230. This difference will likely influence the electrostatic environment and 
reduction potentials of the FMN in both enzymes. For example, reduction of XenA likely 
yields the FMNH- anionic species, whereas reduced XenB likely contains a neutral 
FMNH2 species. The possibility for a FMNH- anionic species in XenA is supported by 
the observation of a λmax at approximately 340 nm in the optical spectra of NADPH 
reduced XenA [2] and is indicative of an anionic reduced FMN [62]. A third region of 
significant differences occurs around XenA-Ala100 and XenB-Trp99, which also extends 
 
 XenA-Ile65, Thr66 and Tyr26 as well as XenB-Gly64, Tyr65 and Cys26. Together, to
these differences result in a set of complementary large to small substitutions and vice 
versa located above the FMN pyrimidine ring in each enzyme. The most structurally 
analogous active site residues are: a) XenA-Cys24 -vs- XenB-Thr24, b) XenA-Ala56 -vs- 
XenB-Ala55, c) XenA-Gln98 -vs- XenB-Gln97, d) XenA-His177 -vs- XenB-His172, e) 
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XenA-His180 -vs- XenB-Asn175 and f) XenA-Tyr182 -vs- XenB-Tyr177. This region of 
similarity is clustered around the FMN pyrimidine ring. Together, the results of the 
similarities and differences between the two enzymes yield active site cavities of similar 
sizes, but with a rather different distribution of hydrogen bond donors and acceptors, 
different solvent accessible surface topology, and different electrostatic surface 
8
characteristics (Figure 5.6D and E). 
 
5.5 Discussion 
5.5.1. Dimerization in Class I (β/α)8 Barrel Family of FMN-Containing Flavoenzymes 
 A number of homologs to XenA are known to exist as dimers, including OYE, 
MorR and OPR-3 [32, 33]. However, the structure of XenA exhibits a unique C-terminal 
domain swapped topology resulting in a dimer interface that is completely different than 
reported for OYE, MorR and OPR-3 (Figure 5.2A and 5.3A). XenA forms a C-terminal 
domain-swapped homodimer where the A and B subunits are crystallographic two-fold 
symmetry mates, rather than from within the same asymmetric unit. The subunits in the 
C-terminal domain-swapped dimer in XenA are arranged in such a way that their active 
sites are exposed on opposite sides of the dimer. Extensive interactions between α-helix 1 
in each monomer include a hydrogen bond between Ser43a and Ser43b and two cation-π 
interactions at either end of the α -helices 1. These two α -helices are positioned around 
the two-fold symmetry axis in a nearly perfect antiparallel orientation with respect to the 
two (β/α)  barrel normals. Interactions between the C-terminal domains of the monomers 
contribute additional binding energy by providing numerous van der Waals contacts 
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between the monomers, including Trp357(a/b) that protrudes into the adjacent active site 
of a neighboring subunit and forms part of the substrate binding pocket by packing 
against the dimethylbenzene portion of the FMN isoalloxazine ring. 
 
 
XenB. A, The backbone ribbon trace of α-helix 1 with the side chains of XenA drawn as 
interface (2σ contours, 36 –1.65 Å resolution). The hydrogen bond between Ser43a and 
1 in XenB and the 2mF
Figure 5.5: Comparison of the dimer interface in XenA with the analogous region in 
ball and stick and the 2mFo – DFc electron density superimposed with residues at the 
Ser43b are drawn as dotted lines and the cation-π interactions are labeled. B, The α-helix 
contours, 31 –2.3 Å resolution). C, The sequence alignment shows the structural elements 
bold.  
o – DFc electron density associated with Glu42 and Gln46 (2σ 
of the proteins. The residues of XenA and their analogs in the homologous are depicted in 
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The C-terminal domain swap observed in XenA has also very recently been 
reported for YqjM from Bacillus subtilis [41, 42]. However, the structure of YqjM is a 
dimer of dimers where two C-terminal domain swapped dimers form a weakly interacting 
tetramer. An analogous tetramer is observed in the crystal packing of the orthorhombic 
 data supports a biologically active 
tetramer.A sequence alignm
ation 
er. Moreover, the 
cation-π
analog to Xe ers of XenA 
ers characterized to 
date, since their prim em from the other 
members. Indeed, XenB is a m α-helix 1 
(Figure 5.5C). Nevertheless, seve are not strictly identified 
as class I (β/α)8 ain-swapping and can be divided 
to two categories. Two monomers of the phosphoenolpyruvate mutase/isocitrate lyase-
ke family [63-67] and HpcH/HpaI aldolase family [68, 69] are domain-swapped at helix 
ut utilize linker regions [70-73]. In theses cases, the additional linker domain of one 
unit cell for XenA, however, no biochemical
ent between XenA and YqjM (Figure 5.5C) shows that 
YqjM-Ser47 is analogous to XenA-Ser43. However, YqjM-Ser47 is in a conform
that will not allow for hydrogen formation with the other monom
 interaction observed in XenA is not possible in YqjM. Although YqjM does 
possess a phenylalanine residue (Phe40) at the position analogous to XenA-Trp36, the 
nA-Arg46 is YqjM-Ile50. Moreover, the domain-swapped dim
and YqjM are unique among all class I (β/α)8 barrel family memb
ary sequences and structures differentiate th
onomer due to the differences particularly at 
ral TIM-barrel proteins, which 
 barrel family members, do exhibit dom
in
li
α8. However, there is no effect on catalytic activity since the residues involved do not 
contribute to the active site. Secondly, a number of proteins such as α-isopropylmalate 
synthase from M. tuberculosis, cytosine deaminase from E. coli, alanine racemace from 
S. lavendulae and sialic acid synthase NeuB from N. meningitidis are domain-swapped, 
b
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monomer contributes to the active site of another monomer and consequently impacts 
function. 
 Some of the other class I (β/α)8 barrel family members do form dimers; however, 
the dimers of OYE, MorR and OPR-3 are very different from XenA. For example, the 
dimer observed in XenA profoundly impacts active site with a portion of the domain-
swapped chain. In contrast, the active sites in OYE, MorR and OPR-3 are independent of 
dimer formation. Moreover, these latter three enzymes must form different dimers 
because their primary sequences yield different topologies, which do not allow for 
domain-swapping, despite similar secondary structures as observed in the C-terminal 
region of XenA. In addition, the equivalent residue to XenA-Ser43 is a glutamine residue 
in all other family members including XenB (Figure 5.5C). These bulkier sidechains 
clearly prevent close association of the first α-helices as observed in XenA. 
Consequently, the dimer observed in OYE, MorR and OPR-3 is formed through entirely 
different interfaces (Figure 5.3A and B). For example, in OYE, the dimer interface 
involves α-helices 4, 5 and 6 of the (β/α)8 barrel, but in OPR-3, the interfaces is less 
extensive and involves α-helices 1 and 2 of one monomer with α-helices 3 and 4 of the 
other (Figure 5.3A). The dimer of MorR differs from OYE and OPR-3 since it does not 
only occur through interactions between α- helices 2 and 8, but also through interactions 
between the N-terminal β-sheet (Nβ1 and Nβ2) that extends over the active sites (Figure 
5.3B). This also considerably alters the conformation of both monomers with respect to 
each other when compared to the dimers for OYE and OPR-3.  
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5.5.2. Comparison of XenA and XenB to Other Family Members 






Figure 5.2). These form a 
β-sheet comprised of antiparallel and parallel strands between β-sheet 3 and α-helix 3. 
The antiparallel portion of the β-sheets are typically formed by β3b and β3c strands in all 
b lavoproteins [31]. The magnitude of their sequence and structural similarity is 
presented in Table 5.3. XenA and XenB share 31% sequence identity to each other and 
can be superimposed using 278 Cα atoms resulting in an r.m.s.d. of 1.3 Å. The structure 
of XenA more closely resembles that of YqjM [41, 42] (42 % sequence identity) where 
322 Cα atoms of one monomer overlay with an r.m.s.d. of 0.85 Å. The structure of XenB 
most closely resembles that of MorR [35] (52 % sequence identity, r.m.s.d. of 0.71 Å 
over 325 Cα atoms) and PETNR [34] (49 % sequence identity, r.m.s.d. of 0.95 Å over 
322 Cα atoms). XenA superimposed with MorR (32 % sequence identity) and PETNR 
(30 % sequence identy) resulted in an r.m.s.d. of 1.23 Å for MorR when using 266 C  
atoms, and an r.m.s.d. of 1.20 Å for PETNR when using 269 C  atoms. Not surprisingly, 
the largest differences between family members occur in the loops observed at the C-
terminal end of the (β/α) -barrel. In XenA these loops are much longer than the other 
homologs and consequently, yield a m re buried active site in XenA. Moreover, 
differences in these loop regions between XenA, XenB and other homologs, is at least 
partially responsible for the different magnitudes of solvent exposure in the active sites of 
the different family members. Indeed, XenB has a more exposed FMN cofactor than 
XenA, and the active site electrostatic surface features of these two proteins also differ. 
 Another structural difference between XenA, XenB and the homologs occurs at 
an insert of four β-strands in XenA (β3a, β3b, β3c and β3d in 
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homologs with the exception of  XenA, where it is formed by β3a and β3b. The parallel 
5.5.3. Active Site Comparison of XenA and XenB 
 Figure 5.6 shows an overview of the active sites of XenA and XenB. The 
differences and similarities between the active sites of XenA and XenB yield active sites  
portion of the β-sheet is typically formed by stands β3a and β3d, but in XenA they are 
formed the by β3c and β3d strands. Considerable diversity is observed for strands β3a 
and β3b among the family members, which serve to partially define the entrance to the 
active site in each homolog. In XenB, MorR, PETNR and OPR-3 these two β-strands 
have conformations that point away from the FMN, whereas in XenA the analogous β-
strands protrude into the active site. Consequently, they provide additional shielding of 
the FMN from bulk solvent.  
 The C-terminal end of the barrel connecting β6 and α6 is another site of 
differences between XenA and the other family members. MorR, PETNR and OYE show 
two loops that connect β5 with α5 and β6 with α6, which both protrude toward the active 
site channel. In contrast, XenA contains one larger loop that connects β6 with α6 and 
extends approximately over the analogous space, but yields an active site entrance 
channel in a more open conformation. To accommodate the larger loop in XenA, the loop 
connection β5 with α5 points away from the active site and consequently also requires 
the β6 - α6 loop to partially shield the active site form the solvent. The analogous β6 - α6 
loop region in XenB is shorter than in MorR, PETNR or OYE, and consequently yields 
an active site that is more exposed than XenA or the other homologs.  
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 Comparison of the active site differences and similarities of XenA and XenB. 
e site residues of XenA (A), XenB (B) and their FMNs drawn in purple, green 
and orange ball and stick respectively with superimposed 2mFo – DFc electron density 
associated with FMN, Trp357b and Arg230 (1σ contours, 36 –1.65 Å resolution) for 
XenA and FMN, His224, Phe334 and Tyr335 (1 σ contours, 31 –2.3 Å resolution) for
XenB. Hydrogen bonds are shown in dotted black lines. C, Divergent stereo im
ite residues and FMNs of XenA and XenB colored as in (A) and (B) respe
The electrostatic potential mapped onto the solvent exposed surface of
XenB (E) with a 1.4 Å probe radius and colored according to Poisson-Boltzm
tatic potentials from red (-0.5) to blue (0.5). 
ilar in size, but are rather different in their distribution of hydrogen bond 
donors and acceptors, solvent accessible and electrostatic surface features (Figure 5.6A 
and B and Figure 5.7). A striking difference between XenA and YqjM with the rest of the 
logs is the presence of a cysteine residue (XenA-Cys24, YqjM-Cys26) whereas all 
ily members have a threonine residue. The thiol group of XenA-Cys24 can 
hydrogen bond with FMN-O4 and is in close proximity to FMN-N5. However, the other 
logs contain a threonine residue in the analogous position. Thus the di
between an R-OH and an R-SH hydrogen bond may impact the reduction potential of the
FMN in the different family members. The presence XenA-Cys69, a residue near the 
active site and Cys24, is unique to XenA among all family members. However, the 
electron density maps, the distance between the thiol groups of Cys24 and Cys69, and 
their relative conformations suggest that a disulfide bond is not present and would require 
additional conformational changes before such a disulfide pair would form
e presence of two active site cysteine residues in XenA, it is not likely th
function analogously to those found in mitochondrial aldehyde dehydrogenase described 
l. [74]. This will be explored further in the next paper in this series [75]
 
Figure 5.7: The flavin hydrogen bonding environment for XenA and XenB. The FMN 
molecule and the protein amino acids interacting with it are shown in black and red 
respectively. Hydrogen bonds are shown in dotted green lines. Water molecules 
interacting with the flavin are shown as blue spheres. A, The flavin hydrogen bonding 
environment for XenA where the FMN is in close contact with the protein along the 
phosphate tail and the pyrimidine ring, however, the more hydrophobic end of the flavin 
ring has no direct interactions with the protein except for a van der Waals contact with 
Trp357b, which is included in this figure as well. B, The flavin hydrogen bonding 
environment for XenB where the FMN is in close contact with the protein along the 
phosphate tail and the pyrimidine ring. The structurally equivalent residues to XenA-
Trp357b are F334 and Y335. 
 
 Comparison of the electrostatic and solvent exposed surface area features for the 
ctive sites of XenA and XenB show rather dramatic differences (Figure 5.6D and E). For a
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exam
approximately 5% (~30 Å exposed to bulk solvent. In 
contrast, approxima
bind bulky substrat sistent with the 
 nitroglycerin and 
transforms over, the narrow and more 
sequestered activ ination of a terminal nitro 
 Some rface features of XenA and 
XenB result from  to XenB-His224, b) 
MNH- species in 
reduced enzyme ced FMN in XenB will be 
 FMN-N1 to stabilize an anionic 
MN-N1. In most other homologs, the analog to XenA-Arg230 is typically an 
enA and XenB active sites occur predominantly near the 
yrimid
ple, the FMN in XenB is more exposed than XenA. Indeed, XenA has 
2) of the surface area of the FMN 
tely 13% (80 Å2) in XenB is exposed. Consequently, XenB should 
e molecules more readily than XenA. This is con
observation that XenB preferentially removes the C2 nitro group from
 TNT to a greater extent than XenA [2, 3]. More
e site of XenA results in a preference for elim
group in nitroglycerin and lower affinity for TNT.  
 of the largest differences in the electrostatic su
: a) XenA-Arg230, which is structurally analogous
XenA-Arg325 versus XenB-Arg286, and c) XenA-Gly302 versus XenB-Arg286 (Table 
5.3). The presence of XenA-Arg230 likely stabilizes the anionic F
. In contrast, it is anticipated that the redu
neutral since XenB-His224 is located too far away from
species at F
arginine residue as well (Figure 5.2, Table 5.3). The residues XenA-Arg325 and XenB-
Arg286 are each located such that they serve as a counter ion for the FMN phosphate in 
their respective enzymes. However, they are donated from different positions in the three 
dimensional structures and consequently, they have different impacts on the electrostatic 
surface features of each active site. 
 Similarities between X
p ine ring of the FMN molecule. For instance, XenA-Tyr182 and XenB-Tyr177 are 
equivalent to OYE-Tyr196. Previous results from OYE suggest that OYE-Tyr196 is 
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important in the oxidative half reaction and is the proton donor [76]. Thus the analogous 
tyrosine residues in XenA and XenB are very likely to influence ligand positioning, 
especially for the oxidative half-reaction. Further similarities are noted between residues 
XenA-His177 and XenA-His180, which are equivalent to XenB-His172 and XenB-
Asn175. By analogy to previous results from studies of OYE [77], these residues are also 
likely to be important in substrate binding. Finally, XenA-Gln98 and XenB-Gln97 each 
hydrogen bond with the FMN in an analogous manner as OYE-Gln119 [78], which 
suggest similar roles in stabilizing the FMN binding site and modest influences to both 
cavity than the hydroxyl group of XenB-Tyr65. In 
reductive and oxidative half-reactions.  
 XenA-Ala100 is the structurally equivalent to XenB-Trp99. The tryptophan 
residue in XenB protrudes much further into the active site cavity and will very likely 
influence ligand binding. However, XenA-Ile65 is donated from a different position, but 
occupies an analogous region as XenB-Trp99 and consequently yields similar 
hydrophobic active site surfaces. Moreover, XenB-Gly64 is analogous to XenA-Ile65, 
which illustrates a pair of compensatory large to small and vice versa substitutions in 
these two active site cavities.  These types of alterations extend further around the active 
site to include XenA-Thr66, which is analogous to XenB-Tyr65. The latter residue 
projects a hydrogen bond donor/acceptor hydroxyl group further into the active site above 
the FMN compared to the former. Consequently, the hydroxyl group of XenA-Thr66 is 
located deeper into the active site 
addition, XenA-Tyr26 is structurally equivalent to XenB-Cys26. Although XenA-Try26 
does provide likely substrate interactions, XenB-Cys26 is most likely too far away 
contribute substrate binding interactions. On the other hand, XenB-Tyr335 and XenB-
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Phe334 line the active site cavity, which is analogous to the domain-swapped XenA-
Trp357b. However, the location of XenB-Tyr335 and XenB-Phe334 are offset with 
respect to XenA-Trp357b and XenA-Tyr26. Taken together, many of the similarities and 
differences outlined here will very likely form binding pockets for nitro groups that are 
different for each active site. Consequently, the structures of the two enzymes suggest a 
structural basis for substrate specificity, which is further addressed in the following 
paper. Those results present several crystal structures of ligand complexes and molecular 
dynamics simulations, that show how each active site does indeed bind identical 
substrates for the oxidative half-reactions in quite different manners. Moreover, the 
 
observed differences correlate well to the different product distributions observed during 
turnover. 
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6. STRUCTURAL INSIGHT INTO REGIOSPECIFIC 
REACTIONS WITH NITROCOMPOUNDS BY 









 Xenobiotic reductases A and B (XenA from, Pseudomonas putida II-B; XenB 
from Pseudomonas fluorescens I-C) catalyze the regiospecific, NADPH-dependent, 
nitrite elimination from nitroglycerin, or the reduction of aromatic nitrocompounds or 
nitroaliphatics. In the previous paper we described the crystal structures for the resting 
state of each enzyme [1]. Here we report the crystal structures of oxidized XenA, co-
crystallized with 1.6 mM metronidazole, or aerobically reduced with NADPH, as well as 
molecular dynamics simulations of substrate binding to reduced XenA and XenB. The 
structures, typically to between 1.9 Å and 1.5 Å resolution at 100 K, of oxidized and 
reduced XenA reveal that spermine binds at the si-face of the FMN, which is replaced by 
metronidazole in the oxidized enzyme. In contrast, nitroglycerin and TNT are not 
observed in the oxidized enyme active site despite several attempts by either co-
crystallization or soaking into preformed crystals of XenA. Rather, spermine, which was 
necessary for crystallization, excludes nitroglycerin and TNT from binding.  
The molecular dynamics binding analysis shows that the complexes formed with either 
nitroglycerin, 1,2- and 1-3dintroglycerin isomers, TNT, or metronidazole are consistent 
with kinetic and product analysis determined previously for these enzymes [2-4].  
 
6.2 Introduction 
 Microbial life started evolving on Earth about four billion years ago [5, 6]. But 
because life is limited to “mild” reaction conditions, the mechanistic strategies utilized in 
the biosphere are also consequently “limited”. Moreover, competition between organisms 
for natural resources has been an important factor for much of evolutionary time. Thus 
microbes have evolved to the point where they are now responsible for most of the 
transformations and flux of the chemical cycles in the biosphere [7]. The success and 
ubiquity of microbes arises from their ability to metabolize diverse compounds in 
response to changes in environmental conditions [8] and exploit chemicals introduced by 
recent human activities [9]. Xenobiotic reductases A (XenA) from Pseudomonas putida 
II-B and B (XenB) from Pseudomonas fluorescens I-C were originally purified from 
bacterial strains isolated from the contaminated, World War II era, Badger munitions 
manufacturing plant in Baraboo, WI. These strains were identified because they not only 
tolerate high concentrations of nitroglycerin that are toxic to nearly all other organisms, 
but they can also obtain all their nitrogen for growth from the xenobiotic compound [2]. 
The enzymes responsible for this process, XenA and XenB, catalyze NADPH-dependent 
reductive elimination of nitrite from nitroglycerin (TNG), resulting in the main product, 
1,2-dinitroglycerol for XenA and 1,3-dinitroglyerol for XenB (Scheme 1). Subsequent 
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turnover of these dinitroglycerols by either enzyme results in 2-mononitroglycerol and 1-
mononitroglycerol, respectively, which are not transformed further. Consequently, 
neither P. putida II-B nor P. fluorescens I-C are capable of utilizing TNG as a source of 
carbon. The nitrite eliminated by either XenA or XenB provides an adequate nitrogen 
source to support growth. XenA and XenB also show differences in their NADPH-
coupled reactions with 2,4,6-trinitrotoluene (TNT). XenB exhibits five times higher 
specific activity with TNT than XenA. Approximately 50% of the reducing equivalents 
yield nitro group reduction and the other half yields aromatic ring reduction. Aromatic 
ring reduction by two and four electrons yields the colored hydride-Meisenheimer (H-
TNT, λmax = 477 nm) and tautomers of the dihydride-Meisenheimer complex (2H-TNT, 
λmax = 449 - 492 nm ) products, respectively [4]. Thus XenB yields more ring reduction 
of TNT than XenA or any of the other characterized homologs. The nitroaliphatic, 
metronidazole, also transformed in vitro by XenA and XenB, yields the toxic nitroso- and 
hydroxylamino-derivatives. Moreover, cultures of E. coli DH5α die in the presence of 
metronidazole when they express either XenA or XenB, suggesting that XenA and XenB 
generate these toxic metabolites in vivo as well (B. G. Fox, personal communication). 
This reactivity is similar to that of pathogens that are susceptible to this class of pro-drug 
[10-12]. 
 XenA and XenB both belong to the class I (β/α)8 barrel family of FMN-
containing flavoenzymes. However, XenA is a C-terminal domain-swapped dimer, 
whereas XenB is a monomer. They each show close sequence homology to the 
prototypical member, old yellow enzyme (OYE) [13, 14], as well as to pentaerythritol 
tetranitrate reductase (PETNR) [15], morphinone reductase (MorR) [16], 1,2-
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oxophytodienoate reductase isoform 1 (OPR-1) [17] and 3 (OPR-3) [18], 2,4-dienoyl-
CoA reductase (DCR) [19] and the isoforms of trimethylamine dehydrogenase (TMADH) 
[20]. These enzymes typically proceeds via a ping-pong kinetic mechanism with an 
NADPH-dependent reductive half-reaction, but a variety of substrates are able to 
participate in the oxidative half-reaction. 
 
Scheme 6.1: Overview of reactivity of XenA and XenB. (A), XenA and XenB exhibit 
giospecific reactions with nitroglycerin, which yield different product distributions. (B) 
 
re
XenA and XenB both reduce TNT to yield nitro group or aromatic ring reduction. (C) 
XenA and XenB reduce metronidazole to yield the nitroso- and hydroxylamino 
intermediates. 
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 Here we report the crystal structures, typically to higher than 1.9 Å resolution, of 
oxidized and reduced XenA from Pseudomonas putida II-B and several ligand complexes 
formed with oxidized enzyme, along with ligand complexes of reduced XenA and XenB 
determined by molecular dynamics calculations. The crystal structures demonstrate that 
ligands bind to the si-face of the FMN and that the isoalloxazine ring experiences 
significant deviations from planarity upon reduction. The active site of XenA contains 
two cysteine residues, one of which (Cys24) hydrogen bonds with the N5 and O4 
positions of the FMN. The structural analysis indicates that this residue also forms a 
sulfenic acid (Cys-SOH), presumably in a H2O2 dependent manner. The molecular 
dynamics models were calculated because no diffraction grade crystals could be obtained 
for XenA and XenB containing ligand molecules. These calculated models are in 
agreement with kinetic and product analysis determined previously for these enzymes [2-
4]. 
 
6.3 Materials and Methods 
6.3.1. Protein Expression and Purification 
 Single crystals were obtained for XenA from Pseudomonas putida II-B or from 
the Escherichia coli expression host and was isolated as previously described [21]. 
Optical spectra were collected at room temperature with an Agilent Technologies 
(Wilmington, DE) 8453 diode array spectrometer. 
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6.3.2. Crystallization and X-ray Diffraction Data Collection 
 All XenA crystals were grown in the presence of 20 mM spermine 
tetrahydrochloride. Oxidized XenA crystals were rapidly transferred to Paratone N and 
flash frozen with liquid N2. Crystals of reduced XenA were obtained by aerobic reduction 
of XenA by placing single crystals into mother-liquor containing 117 mM NADPH. The 
yellow color of the crystals bleached within a few minutes after addition of NADPH, 
equilibrated for approximately 60 minutes, rapidly transferred to Paratone N and flash 
frozen with liquid N2. Single crystals of SeMet-enriched XenA [21] with nitroglycerin, 
TNT and metronidazole were grown via co-crystallization with 1.1 mM nitroglycerin, 1.1 
mM TNT and 1.6 mM metronidazole respectively as previously described [22]. Data 
collection statistics are presented in Table 6.1 and as previously reported [22]. 
 
Table 6.1: Data Collection Statistics. 
 
Crystal Oxidized XenA Reduced XenA Oxidized XenA 




X-ray source (beamline) SSRL (7-1) APS (22ID) APS (22ID) 
Wavelength (Å)  1.08 1.00 1.00 
Temperature (K) 100 100 100 












Resolution Range (Å) 46.9-1.92 45.9-1.51 27.1-1.73 
High resolution (Å) 1.97-1.92 1.56-1.5 1.82-1.73 
Total Observations 204523 2809833 477818 
Unique Observations 56646 119625 71741 
Rsym (%)a,b 0.062 (0.296) 0.072 (0.402) 0.082 (0.506) 
I/σ(I)a,c 9.8 (2.4) 10.5 (2.4) 7.2 (1.5) 
Completeness (%)a 98.4 (82.3) 86.7 (61.8) 88.2 (85.4) 
Multiplicitya 3.7 (2.8) 5.1 (2.9) 6.7 (4.4) 
a Numbers in parenthesis are for the highest resolution shell. b The average agreement between the 
independently measured intensities. c The root-mean-squared value of the intensity measurements divided 
by their estimated standard deviation.
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All the diffraction data sets were collected at beamline 22ID of the SER-CAT facility at 
APS, except for oxidized XenA, which was collected at beamline 7-1 of SSRL. 
 
Table 6.2: Model refinement statistics 
 
Crystal Oxidized XenAa Reduced XenA  
117 mM NADPHa
Oxidized XenA with 
1.6 mM Metronidazolea
Temperature 100 K 100 K 100 K 
Resolution range (Å) 46.9 - 1.92 45.9 - 1.51 27.1 - 1.73 
No. of reflections 50901 90272 64381 
R-factor 17.3 17.6 17.8 
R-freeb 23.1 21.0 22.6 
No. of non-H protein atoms 6423 6508 6636 
No. of residues fit 722 722 722 
No. of disordered residues 2 2 2 
No. of water molecules 681 744 948 
No. of FMN molecules 2 2 2 
Ligand molecules 2 Chloride 
5 Spermine  
6 Spermine 1 Metronidazole 
2 Chloride 
RMS deviations form ideal    
 Bond lengths (Å) 0.013 0.010 0.012 
 Bond angles (°) 1.347 1.313 1.295 
 Mean B, protein atoms (Å2) 23.3 22.6 17.5 
 Mean B, water molecules (Å2) 34.7 39.4 31.3 
 Mean B, FMN molecules (Å2) 23.5 21.0 17.5 
 Mean B, ligand molecules (Å2) 40.7 / 48.9 45.8 37.7 / 29.8 
Ramachandran analysis    
 Most favored regions (%) 88.9 89.2 88.4 
 Additional allowed regions (%) 10.4 10.0 10.9 
 Generously allowed regions (%) 0.7 0.7 0.7 
 Disallowed regions (%) 0.0 0.2 0.0 
PDB Code To be determined To be determined To be determined 
a 20mM Spermine tetrahydrochloride was present during crystallization. b Calculated with 10% of the data. 
 
6.3.3. Crystal Structure Determination 
 All datasets were solved by molecular replacement in MOLREP [23] using 
oxidized XenA [1] as the search model from which the solvent molecules and FMN were 
removed and the B-factors were set to the Wilson B (typically about 28 Å2). The space 
group is P21212 with a = 84 ± 0.3 Å, b = 157 ± 1.0 Å, c = 57 ± 0.2 Å. Model building 
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was carried out with the program O [24] and refinements were with CNS [25-27] and/or 
REFMAC5 [28]. Cross-validated, σA weighted 2mFo - DFc and mFo - DFc maps [23] were 
used to evaluate the model and correct errors. Water molecules were placed in the final 
stages of refinement with ARP/Waters and refined with REFMAC5. All other datasets 
were also solved by molecular replacement in MOLREP using the same search model. 
Data collection, phasing and refinement statistics for all datasets are presented in Table 
6.1 and 2. Validation of the models and Ramachandran analysis were done using 
SFCHECK [29] and PROCHECK [30]. Secondary structure assignments were made 
using KSDSSP [31]. The RMS difference between models was calculated with CCP4 [23] 
or Swiss-PDBViewer (v3.7) [32]. Structure figures were prepared using Swiss-
PDBViewer (v3.7), PovRay (v3.6), CCP4mg (v0.9) [33, 34] and PyMOL (v0.98). 
 
6.3.4. Calculation of Theoretical Models 
 Docking of ligand molecules into the binding pockets of XenA and XenB was 
done using the Affinity® module of the InsightII (Accelrys, San Diego, California) 
software family. Reduced XenA and XenB structures were used for the docking 
experiments with either nitroglycerin, TNT, picric acid or metronidazole as ligand 
molecules. The crystal structure of reduced XenA reported here was used where full 
length chain A was supplemented with residues B355-B361 to account for a complete 
domain-swapped active site of XenA [1]. The crystal structure of oxidized XenB was 
modified by replacing the oxidized FMN with reduced FMN from XenA. Typically two 
or three ligand orientations within the active site were used to initiate the docking 
experiments, including superimposing the nitro groups of the ligand molecules with the 
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nitro groups of either TNT or picric acid in the active site of PETNR (1vyr [35] and 1gvr 
[36]). 
 Hydrogen atoms were added to the protein residues using a pH of 7.5 for XenA 
and XenB. All crystallographic waters were removed from the coordinate file; however, 
the protein was bathed in silico in a 4 Å (XenA) or 5 Å (XenB) layer of water during the 
ligand docking simulations. Hydrogen bond donor and acceptor atoms were defined for 
both the ligand and the atoms within 7 Å of the placed ligand molecule. Torsion angles 
for the ligand molecules for which rotations were allowed were manually defined. A 
Metropolis Monte Carlo simulation (MMC) [37] was performed first using the cvff force 
field (Consistent Valence Force Field) [38] and allowing for conformational flexibility of 
both the ligand molecule and the amino acid side chains within 7 Å of the ligand 
molecule, keeping the FMN rigid in the active site during the docking calculations. 
Possible binding modes of the ligand molecule were generated by energy minimization 
using the conjugate gradient method with non-bonding interactions calculated using a 
repulsive bounded quartic potential for van der Waals interactions with coulombic 
interactions set to zero, followed by random translation and rotation to generate a new 
random ligand placement. The Boltzmann factor was used as the criteria for structure 
acceptance [37] and was calculated using equation 1, 














where V(rN) is the potential energy (V) of each position (rN) for N particles in the system, 
kB is the Boltzmann constant and T is the temperature. Up to twenty accepted structures 
were generated and the best ten were kept. Following the Metropolis Monte Carlo 
simulation, simulated annealing (SA) was used to refine each of the best structures. The 
B
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electrostatic interactions in the SA were calculated using the cell multipole method [39].  
Finally, the ligand-receptor interaction energies for each accepted and minimized 
structure were calculated. In particular, the total energy of the protein-ligand complex, 
the energies of the protein and the ligand individually and the interaction energy between 
the protein and the ligand were calculated. The protein-ligand interaction energy was 
separated into the van der Waals and electrostatic contributions. These energies can be 
used to compare the docked structures to each other. However, the force field does not 
include desolvation terms. Affinity  also does not allow for any global conformational 
changes. These deficiencies must be considered when comparing energies between 




6.4.1. Crystal Structure of Oxidized XenA at 100 K 
 The structure of XenA at cryogenic conditions was determined to support direct 
comparisons with structures determined at 283 K, and cryogenic structures of the 
enzyme-metronidazole complex or NADPH reduced enzyme. The final model for 
oxidized XenA had an R-factor of 17.3% and an R-free of 23.1% with data between 47 – 
1.92 Å resolution (Table 6.2). The typical electron density at an FMN is shown in Figure 
6.1A. The 100 K and 283 K structures of XenA overlay with a r.m.s.d. of 0.22 Å using all 
residues in each protein (361 Cα). The largest difference between the two structures is the 
observation of five spermine molecules in the low temperature structure. Spermine 
tetrahydrachloride (20 mM) was present in the crystallization conditions for the structure  
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Figure 6.1: Overview of the active sites for the three crystal structures of XenA reported 
here. The protein residues are shown as ball and stick drawings colored by atom type, 
where carbon, nitrogen and oxygen are grey, blue and red, respectively. The bonds for the 
FMN, Trp357b, ligand molecules, spermine molecules are colored in orange, red and 
green, respectively. The divergent stereo drawings show 1σ contours for the 2mFo - DFc 
electron density maps around the flavin and ligand molecules. The stereo portion of the 
figure is parallel to the isoalloxazine ring. The insets show the 1.5σ contours for the 2mFo 
- DFc electron density maps around the flavin. (A) Oxidized XenA determined to 1.92 Å 
resolution at 100 K. (B), Reduced XenA at 1.51 Å resolution. (C) The XenA-
metronidazole complex at 1.73 Å resolution. 
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determined at 283 K as well, but they were not observed in the electron density maps, 
presumably due to disorder at high temperature. In contrast, at low temperature the five 
spermine molecules fit the observed electron density with an average thermal factor of 
approximately 49 Å2. Each active site of the XenA dimer contains an ordered spermine 
molecule (Spm501 and Spm502) and a chloride ion (Cl1 and Cl2). The chloride ion is 
located above the pyrimidine ring on the FMN si-face. Spermine501 and 502 are in U-
shape configurations with the central portion located above the FMN dimethylbenzene 
rings (Figure 6.1A). They also make van der Waals contacts with Lys105, His180, 
Tyr182, Phe268, Trp277, Trp301, Arg325, and Trp357a/b (the domain-swapped residue 
in the active site). The three other spermine molecules are observed at the domain-
swapped interface (Figure 6.2A and 6.2B). Spermine504 is located in a cleft created by 
the loop between helices α8a and α8b of chain B, with the C-terminal part of α-helix 1 of 
chain B, and the N-terminal part of α-helix 1 of chain A (Figure 6.2B). The cleft provides 
several van der Waals contacts with Arg46b, Asn34a Trp36a, Met27a, Pro351b, Pro353b, 
Ala90b and Ala91b. Spm504 forms hydrogen bonds with several waters molecules, but 
not with protein residues. The spermine 505 molecule binds to the opposite chain in the 
symmetry related position of Spm504. One spermine molecule, Spm503, is located at 
special position (½, y, ¾) where the crystallographic symmetry axis relates chain A to 
chain B of the domain-swapped dimer. This ligand forms three hydrogen bonds with 
solvent molecules and one hydrogen bond with Ala326-O. It also makes van der Waals 
contacts with Trp333, Phe336, Ala326 and Ala329 (Figure 6.2C). Moreover, four nearby 
anionic groups, two from each subunit, establish a complementary electrostatic 
environment to the Spm503 polyvalent cation (Figure 6.2D). The sidechains of  
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Figure 6.2: Five spermine molecules are observed in the structure of XenA at 100 K. (A) 
A ribbon drawing of the XenA dimer with FMN, Cl- and spermine molecule shown. 
Subunit A is colored by secondary structure and subunit B is colored blue. The FMN has 
orange bonds, the Cl- ions are magneta spheres, the active site spermine molecules 
(Spm501 and 502) are colored with grey carbon atoms, whereas the spermine ligands 
associated with the two-fold symmetry are colored with carbon atoms as either green 
(Spm503) or cyan (Spm504 & Spm505). (B) A ribbon drawing of the domain-swapped 
interface of XenA with the α-helices colored in red showing the spermine molecules 
(Spm503, 504 and 505) in green ball and stick overlayed with their 1σ contours for the 
2mFo - DFc electron density maps. (C) All protein residues are represented by ball and 
stick and are colored by atom type. The spermine molecule is colored green and the 
flavin is colored orange. (D), The same view as in (C) using the same color scheme but 
with the FMNs drawn as spheres. All protein residues are represented by their 
electrostatic potential surfaces and colored with -0.5, 0, 0.5 as red, white and blue 
respectively.  
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Asp330a/b are within van der Waals contact with the Spm530-N5 and Spm503-N10 
atoms, however, the FMN phosphate groups in each subunit are further away. 
Therefore,ionic interactions with this spermine molecule probably help stabilize the 
domain-swapped dimer in XenA. 
 
6.4.2. Crystal Structure of Reduced XenA at 100 K 
 The atomic model of reduced XenA was refined to a final R-factor of 17.6 and an 
R-free of 21.0 % (Table 6.2). Figure 6.1B shows a representation of the active site σA 
weighted 2mFo - DFc density for the reduced FMN at 1.51 Å resolution. The structures of 
oxidized and reduced XenA overlay with a r.m.s.d. of 0.23 Å using 361 Cα. The most 
notable difference between the two structures is the conformation of the FMN. Whereas 
oxidized FMN contains a planar isoalloxazine ring, the two-electron reduced FMN shows 
an approximate 16º bend along the FMN N5-N10 axis. The structure accommodates the 
alternative FMN conformation by allowing the movement of the dimethylbenzene portion 
of FMN. The electron density maps indicate that the chloride ion in the oxidized structure 
has been replaced by a water molecule in the reduced FMN structure. This water 
molecule forms hydrogen bonds to His177, His180 and the N1 and N3 atoms of the 
FMN. There are no qualitative changes in the hydrogen bonding interactions between 
protein and FMN. 
 The active sites of the two subunits in the asymmetric unit are not identical to 
each other. For example, the electron density maps for subunit A of reduced XenA 
suggest that both Cys24 and Cys69 are oxidized to cysteine sulfenic acids (Cys-SOH). 
The temperature factors for the hydroxyl oxygen atoms are 33 and 31 Å2 with 
  141 
occupancies of 0.5 for both Cys24-SOH and Cys69-SOH, respectively (Figure 6.3A). In 
contrast, the electron density for subunit B suggest that Cys69 is a thiol and that Cys24 is 
in two conformations (Figure 6.3B). In the first conformation, the Cys24 thiol group 
hydrogen bonds with the O4 atom of the FMN. This contrasts with the hydrogen bonding 
pattern in subunit A, in which the amide nitrogen of Cys24-SOH interacts with FMN O4. 
Indeed, the conformation of the Cys24-SOH side chain in subunit A does not allow 
hydrogen bonding with the FMN-O4 atom. In the second conformation, the Cys24-SH 
group points toward the sulfhydryl group of Cys69; however, the 3.8 Å distance between 
them does not allow for a disulfide bond. Instead, Cys24-SH hydrogen bonds to the 
backbone nitrogen of Tyr26. Conformation one and two are modeled with occupancies of 
0.6 and 0.4, respectively, and both have temperature factors of approximately 18 Å2 for 
the side chain atoms. 
 Neither NADPH nor NADP+ is observed in either active site of reduced XenA, 
but instead a spermine molecule in a U-shape configurations with the central portion 
located above the FMN dimethylbenzene rings is observed in both active sites (Figure 
6.1B) in addition to spermine molecules located in the domain-swapped interface. The 
presence of spermine does not prevent soaking of NADPH into the active site to produce 
a reduced FMN, but no product (NADP+) remains, most likely due to the low affinity of 
reduced FMN for NADP+. 
 
6.4.3. Crystal Structure of the Oxidized XenA-Metronidazole Complex at 100 K 
 Oxidized XenA was co-crystallized with 1.6 mM metronidazole that yielded a 
dataset to 1.73 Å resolution. The atomic model was refined to a final R-factor of 17.8%  
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and an R-free of 22.6% (Table 6.2). The structures of oxidized XenA and oxidized XenA-
Metronidazole overlay with a r.m.s.d. of 0.23 Å using 361 Cα atoms. Surprisingly, 
spermine molecules are not observed in the structure. Figure 6.1C shows an example of 
the σA weighted 2mFo - DFc electron density for the FMN and the metronidazole in 
subunit A. However, differences between the active sites of the two subunits in the 
asymmetric unit are observed. For example, in subunit A, the metronidazole is bound 
parallel to the FMN si-face and modeled with an occupancy of 0.5. In addition, a full-
occupancy chloride is located above the FMN pyrimidine ring. The nitro group from 
metronidazole is not positioned above the FMN N5 atom, suggesting a non-catalytic 
orientation. Rather the nitro group is approximately 6 Å from the FMN-N5 atom and 
positioned above the dimethylbenzene ring. In addition, electron density for Cys69 
suggests that it is oxidized to Cys-SOH, but in two distinct conformations with 
occupancies of 0.5 for each. Both conformations have temperature factors of ~19 Å2. In 
contrast, Cys24 is present in its thiol form and hydrogen bonds to the O4-FMN (Figure 
6.3C). 
 In contrast to subunit A, neither a metronidazole ligand nor a chloride ion is 
observed in the active site of subunit B. Instead, the 16º bend observed in the 
isoalloxazine ring suggests that the FMN has been photo-reduced by the synchrotron x-
ray irradiation. In addition, both Cys24 and Cys69 have been oxidized to Cys-SOH. The 
Cys24-SOH hydroxyl group is oriented so that it can hydrogen bond with both the N5 
and O4 atoms of the FMN. This is supported by 2mFo-DFc electron density connecting 
the Cys24-SOH with the N5 of FMN (Figure 6.3D). The temperature factor for Cys24-
SOH is ~ 18 Å2. Similar to that observed in NADPH reduced XenA, the Cys69-SOH 
  143 
 
Figure 6.3: Overview of the differences occurring between the active sites cysteines of 
different subunits. (A), The active site cysteines of reduced XenA showing subunit A 
with an oxidized Cysteine-sulfenic acid (Cys69) and (B), subunit B with Cys24 
portraying two distinct conformational sites. (C), The active site cysteines of native XenA 
complexed with metronidazole showing subunit A with an oxidized Cysteine-sulfenic 
acid (Cys69) in two conformations and (D), subunit B with oxidized Cysteine-sulfenic 
acid for Cys24 and Cys69 (two conformations). 
 
  144 
occurs in two conformations with occupancies of 0.5 each and temperature factors of 
approximately 15 Å2. A second dataset was collected from another oxidized XenA co-
crystal with metronidazole to 1.49 Å resolution. The atomic model was refined to a final 
R-factor of 19.2% and an R-free of 23.4% (Supplementary Information (§6.8), Table 
6.S1). However, no metronidazole was observed in either active site. Rather, the active 
site in subunit A is consistent with reduced FMN as can be judged from the characteristic 
~ 16º bend along the FMN N5-N10 axis, accompanied by a water molecule above the 
pyrimidine ring (Supplementary Information (§6.8), Figure 6.S1C), while the active site 
in subunit B contains an oxidized FMN accompanied with a chloride ion (Supplementary 
Information (§6.8), Figure 6.S1D). In both active sites, Cys24 is present in its thiol form 
in two different conformations with partial occupancies of ~ 0.6 and ~ 0.4, while Cys69 
occur as a Cys-SOH in two conformations with partial occupancies of ~ 0.5 for both 
conformations. Their B-factors are ~ 22 and ~ 24 Å2 and are similar to those discussed 
above. In the second dataset for the XenA metronidazole complex, four spermine 
molecules could be placed, however, not in the active sites. They are in similar 
orientations as previously discussed. 
 
6.4.4. Oxidized XenA with Nitroglycerin or TNT 
 Several additional ligand complexes were studied through co-crystallization of 
oxidized XenA, including nitroglycerin and TNT. The best dataset for XenA with 1.1 
mM nitroglycerin diffracted to 1.8 Å resolution. The final model for this dataset refined 
to an R-factor of 19.1% and an R-free of 23.6% (Supplementary Information (§6.8), 
Table 6.S1). However, nitroglycerin was not observed in either active site. Instead, a well 
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defined spermine molecule (B-factors of approximately 49 Å2) bind in the entrance to 
both active sites (Supplementary Information (§6.8), Figure 6.S1A). The best dataset for 
a co-crystal of oxidized XenA with 1.1 mM TNT diffracted to 2.1 Å resolution. The final 
model refined to an R-factor of 19.8% and an R-free of 25.1% (Supplementary 
Information (§6.8), Table 6.S1). TNT was not observed in either active site; however, the 
electron density maps indicated that spermine molecules occupied the active sites 
(Supplementary Information (§6.8), Figure 6.S1B). Consequently, in oxidized XenA 
crystals the 1.1 mM nitroglycerin and TNT ligands do not displace spermine, which is 
present at 20 mM in the crystals. Unfortunately, attempts to reduce the spermine or 
increase the nitroglycerin concentration in the crystallization conditions did not yield 
crystals suitable for high resolution diffraction studies. Oxidized XenB also failed to 
yield useful crystals by either co-crystallization or by soaking nitroglycerin or TNT 
ligands into preformed crystals. Therefore, crystal structures of nitroglycerin or TNT 
complexes of either XenA or XenB, albeit in the incorrect oxidation state, are not 
available at this time. 
 
6.4.5. Molecular Dynamics R-NO2 Ligand Docking to Reduced XenA and XenB 
 To better understand the regiospecific oxidative half-reactions of XenA and 
XenB, molecular dynamics ligand-docking calculations were obtained for reduced XenA 
and XenB with nitroglycerin, TNT, picric acid and metronidazole ligands. For XenA, the 
starting coordinates were based upon the crystal structures of reduced XenA and/or the 
oxidized XenA-metronidazole complex reported here. We also used the reduced FMN 
from the NADPH-reduced XenA structure to estimate a structure of reduced XenB based 
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on the assumption that no qualitative changes occur upon reduction of the FMN in XenB 
in hydrogen bonding interactions between protein and FMN or protein sidechain 
positions and conformations. This assumption is supported by the observation that this is 
indeed the case for reduction of XenA [1], OYE [13] and PETNR [15]. For these 
proteins, the only notable differences upon reduction are the replacement of an anion 
above the pyrimidine ring in the oxidized active site with a water molecule in the reduced 
active site and the increased butterfly bending of the isoalloxazine ring around the N5-
N10 axis in the reduced form which primarily involves movement of the 
dimethylbenzene portion of the FMN. The electrostatic potential surface features for the 
FMN in oxidized XenA, reduced XenA (FMNH-) and reduced XenB (FMNH2) are 
shown in Figure 6.4. The presumed FMNH- or FMNH2 species are based on the 
observation that XenA-Arg230 will likely stabilize the reduced anionic species, whereas 
XenB-His224 does not. In addition, the possibility for a FMNH- anionic species in XenA 
is supported by the observation of a λmax at approximately 340 nm in the optical spectra 
of NADPH reduced XenA [2] and is indicative of an anionic reduced FMN [40]. To 
reduce potential bias, a number of starting R-NO2 ligand orientations were explored, as 
discussed in the methods section above. The binding pocket was defined as comprised of 
all atoms within 7 Å of the ligand complex and was allowed to vary during the molecular 
dynamics simulations. A Monte Carlo simulation was performed first, from which at 
most ten structures were subjected to simulated annealing. The family of protein-ligand 
structures were ranked by relative total energy among the family members to yield the 
best docked conformations. Figure 6.5 show the best model obtained for 1,2,3-
trinitroglycerin (TNG) and the other nitroester isomers in the active sites of XenA and 
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XenB. Ligand complexes for reduced XenA and XenB with TNT, picric acid and 
metronidazole are shown in Figure 6.6. Several overlays of the two enzyme-ligand 
complexes are shown in Figure 6.7, which permit direct comparisons of the results. 
 
 
Figure 6.4: The electrostatic potential mapped onto the solvent exposed surfaces of FMN 
in oxidized XenA (A), FMNH- in reduced XenA (B) and FMNH2 in oxidized XenB (C). 
The solvent exposed surface was determined with a 1.4 A probe radius and colored  
according to Poisson-Boltzmann electrostatic potential from red (-0.5) to blue (0.5). The 
protein residues are shown as ball and stick with C, N, O and S colored grey, blue, red 
and yellow respectively. Hydrogen bonds are drawn as green dotted lines. 
 
 TNG bound to reduced XenA and XenB occurs above the si-face of the FMN, and 
is stabilized by numerous protein-ligand hydrogen bonds in each case (Figure 6.5A and 
6.5D). For example, XenA binds TNG in the active site so that a terminal nitro group is 
approximately 3.2 Å from the FMN-N5 atom. This conformation is stabilized by 
hydrogen bonds between every nitro group and several active site residues. 
Consequently, one of the terminal nitro groups is ideally positioned for elimination. In 
contrast, reduced XenB binds TNG with the C2 nitro group located nearest the C4a of the 
flavin, and only 3.5 Å separation between the ligand and the isoalloxazine ring. 
Therefore, the ligand orientation in XenB appears ideal for elimination of the internal 
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nitro group from TNG. Thus the predicted models correlate perfectly with the kinetic 
preferences observed by steady-state turnover of TNG by each enzyme.  
 
Figure 6.5: Overview of the active sites of calculated structures for reduced XenA and 
enB with nitroglycerin isomers. All protein residues are shown as ball and stick 
 
X
drawings colored by atom type. The FMN, Trp357b and nitroglycerin are colored in 
orange, red and green, respectively. Hydrogen bonds between ligand and protein are 
indicated as dotted black lines. (A) Reduced XenA with TNG; (B) reduced XenA with 
1,2-DNG and 1,3-DNG; (C) reduced XenA with 1-MNG and 2-MNG; (D) reduced XenB 
with TNG; (E) reduced XenB with 1,2-DNG and 1,3-DNG; (F) reduced XenB with 1-
MNG and 2-MNG. 
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 Theoretical models were also calculated for 1,2-dinitroglycerin (1,2-DNG), 1,3-
dinitroglycerin (1,3-DNG), 1-mononitroglycerin (1-MNG) and 2-mononitroglycerin (2-
MNG) with XenA (Figure 6.5B and 6.5C) or XenB (Figure 6.5E and 6.5F). These ligands 
represent the products of nitrite elimination from TNG by either enzyme and are also 
slower substrates for NADPH-dependent nitrite elimination [2]. In every case there are 
several protein-ligand hydrogen bonds, but most often there are fewer than predicted in 
the TNG complexes. The predicted models are also consistent with the observed 
regiospecific reactions of the two enzymes. For example, XenA is likely to bind 1,3-DNG 
better than 1,2-DNG as deduced by a larger number of predicted hydrogen bonds in the 
former than the latter complex (Figure 6.5B). The theoretical models calculated for XenA 
with 1-mononitroglycerin or 2-mononitroglycerin predict fewer protein-ligand hydrogen 
bonds, but also yield larger distances between the R-NO2 group and the FMN N5 atom 
(>4Å). Moreover, the nitro group points away from the flavin, and consequently, the 
models suggest that the reduced enzymes will not bind the ligands to promote nitrite 
elimination (Figure 6.5C). Models calculated for XenB with 1,2-DNG and 1,3-DNG also 
yield ligand conformations that are stabilized by numerous hydrogen bonds. However, 
only the XenB complex with 1,2-DNG yields an orientation with the C2 nitro group 
above the C4a of the FMN, which suggests a reactive complex (Figure 6.5E). Finally, 
ligand complexes calculated for XenB with 1-MNG and 2-MNG also show the ligand 
molecule located greater than 4 Å above the si-face of the flavin ring, and the nitro group 
points away from the FMN-N5 atom (Figure 6.5F). Together, all the molecular dynamics 
binding models are remarkably consistent with the regiospecific reactions observed for 
each enzyme by steady state assays in vitro. 
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 As shown in Figure 6.6, reduced XenB binds TNT, picric acid and metronidazole 
approximately parallel to the FMN to a larger degree than does XenA. For example, the 
. This result is consistent with the 
 4 Å above the si-face of the FMN and hydrogen bonds with 
XenB-TNT complex shows that every TNT ligand orientation in the active site is nearly 
parallel to the FMN ring (Figure 6.6B). In contrast, the XenA-TNT complexes reveal that 
most of the time, the TNT ligands bind almost perpendicular to the FMN. Indeed, only a 
minority of the XenA-TNT complexes yield a ligand more parallel to the FMN (Figure 
6.6A). Moreover, each orientation of TNT in the XenB active site places a nitro group 
approximately 3.7 Å from the FMN-N5 atom, and approximately 3.3 Å from the nearest 
aromatic carbon. Consequently, XenB should reduce either the nitro group or the 
aromatic ring of TNT with similar capacity and much more readily than XenA. This is in 
fact what is observed by steady state assays in vitro. 
 Picric acid is predicted to form similar complexes as obtained with TNT for both 
reduced XenA and XenB (Figure 6.6C and 6.6D)
observation that picric acid is a substrate for the oxidative half-reaction, but reacts at 
different rates with both enzymes (B. G. Fox, personal communication). These types of 
parallel aromatic ligand-flavin orientations also suggest that they should elicit a charge-
transfer transition at long-wavelength that derives from the electron rich ligand and the 
oxidized isoalloxazine ring within the enzyme. The p-chlorophenol complex with 
oxidized XenA does, indeed yield such a spectrum (Figure 6.8). Thus the molecular 
dynamics simulations have spectroscopic support as well as nearly complete correlation 
with catalytic studies [2, 4]. 
 The molecular dynamics simulations show that reduced XenA binds 
metronidazole approximately
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Lys105, Tyr26 and Tyr182. (Figure 6.6E). The lowest-energy conformation (Figure 6.7E, 
red) places the nitro group 5.8 Å away from the FMN-N5 atom and pointing toward the 
His180-Cα atom. In crystal structure for the oxidized XenA-metronidazole complex, the 
ligand molecule is located approximately parallel to the FMN, but is only about 3 Å 
away. However, the nitro group is located ~ 5.5 Å from the FMN-N5 atom suggesting it 
is too far away for reaction. Therefore, neither the crystal structure nor the docked 
conformations are likely mimics of a complex that yields R-NO2 reduction. The predicted 
lowest-energy structure for the reduced XenB-metronidazole complex also places the 
ligand approximately 4.5 Å above the FMN, where it is predicted to hydrogen bond with 
the side chains of Thr24, Asn175 and Tyr335 (Figure 6.6F). The nitro group is 
approximately 6.5 Å away from the FMN-N5 atom, but is orientated away from the FMN 
(Figure 6.6F and 6.7D, blue) Consequently, this conformation is not likely to result in 
nitro group reduction either. However, a reasonable conformation that reflects a 
catalytically relevant complex for both XenA (Figure 6.7E, green) and XenB by 
molecular dynamics simulations is less than 5% higher in energy than the ground-state 
structures. These structures place the R-NO2 moiety only 3.5 Å from the FMN-N5 atom 
and are stabilized by hydrogen bonding with the side chains of Cys24, Tyr182 and the 
His180-O and FMN-N5 atoms in XenA and the sidechains of Thr24, Asn175 and Tyr335 
in XenB. Thus the second-lowest energy conformers appear to mimic complexes that 
could provide the sensitivity phenotype observed by in vivo assays with whole cells 
expressing either XenA or XenB (B.G. Fox, personal communication). 
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Figure 6.6: Overview of protein-ligand interactions for TNT, picric acid and 
metronidazole complexes with reduced XenA and XenB. All protein residues are shown 
as ball and stick drawings colored by atom type. The FMN and ligand molecules are 
colored in orange and green, respectively. Hydrogen bonds between ligand and protein 
are indicated as dotted green lines. The insets in each figure shows all conformations 
calculated for each ligand complex in a view approximately parallel to the isoalloxazine 
ring, with the exception of B and D, which are shown as perpendicular views. (A) 
Reduced XenA with TNT; (B) Reduced XenB with TNT; (C) Reduced XenA with picric 
acid; (D) Reduced XenB with picric acid; (E) Reduced XenA with metronidazole; (F) 
Reduced XenB with metronidazole. 
 
6.5 Discussion 
6.5.1. Oxidized Versus Reduced XenA and XenB 
 The FMN binds to the C-terminal end of the (β/α)8 barrel structural motif in both 
XenA and XenB. The si-face is exposed to bulk solvent and the electron density for the 
oxidized isoalloxazine ring yields a planar ring system in each case. However, after 
reduction, the ring system in XenA exhibits a 16º bend along the N5-N10 axis (Figure 
6.1B). Similar alterations are observed for several homologs, including OYE (15º, 1oyc, 
[13]), PETNR (12º, 1h63, [15]) and YqjM (10º, 1z48, [41]) and most likely XenB as 
well. There are almost no observable hydrogen bonding differences between the oxidized 
and reduced structures of XenA. The guanidino group of XenA-Arg230 is only 2.9 Å 
from the FMN-N1 atom, where the positive charge likely stabilizes the anionic FMNH- 
species (Figure 6.4B). In contrast, XenB-His224, which is structurally analogous to 
XenA-Arg230, does not likely provide equivalent stabilization of an anion (Figure 6.4C). 
Consequently, a neutral FMNH2 species is predicted in reduced XenB, which highlights 
an important difference in the active site electronic environment of the two homologs. 
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 Small changes aroung the FMN do occur in addition to major changes such as the 
16º bend along the N5-N10 axis and the replacement of a chloride ion for a water 
molecule. In XenA, the Cys24-SH and Ala56-NH atoms hydrogen bond to the FMN-O4 
atom, whereas the Cys24-NH atom hydrogen bonds to the FMN-N5 atom. Analogous 
protein-FMN interactions are formed in XenB by Thr24-OH, Ala55-NH and Thr24-NH. 
The FMN ribityl chain in XenA is anchored by interactions with main chain atoms of 
Pro22 and sidechain atoms of Arg230 and Trp301. The Pro22-O atom is approximately 
equidistant to the FMN-N5 (3.3 Å) and FMN-N1 (3.4 Å) atoms. However, as a result of 
the bend along the FMN N5-N10 axis after FMN reduction, the FMN-N5 and FMN-N1 
atoms are 3.7 Å and 3.3 Å from the Pro22-O atom, respectively, potentially providing 
additional stabilization to the reduced FMN. Similar subtle changes are anticipated in the 
structure of XenB.  
 Another striking difference between XenA and other homologous, with the 
exception of YqjM, is that the XenA-FMN-O4 atom does not hydrogen bond to a 
threonine residue, but rather to Cys24 instead. Adjacent to XenA-Cys24 is Cys69; 
however, the distance between the two thiol groups (4.5 - 4.7 Å in the oxidized dataset at 
100 K) is too large to form a disulfide bond. In the structure of NADPH reduced XenA, 
the electron density for Cys24 in subunit B suggests that it adopts two conformations, 
each with partial occupancy of 0.5 (Figure 6.3B). The thiol group in the first 
conformation likely forms hydrogen bonds with the FMN-O4 atom (2.9 Å) and the FMN-
N5 atom (3.6 Å). In contrast, the Cys24-SH atom in the second conformation is toward 
the Cys69-SH atom and the side chain of Tyr26. In all the molecular dynamics 
simulations, XenA-Cys24 adopts the latter conformation with the thiol group toward the 
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Cys69-SH atom, but the distance remains to large to form a disulfide bond. In contrast, 
the electron density for both these cysteine residues in subunit A is consistent with 
oxidation to cysteine sulfenic acids (Cys-SOH) with occupancies of 0.5. Moreover, a 
potential second orientation of Cys24-SOH could allow for a hydrogen bond to Cys69-
SOH at a distance of apprimately 2.5 Å (data not shown). Reduced FMN is capable of 
reacting with molecular oxygen at the FMN-C4a atom. Typically, molecular oxygen is 
present in the aqueous solutions at approximately 280 μM. In the absence of a suitable R-
NO2 or organic substrate molecules for the oxidative half-reaction, the reduced flavin in 
XenA and XenB reacts slowly with O2 to produce hydrogen peroxide (H2O2) [2]. 
Hydrogen peroxide is a reactive oxygen intermediate and often oxidizes metal centers 
and/or amino acid side chain residues in many proteins [42-48]. However, the thiolate 
moiety from a deprotonated cysteine residue is particularly susceptible to oxidation to the 
sulfenic acid (Cys-SOH), cysteine-sulfenic acid (Cys-SOH) or cystein-sulfonic acid (Cys-
SO3H) states [42, 48]. Thus in several structures of XenA, Cys24 and Cys69 appear to be 
oxidized by H2O2 generated in situ by reaction with FMNH- generated by either 
incubation with NADPH or by photoreduction via X-ray irradiation.  
 
6.5.2. Ligand Binding to Oxidized and Reduced XenA 
 In order to prevent turnover, oxidized XenA was co-crystallized with a variety of 
substrate molecules for the oxidative half-reaction. However, in all but the metronidazole 
complex, spermine was observed in the active site, rather than the ligand utilized for the 
co-crystallization. The refined XenA structures suggest a rationale for the requirement to 
include spermine in the crystallization buffers since it also stabilizes several crystal 
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contacts. Thus multiple spermine ligands are found in cryogenic crystals of XenA 
including oxidized and reduced XenA, and co-crystals with TNG and TNT, but not in the 
oxidized XenA-metronidazole co-crystal. Most often, the XenA active site entrance is 
almost completely blocked by spermine, which thus prevents access of most of the R-
NO2 molecules. Moreover, the active site spermine molecules (Spm501 or Spm502) bury 
more than 71% (~21 Å2) of the FMN solvent exposed surface area compared to the 
ligand-free active sites. Nevertheless, metronidazole is able to bind to at least one of the 
oxidized active sites in XenA, despite the presence of spermine in the crystallization 
conditions. However, the orientation of the metronidazole R-NO2 group with respect to 
the FMN-N5 atom suggests that the observed complex does not mimic a potentially 
reactive species. The R-NO2 nitrogen atom is located 5.6 Å from the FMN-N5 atom and 
is pointing toward the FMN ribityl chain with its imidazole ring located above the 
dimethylbenzene ring (Figure 6.1C and 6.3C). Indeed, the molecular dynamics 
simulations yield several alternative orientations with reduced XenA and some of these 
mimic the conformation necessary to yield catalysis. For example, approximately half of 
the structures calculated for reduced XenA with metronidazole place the R-NO2 group in 
close proximity to the FMN-N5 atom (3.5 – 3.9 Å), which would be expected to facilitate 
hydride transfer between the FMNH- species and the metronidazole (Figure 6.6E, inset). 
 
6.5.3. Regiospecific Elimination of Nitrite from Nitroglycerin by XenA and XenB 
 To explore the structural basis of the regiospecific transformations observed for 
XenA and XenB with respect to nitroglycerin [2], a series of molecular dynamics models 
of reduced XenA or XenB with either nitroglycerin (Figure 6.5A and 6.5D), 1,2- or 1,3-
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ditroglycerin (Figure 6.5B and 6.5E), and 1- or 2-nitroglycerin (Figure 6.5C and 6.5F) 
were evaluated. The reactive intermediate, which is intractable for crystallographic 
analysis, most likely facilitates reductive nitrite elimination via hydride transfer from the 
reduced FMN-N5 atom position to the R-NO2 substrate. Thus we anticipate that a hydride 
attacks the nitrogen atom of the nitro group on the nitroester substrate (R-O-NO2), 
resulting in release of nitrite, R-OH and the regeneration of the oxidized flavin. To mimic 
the catalytic complex therefore, these atoms must be in close proximity in one or more of 
the final molecular dynamics simulation models. As described in the following 
paragraphs, our molecular dynamics simulations suggest that structural differences 
between XenA and XenB influence ligand binding in the active site and correlate with the 
regiospecific kinetic bias exhibited by the two enzymes. 
 Steady-state kinetic analysis demonstrates that XenA exhibits a kinetic preference 
for elimination of a terminal nitro group, rather than the C2 nitro group [2]. For example, 
XenA produces approximately 2-fold molar excess of 1,2-DNG relative to 1,3-DNG, and 
nitrite elimination of 1,2-DNG shows 1.3-fold selectivity for a terminal nitro group. In 
the ten-best structures obtained for the reduced XenA-TNG complex, eight of them 
placed a terminal nitro group in an appropriate location to promote nitrite elimination. 
Moreover, these conformers all differed by only approximately 12% in their calculated 
energy. Only two of the ten structures resulted in the C2 nitro group nearest the reduced 
FMN-N5 atom moiety. Similar results were obtained for the two isomers of DNG bound 
to reduced XenA; seven out of ten structures yield a terminal nitro group above the 
flavin. However, neither the 1- or 2-nitroglycerol complexes resulted in a catalytically 
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relevant complex (Figure 6.5C), which is consistent with both isomers failing to serve as 
substrates for the oxidative half-reaction under steady-state conditions.  
 XenB exhibits selectivity for removal of C2 nitro group by 4.6- and 2.4-fold from 
nitroglycerin and 1,2-DNG, respectively. The structural basis for the selectivity bias is 
not as clearly established by the XenB molecular dynamics simulations compared to 
XenA. We anticipate that the more accessible active site environment of XenB and 
neutral FMNH2 species in the reduced enzyme are at least partially responsible. The 
calculations for nitroglycerin complexes with XenB resulted in eight docked 
conformations with energies that differed by less than 19%. Three of the best eight 
nitroglycerin conformations place the C2 nitro group above the FMN-N5 atom (Figure 
6.5D), whereas the other five conformations place a terminal nitro group in close 
proximity to the FMN-N5 atom. Similarly, seven conformations of 1,2-DNG bound to 
XenB differed by less than 7% in energy, and two of these have the C2 nitro group 
nearest the FMN-N5 atom (Figure 6.5E). The XenB models with 1-MNG and 2-MNG 
revealed both ligands in an unproductive binding mode similar to the analogous 
complexes with XenA (Figure 6.5F).  
 
6.5.4. Regiospecific Reduction of TNT or Picric Acid by XenA and XenB 
 Reduction of the aromatic ring or one of the nitro groups of TNT, presumably by 
hydride transfer, yields a variety of products and has been documented by both XenA and 
XenB [3, 4]. For example, both enzymes will reduce the aromatic ring of TNT by two or 
four electrons, although XenB shows five times higher specific activity than XenA. 
Similarly, XenB also reduces the nitro group of TNT to a greater extent than XenA. The 
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molecular dynamics simulations for TNT complexes with reduced XenB resulted in nine 
structures with energies that differed by no more than 2%. These models show TNT 
bound in an orientation with the aromatic ring approximately parallel to the isoalloxazine 
ring. They differ by a rotation about the normal of the TNT aromatic ring with respect to 
the FMN isoalloxazine ring. An overlay of these structures yields an image in which a 
nitro group is distributed in almost every direction about the centrally-located aromatic 
ring (Figure 6.6B, inset). Consequently, the nine models of TNT bound to XenB all have 
either a nitro group or an aromatic carbon atom approximately 3 Å above the redox-
active FMN-N5 atom position. Thus the molecular dynamics models illustrate XenB 
readily reduces both the aromatic ring and R-NO2 groups of TNT. In addition, models 
calculated for XenB with picric acid show comparable results as TNT, suggesting that 
similar reactions should be observed with this substrate (Figure 6.6D, inset). 
 A very different situation is obtained for reduced XenA with TNT or picric acid, 
where the five best TNT structures differed by less than 4.5% in energy. In contrast to 
XenB, none of these models place the TNT aromatic ring parallel to the FMN 
isoalloxazine ring, but rather yield more perpendicular arrangements (Figure 6.6A, inset). 
The average distance from FMN-N5 atom to the nearest reactive atom on TNT is ≥ 3.6 Å, 
and is most often an aromatic ring carbon. The greater distance and orientation of the 
TNT ligand within the XenA active site rationalizes the lower activity XenA with TNT 
compared to XenB. Moreover, a nitro group is almost always placed in a distinct binding 
site in XenA with hydrogen bonds to the side chains of Lys105 and His180, and the other 
nitro groups frequently hydrogen bond with the side chains of Tyr26, Tyr182, Trp357b 
and/or the FMN-N5 atom. Indeed, as a family, the nitro groups from TNT or 
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nitroglycerin are always located in equivalent XenA binding sites with hydrogen bonds to 
one or more of these residues. However, the hydrogen bonds with Lys105 are almost 
always satisfied in the models. Since this residue is further from the FMN, it appears to 
be a major determining factor for which of the remaining nitro groups can be presented to 
the flavin for reaction. Moreover, hydrogen bonds with Tyr182 also position a nitro 
group near the FMN-N5 atom, which will enhance nitrite elimination from nitroester 
substrates. Models calculated for XenA with picric acid show comparable results as the 
XenA models with TNT. 
 
6.5.5. Metronidazole Complexes with XenA and XenB 
 Molecular dynamics models calculated for reduced XenA with metronidazole 
resulted in the five best structures that differed by less than 5% in energy. The ligand 
conformation is very different in each structure (Figure 6.6E, inset), and two models 
place the nitro group within approximately 4 Å of the FMN-N5 atom. In almost all of the 
models, hydrogen bonds are suggested with the side chains of Lys105, Tyr182 and Cys24 
and/or Tyr26. The simulations suggest that the lowest-energy configuration places 
metronidazole almost parallel with the FMN dimethylbenzene ring (Figure 6.6E) and is 
stabilized by several hydrogen bonds. The next model is only 0.5% higher in energy and 
is quite similar to the perpendicular complexes obtained with TNT and picric acid (Figure 
6.7E, green). However, in the latter conformation, the metronidazole nitro group 
hydrogen bonds to the FMN-N5 atom as well as the Cys24-SH atom. Therefore, we 
anticipate that this represents the reactive complex because of the proper orientation of 
the FMN and nitro group. However, the lowest-energy conformation correlates 
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Figure 6.7: Comparison of ligand conformations in calculated structures for reduced 
XenA and reduced XenB with nitroglycerin (A), TNT (B and C) and metronidazole (D 
and E). All residues, FMN molecules and ligand molecules are drawn as sticks where 
residues are colored red for lowest-energy calculated structures of XenA (A-E), blue for 
lowest-energy calculated structures of XenB (A-D) or the crystal structure of 
XenA•metronidazole (E) and green for the crystal structure of PETNR (C) or the second-
lowest, catalytically relevant calculated structure for XenA •metronidazole (E). FMN 
molecules are always colored orange and the ligand molecule is colored the same as the 
residues. The structures shown in Figures A, B, and D are identical to Figure 6.5A&D, 
Figure 6.6A&B and Figure 6.6E&F for XenA and XenB respectively. 
 
reasonably well with the crystal structure of the oxidized XenA-metronidazole complex. 
Consequently, we anticipate that the ground-state molecular dynamics model (Figure 
6.7E, red) and the crystal structure configuration (Figure 6.7, blue) probably represent 
inactive complexes. On the other hand, the structures show that the smaller ring in 
metronidazole can adopt a nearly parallel arrangement between the ligand and the FMN. 
 
Figure 6.8: The optical spectrum of 20 μM oxidized XenA in 50 mM MOPS buffer, pH 
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This correlates with the observation that ligands such as p-Cl- and p-Br-phenol do form 
charge-transfer complexes with XenA (Figure 6.8) and support one or more parallel 
ligand binding modes. Similar to the XenA results, the ten-best complexes obtained with 
XenB bound to metronidazole often reflect potentially inactive configurations. However, 
at least one places the nitro group in an active configuration, within hydrogen bonding to 
Thr24, Tyr335 and the FMN-N5 atom. 
 
6.6 Conclusion 
 Molecular dynamics calculations were carried out for reduced XenA and XenB 
with a variety of ligand complexes, such as TNG, TNT, picric acid and metronidazole. 
The resulting energy-minimized structures for XenA and XenB with these ligand 
molecules show differing preferences for hydrogen bonding in the active sites of these 
proteins. XenA prefers to satisfy hydrogen bonds with Tyr26, Lys105 and Tyr182. These 
are residues located above the si-face of the flavin. The equivalent residues in XenB do 
not appear to be involved in ligand binding for XenB (Cys26, Ile104 and Tyr177). 
Instead, XenB prefers to satisfy hydrogen bonds with Thr24, Tyr177 and Tyr335, which 
are residues that can be found flanking the flavin ring. As a result, the binding 
conformations for ligand molecules that are catalytically relevant are different for XenA 
and XenB. Their differing pattern of hydrogen bonding with ligand molecules is 
suggestive of the formation of different binding pockets for nitro groups in XenA and 
XenB that would result in differing selectivities and catalysis for identical ligand 
molecules. 
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6.8 Supplementary Information 
Table 6.S1: Data Collections and Model Refinement Statistics  
 


















Wavelength (Å)  1.00 1.0332 0.99997 















Resolution Range (Å) 27.7-1.8 31.1-2.1 46.1-1.5 
High resolution (Å) 1.90-1.8 2.21-2.10 1.59-1.49 
Total Observations 287037 254961 236178 
Unique Observations 63499 43637 120908 
Rsym (%)a,b 6.8 (48.2) 11.1 (49.2) 8.3 (0.45) 
I/σ(I)a,c 6.7 (1.5) 5.6 (1.5) 8.8 (1.3) 
Completeness (%)a 90.0 (86.8) 93.2 (69.1) 80.6 (44.4) 
Multiplicitya 4.6 (4.1) 6.1 (3.0) 7.2 (1.5) 
Model Refinement Statistics 
No. of reflections 57
030 
35483 91939 
R-factor 19.1 19.8 19.2 
R-freeb 23.5 25.1 23.4 
No. of non-H protein atoms 6355 6080 6650 
No. of residues fit 722 722 722 
No. of disordered residues 2 2 2 
No. of water molecules 599 362 918 
No. of FMN molecules 2 2 2 
Ligand molecules 2 Chloride  
6 Spermine 
2 Chloride  
3 Spermine 
1 Chloride  
4 Spermine 
RMS deviations form ideal    
 Bond lengths (Å) 0.010 0.012 0.010 
 Bond angles (°) 1.156 1.349 1.267 
 Mean B, protein atoms (Å2) 20.6 21.2 22.1 
 Mean B, water molecules (Å2) 31.3 21.9 35.8 
 Mean B, FMN molecules (Å2) 20.0 22.3 21.6 
 Mean B, ligand molecules (Å2) 38.7 / 46.8 38.1 / 50.4 33.6 / 53.3 
Ramachandran analysis    
 Most favored regions (%) 89.3 88.4 89.4 
 Additional allowed regions (%) 9.9 10.9 9.8 
 Generously allowed regions (%) 0.8 0.7 0.8 
 Disallowed regions (%) 0.0 0.0 0.0 
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Figure 6.S1: Overview of the active sites for the two crystal structures of XenA co-
crystallized with TNG, TNT and metronidazole. The protein residues are shown as ball 
and stick drawings colored by atom type, where carbon, nitrogen and oxygen are grey, 
blue and red, respectively. The bonds for the FMN, Trp357b, ligand molecules, spermine 
molecules is colored in orange, red and green, respectively. The divergent stereo 
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drawings show 1σ contours for the 2mFo - DFc electron density maps around the flavin 
and ligand molecules. The stereo portion of the figure is parallel to the isoalloxazine ring. 
The insets show the 1.5σ contours for the 2mFo - DFc electron density maps around the 
flavin. (A) Oxidized XenA co-crystallized with 1.1mM TNG determined to 1.8 Å 
resolution at 100 K. (B), Oxidized XenA co-crystallized with 1.1mM TNT determined to 
2.1 Å resolution at 100 K. (C) Oxidized XenA co-crystallized with 1.6 mM 
metronidazole to 1.5 Å resolution at 100 K for active site A (C) and active site B (D) In 
none of these datasets was the ligand molecule observed. Instead, spermine was found in 
the active sites and was present at 20 mM in the crystallization buffer except in the case 
of XenA co-crystallized with metronidazole. 
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